Novel G protein-coupled receptor encoding gene and diagnostic uses therefor

ABSTRACT

The present invention provides GPR56 genes and polypeptides encoded therefor. The GPR56 genes of the invention are expressed highly in malignant tissues and the invention also provides diagnostic processes for detecting cancer or malignant tumors in human subjects The diagnostic and prognostic test of the present invention is particularly useful for the early detection of ovarian cancer or metastases thereof and for monitoring the progress of disease, such as, for example, during remission or following surgery or chemotherapy. The GPR56 gene of the invention is also expressed in effector memory T cells, and the invention therefor provides methods of identifying and/or quantifying effector memory T cells, which methods are useful for determining the immune status of a subject.

RELATED APPLICATION DATA

[0001] This application is a continuation-in-part application of U.S. Ser. No. 09/308,696 filed on Jun. 11, 1999, which is a 371 of International Application No. PCT/AU98/00805 filed on Sep. 24, 1998, which claims the benefit of priority under Title 35 U.S.C. 119 from Australian Patent Application No. PO 9386 filed on Sep. 24, 1997. These applications are incorporated herein by reference in their entirety and for all purposes.

FIELD OF THE INVENTION

[0002] This invention relates to novel genes that are expressed highly in malignant tissues and uses therefor in the diagnosis of cancer or malignant tumors in human subjects. More specifically, this invention relates to the use of nucleic acid or antibody probes to specifically detect over-expression of a G protein-coupled receptor gene in ovarian cells, such as, for example, the ovarian surface epithelium, which over-expression is highly associated with the occurrence of ovarian tumors. The diagnostic and prognostic test of the present invention is particularly useful for the early detection of ovarian cancer or metastases thereof, or other cancers, and for monitoring the progress of disease, such as, for example, during remission or following surgery or chemotherapy. The present invention is also directed to methods of therapy wherein GPR56 activity is modulated.

BACKGROUND OF THE INVENTION

[0003] 1. General

[0004] This specification contains nucleotide and amino acid sequence information prepared using Patentln Version 3.1, presented herein after the claims. Each nucleotide sequence is identified in the sequence listing by the numeric indicator <210> followed by the sequence identifier (e.g. <210>1, <210>2, <210>3, etc). The length and type of sequence (DNA, protein (PRT), etc), and source organism for each nucleotide sequence, are indicated by information provided in the numeric indicator fields <211>, <212> and <213>, respectively. Nucleotide sequences referred to in the specification are defined by the term “SEQ ID NO:”, followed by the sequence identifier (eg. SEQ ID NO: 1 refers to the sequence in the sequence listing designated as <400>1).

[0005] The designation of nucleotide residues referred to herein are those recommended by the IUPAC-IUB Biochemical Nomenclature Commission, wherein A represents Adenine, C represents Cytosine, G represents Guanine, T represents thymine, Y represents a pyrimidine residue, R represents a purine residue, M represents Adenine or Cytosine, K represents Guanine or Thymine, S represents Guanine or Cytosine, W represents Adenine or Thymine, H represents a nucleotide other than Guanine, B represents a nucleotide other than Adenine, V represents a nucleotide other than Thymine, D represents a nucleotide other than Cytosine and N represents any nucleotide residue.

[0006] As used herein the term “derived from” shall be taken to indicate that a specified integer may be obtained from a particular source albeit not necessarily directly from that source.

[0007] Throughout this specification, unless the context requires otherwise, the word “comprise”, or variations such as “comprises” or “comprising”, will be understood to imply the inclusion of a stated step or element or integer or group of steps or elements or integers but not the exclusion of any other step or element or integer or group of elements or integers.

[0008] Those skilled in the art will appreciate that the invention described herein is susceptible to variations and modifications other than those specifically described. It is to be understood that the invention includes all such variations and modifications. The invention also includes all of the steps, features, compositions and compounds referred to or indicated in this specification, individually or collectively, and any and all combinations or any two or more of said steps or features.

[0009] The present invention is not to be limited in scope by the specific embodiments described herein, which are intended for the purposes of exemplification only. Functionally-equivalent products, compositions and methods are clearly within the scope of the invention, as described herein.

[0010] 2. Description of the Related Art

[0011] The actions of many extracellular signals are mediated by the interaction of a G protein-coupled receptor (hereinafter “GPCR” or “GPR”) with its cognate guanine nucleotide-binding regulatory protein (G protein). G protein-mediated signaling systems have been identified in many divergent organisms, such as mammals and yeast. GPCRs respond to, among other extracellular signals, neurotransmitters, hormones, odorants and light (Watson, S. and Arkinstall, S., The G-protein Linked receptor facts Book, Academic Press, London, 1994).

[0012] The movement and biological activities of leukocytes (i.e. neutrophils, monocytes, eosinophils, basophils, lymphocytes, dendritic cells, etc.) in the ontogeny of cancer, including the mobilization of hematopoietic stem cells in chemotherapy or myeloprotection during chemotherapy, is also regulated by the GPCR-mediated activity of chemokines. Similarly, GPCR-mediated chemokine activity regulates the movement and biological activities of leukocytes during chronic inflammation, chronic rejection of transplanted organs or tissue grafts, chronic myelogenous leukemia, and infection by HIV and other pathogens. For reviews, see Baggiolini et al. (1997) Ann. Rev. inmmunol. 15, 675-705; Premack et al., Nature Medicine 2, 1174-1178, 1996; and Yoshie et al., J. Leukocyte Biol. 62, 634-644, 1997). Over 30 different human chemokines have been described to date, which vary in specificity for different leukocyte types, however they typically are produced at sites of tissue injury or stress, where they promote infiltration of leukocytes to facilitate an inflammatory response. Some chemokines act selectively on immune system cells such as subsets of T cells or B lymphocytes or antigen presenting cells, and may thereby promote immune responses to antigens. Some chemokines also have the ability to regulate the growth or migration of hematopoietic progenitor and stem cells that normally differentiate into specific leukocyte types, thereby regulating leukocyte numbers in the blood.

[0013] In consideration of the role of GPCRs in regulating chemokine activity, the identification of immunodominant T cell epitopes and enumeration of frequencies of T cell sub-populations is a particularly desirable outcome. Known means for achieving this end include a modified proliferation assay (Plebanski, et al., J. Immunol. Meth. 170,15, 1994), a limiting dilution assay (LDA) employing relatively large peripheral blood mononuclear cell (PBMC) quantities and requiring two rounds of in vitro stimulation to detect a T cell response to whole antigen or peptide (Sharrock et al., Immunol. Today 11, 281-286, 1990), and several formats of flow cytometric methods to detect T cell activation by up-regulation of characteristic markers such as CD69, measurement of lymphokine production (Jung et al., J. Immunol. Meth. 159, 197, 1993), or by trapping secreted lymphokines on the surface of the secreting cell (Manz et al., Proc. Natl. Acad. Sci. USA 92, 1921, 1995). The identification of T cell markers is particularly important to facilitating the identification of immunodominant T cell epitopes and enumeration of frequencies of T cell sub-populations. T cell markers act as surrogate markers for disease activity, indicating the significance of GPR56 in diagnostic, prognostic, and therapeutic applications with respect to hyperproliferative disorders or inflammatory disease.

[0014] Several GPCRs have been identified and sequence analysis reveals that they are structurally similar, possessing a number of highly conserved amino acid residues. Accordingly, GPCRs collectively form a large “superfamily” of receptor proteins capable of associating with the plasma membrane such that the N-terminal portion is localized in the extracellular space, the C-terminus is cytoplasmic, and three extramembranous loops are forms. This means that there are seven transmembrane domains (i.e. 7-TM) in the GPCR polypeptide.

[0015] Individual GPCR types activate particular signal transduction pathways. At least ten different signal transduction pathways are known to be activated via GPCR polypeptides. For example, the secretin receptor sub-family of GPCR polypeptides are activated by a ligand selected from the group consisting of: secretin, glucagon, calcitonin, glucagon-like peptide 1, parathyroid hormone, parathyroid-related peptide, corticotropin-releasing factor (CRF), growth hormone-releasing hormone (GHRH), gastric inhibitory polypeptide, pituitary adenylate cyclase-activating polypeptide (PACAP), vasoactive intestinal peptide (VIP), and insect diuretic hormone (DHR). Known human chemokine receptors include CCR1, CCR2, CCR3, CCR4, CCR5, CCR6, CCR7, CCR8, CXCR1, CXCR2, CXCR3, and CXCR4.

[0016] Cancer is a multi-factorial disease and major cause of morbidity in humans and other animals, and deaths resulting from cancer in humans are increasing and expected to surpass deaths from heart disease in future. Carcinomas of the lung, prostate, breast, colon, pancreas, and ovary are major contributing factors to total cancer death in humans. For example, prostate cancer is the fourth most prevalent cancer and the second leading cause of cancer death in males. Similarly, cancer of the ovary is the second most common cancer of the female reproductive organs and the fourth most common cause of cancer death among females. With few exceptions, metastatic disease from carcinoma is fatal. Even if patients survive their primary cancers, recurrence or metastases are common.

[0017] It is widely recognized that simple and rapid tests for solid cancers or tumors have considerable clinical potential. Not only can such tests be used for the early diagnosis of cancer but they also allow the detection of tumor recurrence following surgery and chemotherapy. A number of cancer-specific blood tests have been developed which depend upon the detection of tumor-specific antigens in the circulation (Catalona, W. J., et al., 1991, “Measurement of prostate-specific antigen in serum as a screening test for prostate cancer”, N. Engl. J. Med. 324, 1156-1161; Barrenetxea, G., et al., 1998, “Use of serum tumor markers for the diagnosis and follow-up of breast cancer”, Oncology, 55, 447-449; Cairns, P., and Sidreansky, D., 1999, “Molecular methods for the diagnosis of cancer”. Biochim. Biophys. Acta. 1423, C 11 -C 18).

[0018] Most ovarian cancers are thought to arise from the ovarian surface of epithelium (OSE). Epithelial ovarian cancer is seldom encountered in women less than 35 years of age. Its incidence increases sharply with advancing age and peaks at ages 75 to 80, with the median age being 60 years. The single most important known risk factor is a strong familial history of breast or ovarian cancer. To date, little is known about the structure and function of the OSE cells. It is known that the OSE is highly dynamic tissue that undergoes morphogenic changes, and has proliferative properties sufficient to cover the ovulatory site following ovulation. Morphological and histochemical studies suggest that the OSE has secretory, endocytotic and transport functions which are hormonally-controlled (Blaustein and Lee, Oncol. 8, 34-43, 1979; Nicosia and Johnson, Int. J. Gynecol. Pathol., 3, 249-260, 1983; Papadaki and Beilby, J. Cell Sci. 8, 445-464, 1971; Anderson et al., J. Morphol., 150, 135-164, 1976).

[0019] Ovarian cancers are not readily detectable by diagnostic techniques (Siemens et al., J. Cell. Physiol., 134: 347-356, 1988). In fact, the diagnosis of carcinoma of the ovary is generally only possible when the disease has progressed to a late stage of development. A number of proteinaceous ovarian tumor markers were evaluated several years ago, however these were found to be non-specific, and determined to be of low value as markers for primary ovarian cancer (Kudlacek et al., Gyn. Onc. 35, 323-329, 1989; Rustin et al., J. Clin. Onc., 7, 1667-1671, 1989; Sevelda et al., Am. J. Obstet. Gynecol., 161, 1213-1216, 1989; Omar et al., Tumor Biol., 10, 316-323, 1989). Several monoclonal antibodies were also shown to react with ovarian tumor associated antigens, however they were not specific for ovarian cancer and merely recognize determinants associated with high molecular weight mucin-like glycoproteins (Kenemans et al., Eur. J. Obstet. Gynecol. Repod. Biol. 29, 207-218, 1989; McDuffy, Ann. Clin. Biochem., 26, 379-387, 1989). More recently, oncogenes associated with ovarian cancers have been identified, including HER-21neu (c-erbB-2) which is over-expressed in one-third of ovarian cancers (U.S. Ser. No. 6,075,122 by Cheever et al., issued Jun. 13, 2000), the fms oncogene, and abnormalities in the p53 gene, which are seen in about half of ovarian cancers. Oncogene markers are not generally amenable to rapid and simple diagnosis of ovarian cancer, because they may be limited to cancer cell tissues and do not necessarily appear in mestases or in the circulation.

[0020] Recently, a GPCR designated as PHOR-1 was identified as having utility in the early detection of prostate cancer (see International Patent Publication No. WO01/25434, Apr. 12, 2001). Expression of PHOR-1 is localized to the prostate gland of healthy individuals, however is up-regulated in prostate tumors and can also be detected in tumors of the kidney, uterus, cervix, stomach and rectum. No other correlation has been recognized between GPCR polypeptide expression and cancer.

[0021] Whilst previously identified markers for carcinomas of the lung, prostate, breast, colon, pancreas, and ovary have facilitated efforts to diagnose and treat these serious diseases, there is a clear need for the identification of additional markers and therapeutic targets. The identification of tumor markers that are amenable to the early-stage detection of localized tumors is critical for more effective management of carcinomas of the lung, prostate, breast, colon, pancreas, and ovary.

SUMMARY OF THE INVENTION

[0022] The present invention provides a novel GPCR-encoding gene, designated GPR56-1 or TSR32 (SEQ ID NO: 1). The structure of the encoded GPR56-1 polypeptide (i.e. SEQ ID NO: 2) is characteristic of known GPCR polypeptides of the secretin sub-family. The encoded polypeptide comprises about 693 amino acid residues in length (SEQ ID NO: 2) and includes the N-terminal sequence MTPQSLLQTT (SEQ ID NO: 20).

[0023] Homology searching has identified three additional human genes having at least about 95% identity, and more particularly about 99% identity to the GPR56-1 nucleotide sequence. These alleles are designated herein as GPR56-2, GPR56-3, and GPR56-4, respectively. At the protein level, the amino acid sequences of GPR56-1 (SEQ ID NO: 2) and GPR56-3 (SEQ ID NO: 6) are 100% identical, and GPR56-2 (SEQ ID NO: 4) differs from this isoform only by the substitution of Gln306 for His306. In contrast, the amino acid sequence of GPR56-4 (SEQ ID NO: 8) comprises a six amino acid deletion at positions 430-435 relative to the other two isoforms. These data indicate the existence of a small multigene family encoding GPR56 in humans.

[0024] Homology searching has also revealed a murine homologue (SEQ ID NO: 9) having about 80% identity to the nucleotide sequence encoding human GPR56-1. At the protein level the murine and human GPR56 polypeptides are about 80% identical over their entire lengths. The occurrence of long amino acid stretches that are highly conserved between the human and murine polypeptides indicates that these polypeptides are antigenically cross-reactive. Additionally, the high conservation between the human and murine nucleotide sequences is indicative that they cross-hybridize. This means that the murine GPR56-encoding nucleotide sequence can be used to detect the human GPR56-encoding genes. Similarly, the complement of the murine GPR56-encoding gene can be used to detect RNA encoding human GPR56 isoforms.

[0025] The present invention clearly encompasses any plasmids or expression vectors, including any viral vectors, comprising the nucleic acid described herein. Such vectors may be introduced into suitable host cells, such as, for example, bacterial cells, yeast cells, insect cells, or mammalian cells, for the purposes of expressing a recombinant GPR56 polypeptide or a functional fragment thereof, in particular an immunogenic peptide fragment.

[0026] The present invention further provides a method of producing a GPR56 polypeptide or a functional fragment thereof, said method comprising culturing a host cell comprising the nucleic acid of the invention in an expressible format under conditions sufficient for expression to occur and then recovering the expressed polypeptide. Preferably, the expressed polypeptide is directed to the cell surface. Preferably, the recovered polypeptide is rendered substantially free of conspecific proteins using known protein isolation/purification techniques. Preferred cell lines for this purpose are insect or mammalian cells. Baculovirus cell expression systems using Sf9 or Sf21 cells, or vaccinia virus expression systems using COS cells, CHO cells, or HEK 293 cells, are especially preferred for the synthesis of GPCR polypeptides.

[0027] Expression analyses using GeneChip microarray hybridization technology indicates that human GPR56 gene expression is up-regulated in patients suffering from ovarian cancer, including those subjects having metastases in the omentum or other tissues. At the RNA level, expression of GPR56 in ovarian tumor samples from both early and advanced ovarian cancer patients was up-regulated several-fold in the ovary and omentum, when compared to the level of expression detected in the ovary and omentum, respectively, of healthy subjects, indicating that GPR56 is a useful cancer marker, particularly for the detection of ovarian cancer and metastases thereof, and preferably for the early detection of ovarian cancer and metastases thereof. The actual enhancement of expression that was detected is much higher than for other known markers of ovarian cancer, making the instant invention particularly useful in terms of providing a definitive diagnostic or prognostic assay, since there is a significant distinction between GPR56 levels in diseased tissue and those of normal or healthy subjects. Moreover, the ability to detect ovarian cancer by measuring GPR56 expression in the omentum of a subject indicates that the present invention is not limited by the source of tissue used for the diagnosis of ovarian cancer. GPR56 expression was also detectable in prostate tumor samples.

[0028] The present invention clearly encompasses nucleic acid-based methods and protein-based methods for diagnosing cancer in humans and other mammals.

[0029] Those skilled in the art will be aware that as a carcinoma progresses, metastases occur in organs and tissues outside the site of the primary tumor. For example, in the case of ovarian cancer, metastases commonly appear in a tissue selected from the group consisting of omentum, abdominal fluid, lymph nodes, lung, liver, brain, and bone. The present inventors have found that GPR56 expression is useful for detecting any stage of progression of ovarian cancer, including early stages of the disease and metastases outside the ovary. Accordingly, the term “ovarian cancer” as used herein shall be taken to include an early or developed tumor of the ovary and any metastases outside the ovary that occurs in a subject having a primary tumor of the ovary.

[0030] As used herein, the term “diagnosis”, and variants thereof, such as, but not limited to “diagnose”, “diagnosed” or “diagnosing” shall not be limited to a primary diagnosis of a clinical state, however should be taken to include any primary diagnosis or prognosis of a clinical state. For example, the “diagnostic assay” formats described herein are equally relevant to assessing the remission of a patient, or monitoring disease recurrence, or tumor recurrence, such as following surgery or chemotherapy, or determining the appearance of metastases of a primary tumor. All such uses of the assays described herein are encompassed by the present invention.

[0031] Expression analyses using GeneChip microarray hybridization technology also indicate that human GPR56 gene expression on the surface of T cells is restricted to a sub-population of T cells that lack the CCR7 receptor (i.e. CCR7⁻ T cells). These data indicate that GPR56 is also a useful marker for detecting effector memory T cells that are involved in expressing receptors for migration to sites of inflammation and that possess immediate effector function. Such effector memory T cells contrast with the role of generally quiescent CCR7⁺ central memory T cells that express receptors for homing to lymph nodes and that lack immediate effector function. The detection of GPR56 expression on T cells is thus indicative of T cell activation in a sample.

[0032] Accordingly, the level of GPR56 expression, at either the RNA level or the protein level, can be used in a number of applications. Those applications include, for example, the identification of an effector memory T cell in a sample and the determination of an activated memory T cell count. Addtionally, GPR56 can be used to determine the infection status of an individual, and to determine whether or not an individual has been re-infected with an infectious agent, such as a bacterium or viral agent. Additionally, GPR56 expression can be used to diagnose inflammatory disease, or as a prognostic to monitor the progress of a disease state, such as, for example, a cancer, inflammatory disease, or chronic infection.

[0033] Based upon the nucleotide and amino acid sequence comparisons described herein, the present invention provides nucleic acid-based assays and immunoassays for the detection of cancer and/or effector memory T cells and/or T cell activation and/or diagnosing an inflammatory disorder which involves T cell activation.

[0034] More particularly, the nucleic acid-based assays described herein rely upon the detection or relative quantification of RNA levels in samples using probes of at least about 20 nucleotides in length that hybridize specifically to RNA encoding the GPR56 polypeptide, or alternatively, amplify cDNA from RNA encoding the GPR56 polypeptide. Such probes are derived from unique regions of any one or more of the GPR56-encoding genes described herein, such as, for example, any 20 contiguous nucleotides within residues 131-1400, 1423-2239, or 2264-2282 of SEQ ID NO: 1 or the protein-encoding region of SEQ ID NO: 1 or a complementary nucleotide sequence thereto or identical sequence in any other mammalian GPR56-encoding gene. The use of full-length antisense cDNA or cRNA derived from any one of SEQ ID NOS: 1, 3, 5, 7, or 9 is also encompassed by the present invention. Conveniently, any hybridization assay format can be used to detect GPR56-encoding RNA in samples, such as, for example, high-throughput screening using microarray technology, or conventional northern hybridization or reverse transcription polymerase chain reaction (i.e. RT-PCR). In situ localization can also be employed using histology specimens. Particularly preferred probes exemplified herein are those oligonucleotides having the nucleotide sequences set forth in any one of SEQ ID NOS: 11-19. Additional probes for use in these assays, including any allele-specific probes that selectively hybridize to one or more GPR56-encoding alleles, are not to be excluded and are readily identified by those skilled in the art based upon the nucleotide sequences, and the amino acid sequence alignment, provided herein.

[0035] The present invention clearly encompasses any nucleic acid probes or primers, including any synthetic oligonucleotides, suitable for use in the assays described herein.

[0036] In another embodiment, the nucleic acid encodes an antisense nucleic acid which can hybridize with a second nucleic acid encoding a GPR56 protein and which, when introduced into cells, can inhibit the expression of the GPR56 polypeptide in a cell, tissue, organ, or whole organism.

[0037] In another embodiment, the nucleic acid encodes an interfering RNA that can inhibit the expression of the GPR56 polypeptide in a cell, tissue, organ, or whole organism. By “interfering RNA” means an RNA molecule having a region of self-complementarity and/or capable of forming a hairpin loop structure in a cell, wherein said region of self-complementarity comprises a nucleotide sequence of at least about 20 contiguous nucleotides in length from a sequence having at least about 80% identity to SEQ ID NO: 1 or a complementary sequence thereto.

[0038] The immunoassays described herein utilize antibodies, including monoclonal and polyclonal antibodies, or a Fab fragment, F(ab′)₂ fragment, or scFv fragment, that binds to a unique peptide region comprising at least about 5-10 contiguous amino acid residues of a human GPR56 polypeptide. Homology searching indicates that most peptide regions of 5-10 amino acids in length from the human GPR56 polypeptide are unique, optionally excluding residues 414-419. Regions of the murine GPR56 polypeptide that are highly conserved with the human sequence (eg. any peptide comprising at least about 5-10 contiguous amino acid residues of SEQ ID NO: 10 that is identical to the corresponding region of SEQ ID NOS: 2, 4, 6, or 8, as shown in FIG. 1) are particularly useful for preparing antibodies against human GPR56. Isoform-specific amino acid sequences (eg. Amino acids 430-435 of SEQ ID NO: 2) are also readily derived from the alignment provided in FIG. 1, and these are used conveniently to prepare antibodies that detect specific GPR56 isoforms.

[0039] The present invention further encompasses any synthetic or recombinant peptides, or antibodies suitable for use in the assays described herein.

[0040] Antibodies or fragments thereof are useful in therapeutic, diagnostic and research applications, including the purification and study of the receptor proteins, identification of cells expressing surface receptor, and sorting or counting of cells. Thus, the present invention encompasses use of an antibody or fragment thereof described herein (e.g., monoclonal antibodies or an antigen-binding fragment thereof) in therapy, including prophylaxis, or diagnosis, and use of such antibodies or fragments for the manufacture of a medicament for use in treatment of diseases or conditions as described herein.

[0041] Also encompassed by the present invention are methods of identifying ligands of the GPR56 receptor polypeptide, such as, for example, inhibitors or antagonists, or alternatively, agonists of GPR56 receptor function. In one embodiment, suitable host cells that have been engineered to express GPR56 or a GPR56 homolog encoded by nucleic acid having at least about 80% identity to SEQ ID NO: 1 are are used in an assay to identify and assess the efficacy of ligands, agonists or antagonists of GPR56 function. Such cells are also useful in assessing the function of the expressed GPR56 protein or homolog.

[0042] According to the present invention, ligands, agonists, or antagonists of GPR56 function are identified in a suitable assay, and further assessed for their therapeutic efficacy. Antagonists of GPR56 are used to inhibit (ie. reduce or diminish or prevent) GPR56-mediated effects in cells, such as, for example, any hypoproliferative disease, inflammatory state, inflammation, or cancer. Alternatively, ligands and/or agonists of GPR56 are useful for inducing or enhancing GPR56-mediated effects in cells.

[0043] Accordingly, a further aspect of the present invention provides a method of treating a hypoproliferative disease, such as, for example, cancer, hyperimmune response, inflammatory disorder (eg. rheumatoid arthritis), autoimmune disease, or graft rejection, comprising administering an antagonist of GPR56 function to an individual (e.g., a mammal) for a time and under conditions sufficient to reduce or prevent GPR56 activity in said individual, thereby reducing or preventing one or more GPR56-mediated effects. Preferably, the antagonist comprises nucleic acid, such as, for example, antisense nucleic acid, a ribozyme, or nucleic acid that forms a triple helical structure, capable of reducing GPR56 expression in a cell of the individual. As will be known to those skilled in the art, the expression can be reduced at the RNA level or the protein level. Accordingly, antibodies that bind GPR56 and inhibit its activity are also useful in this context.

[0044] The present invention further provides a method of agonising or otherwise enhancing GPR56 activity in an individual comprising administering a GPR56 ligand or GPR56 agonist to said individual for a time and under conditions sufficient to enhance GPR56 activity. This embodiment of the invention clearly provides a new approach to selective enhancement of leukocyte activity, which is useful, for example, in the treatment of infectious diseases, particularly enhancing a response to re-infection by bacterial or viral pathogens.

BRIEF DESCRIPTION OF THE DRAWINGS

[0045]FIGS. 1a-1 k are a schematic representation of an alignment between the amino acid sequences of four human GPR56 polypeptides designated GPR56-1 (SEQ ID NO: 2), GPR56-2 (SEQ ID NO: 4), GPR56-3 (SEQ ID NO: 6) and GPR56-4 (SEQ ID NO: 8), and a single murine GPR56 polypeptide (SEQ ID NO: 10). Amino acid residues that differ from the amino acid sequence of GPR56-1 (SEQ ID NO: 2) are indicated in bold typeface. Numbering below each block of five sequences indicates the amino acid residue number relative to the full-length sequence set forth in SEQ ID NO: 2.

[0046]FIGS. 2a-2 d are a graphical representation of an RNA-DNA hybridization showing relative expression of human GPR56 RNA in normal and tumorigenic ovary or omentum samples from human subjects. Subjects included 6 patients diagnosed as having borderline ovary cancer using conventional screens (columns numbered 1 through 6); 34 patients definitively diagnosed as having ovarian cancer, using conventional screens (columns numbered 7 through 44); and 11 ovarian cancer patients diagnosed with metastases or secondary cancers of the omentum using conventional screens (columns numbered 45 through 55). Control samples comprised non-cancerous ovary tissue (columns numbered 56 through 59) and non-cancerous omentum (column 60). The x-axis indicates sample number. The abscissa indicates relative GPR56 RNA expression. Numbers at the top of each column indicate the relative expression for each sample. Data indicate a 6- to 7-fold enhancement of GPR56 expression in early and advanced cancers of the ovary, and/or metastases of the omentum (ie. peritoneum connecting the stomach and other abdominal organs).

DETAILED DESCRIPTION OF THE INVENTION

[0047] One aspect of the present invention provides an isolated nucleic acid molecule comprising a nucleotide sequence that encodes a G protein-coupled receptor (GPCR or GPR) polypeptide, and preferably a GPR56 polypeptide or an immunologically active derivative thereof.

[0048] As used herein, the term “nucleic acid” shall be taken to mean any single-stranded or double-stranded RNA, DNA, cDNA, cRNA, or synthetic oligonucleotide, or alternatively, an analog of RNA, DNA, cDNA, cRNA, or a synthetic oligonucleotide. “Nucleic acid” also includes any genomic gene equivalents of a cDNA molecule.

[0049] In a preferred embodiment, the isolated nucleic acid of the invention is from humans (ie. it encodes a human GPR56 polypeptide).

[0050] As used herein, the term “GPR56 polypeptide” shall be taken to mean a GPR polypeptide of mammals having at least about 80% identity at the amino acid level to the amino acid sequence set forth in SEQ ID NO: 2. Preferably, the percentage identity to SEQ ID NO: 2 is at least about 90%, more preferably at least about 95%, or at least about 99%.

[0051] In determining whether or not two amino acid sequences fall within these defined percentage identity limits, those skilled in the art will be aware that it is necessary to conduct a side-by-side comparison of amino acid sequences. In such comparisons or alignments, differences will arise in the positioning of non-identical amino acid residues depending upon the algorithm used to perform the alignment. In the present context, references to percentage identities and similarities between two or more amino acid sequences shall be taken to refer to the number of identical and similar residues respectively, between said sequences as determined using any standard algorithm known to those skilled in the art. In particular, amino acid identities and similarities are calculated using the GAP program of the Computer Genetics Group, Inc., University Research Park, Madison, Wis., United States of America (Devereaux et al, Nucl. Acids Res. 12, 387-395,1984), which utilizes the algorithm of Needleman and Wunsch J. Mol. Biol. 48, 443-453, 1970, or alternatively, the CLUSTAL W algorithm of Thompson et al., Nucl. Acids Res. 22, 4673-4680, 1994, for multiple alignments, to maximize the number of identical/similar amino acids and to minimize the number and/or length of sequence gaps in the alignment.

[0052] Alternatively, or in addition, an isolated nucleic acid encoding a GPR56 polypeptide hybridizes under high stringency conditions to a sequence that is complementary to SEQ ID NO: 1. For the purposes of defining the level of stringency, a high stringency hybridization is achieved using a hybridization buffer and/or a wash solution comprising the following:

[0053] (i) a salt concentration that is equivalent to 0.1×SSC-0.2×SSC buffer or lower salt concentration;

[0054] (ii) a detergent concentration equivalent to 0.1% (w/v) SDS or higher; and

[0055] (iii) an incubation temperature of 55° C. or higher.

[0056] Conditions for specifically hybridizing nucleic acid, and conditions for washing to remove non-specific hybridizing nucleic acid, are well understood by those skilled in the art. For the purposes of further clarification only, reference to the parameters affecting hybridization between nucleic acid molecules is found in Ausubel et al. (Current Protocols in Molecular Biology, Wiley Interscience, ISBN 047150338, 1992), which is herein incorporated by reference.

[0057] Preferably, the isolated nucleic acid is expressed in hematopoietic cells, including stem cells, epithelial cells, and T cells and/or in one or more tissues selected from the group consisting of serum, abdominal fluid, lymph, lung, prostate, omentum, ovary, liver, placenta, and brain, as determined by the appearance of RNA encoding said polypeptide in those tissues.

[0058] Preferably, the isolated nucleic acid of the invention is also expressed in a range of cancer cells, such as, for example, in carcinomas of the lung, prostate, breast, colon, pancreas, placenta, omentum or ovary, and in cells of brain anaplastic oligodendrogliomas, as determined by the appearance of RNA encoding said polypeptide in those cells.

[0059] In the present context, the term “cancer cell” includes any biological specimen or sample comprising a cancer cell irrespective of its degree of isolation or purity, such as, for example, tissues, organs, cell lines, bodily fluids, or histology specimens that comprise a cell in the early stages of transformation or having been transformed. Bodily fluids shall be taken to include whole blood, serum, peripheral blood mononuclear cells (PBMC), or buffy coat fraction.

[0060] As the present invention is particularly useful for the early detection of cancer, the definition of “cancer cell” is not to be limited by the stage of a cancer in the subject from which said cancer cell is derived (ie. whether or not the patient is in remission or undergoing disease recurrence or whether or not the cancer is a primary tumor or the consequence of metastases). Nor is the term “cancer cell” to be limited by the stage of the cell cycle of said cancer cell.

[0061] Even more preferably, the isolated nucleic acid is expressed at elevated levels in cancer cells compared to non-cancer cells, as detected by measuring the level of GPR56 RNA or GPR56 polypeptide. In a particularly preferred embodiment, the isolated nucleic acid of the invention is expressed at an elevated level in ovarian cancer cells, such as, but not limited to, cancerous OSE cells, and metastases thereof, such as, for example, omentum, abdominal fluid, lymph nodes, lung, liver, brain, or bone.

[0062] In an alternative preferred embodiment, the isolated nucleic acid is expressed on the surface of effector memory T cells, wherein it is capable of being used for providing a number of beneficial data sets for an individual, such as, for example, immune status, infection status, response to re-infection, activated memory T cell count, inflammation status, or inflammatory disease state. As used herein, the term “effector memory T cell” shall be taken to mean a memory T cell that expresses a receptor to facilitate its migration to a site of inflammation and/or that possesses immediate effector function and/or that lacks a functional CCR7 receptor.

[0063] In a particularly preferred embodiment, the isolated nucleic acid of the present invention comprises a nucleotide sequence selected from the group consisting of:

[0064] (i) the nucleotide sequence set forth in SEQ ID NO: 1;

[0065] (ii) nucleotide residues 163 to 2241 of SEQ ID NO: 1;

[0066] (iii) a nucleotide sequence that encodes the amino acid sequence set forth in SEQ ID NO: 2; and

[0067] (iv) a sequence that is complementary to any one of (i) to (iii).

[0068] The term “immunologically active derivative” shall be taken to mean any peptide fragment of a GPR56 polypeptide that is of a sufficient length and/or sufficiently antigenic to: (i) facilitate the production of antibodies that can detect GPR56 in samples; and/or (ii) bind to antibodies against a GPR56 polypeptide.

[0069] Such “derivatives”, or their functional equivalents, may be generated by several means known to those skilled in the art, such as, for example:

[0070] (i) digestion of a GPR56 polypeptide comprising the amino acid sequence of SEQ ID NO: 2 or an immunologically active derivative thereof or a functional equivalent thereof, using a reagent such as, for example, cyanogen bromide, S-ethyltrifluorothioacetate, trypsin, chymotrypsin, pepsin, or thermolysin;

[0071] (ii) chemical peptide synthesis of a peptide comprising at least about 5-10 contiguous amino acids in length of SEQ ID NO: 2 or a functionally equivalent peptide thereto, using art-recognized techniques, such as, for example, Fmoc chemistry (reviewed by Fields (ed), Methods. Enzymol. 289, Academic Press, 1997 (whole of volume); Hecht, S. M. (ed) Bioorganic Chemistry: Peptides and Proteins, Oxford University Press: New York, ISBN 0-19-508468-3, 1998; Mayo, TIBTECH 18, 212-217, 2000);

[0072] (iii) by recombinant expression of a nucleic acid fragment of the full-length protein-encoding region of SEQ ID NO: 1 or an equivalent thereof in a suitable cellular or cell-free expression system (see below); and

[0073] (iv) subjecting the nucleotide sequence of the full-length protein-encoding region of SEQ ID NO: 1 or a functional equivalent thereof to site-directed mutagenesis (reviewed by Hecht, S. M. (ed) Bioorganic Chemistry: Peptides and Proteins, Oxford University Press: New York, ISBN 0-19-508468-3, 1998), so as to produce single or multiple nucleotide substitutions, deletions and/or insertions that have minimal adverse effect on the antigenicity of the peptide encoded by the mutated sequence relative to the wild-type (non-mutant) sequence or the ability of said peptide to bind antibodies that recognize the full-length native GPR56 polypeptide.

[0074] For producing full-length polypeptides or immunologically active derivatives thereof by recombinant means, a protein-encoding region comprising at least about 15 contiguous nucleotides of the protein-encoding region of SEQ ID NO: 1, or an equivalent region from another GPR56-encoding gene, is placed in operable connection with a promoter or other regulatory sequence capable of regulating expression in a cell-free system or cellular system.

[0075] Reference herein to a “promoter” is to be taken in its broadest context and includes the transcriptional regulatory sequences of a classical genomic gene, including the TATA box which is required for accurate transcription initiation, with or without a CCAAT box sequence and additional regulatory elements (i.e., upstream activating sequences, enhancers and silencers) which alter gene expression in response to developmental and/or external stimuli, or in a tissue-specific manner. In the present context, the term “promoter” is also used to describe a recombinant, synthetic or fusion molecule, or derivative which confers, activates or enhances the expression of a nucleic acid molecule to which it is operably connected, and which encodes the polypeptide or peptide fragment. Preferred promoters can contain additional copies of one or more specific regulatory elements to further enhance expression and/or to alter the spatial expression and/or temporal expression of the said nucleic acid molecule.

[0076] Placing a nucleic acid molecule under the regulatory control of, i.e., “in operable connection with”, a promoter sequence means positioning said molecule such that expression is controlled by the promoter sequence. Promoters are generally positioned 5′ (upstream) to the coding sequence that they control. To construct heterologous promoter/structural gene combinations, it is generally preferred to position the promoter at a distance from the gene transcription start site that is approximately the same as the distance between that promoter and the gene it controls in its natural setting, i.e., the gene from which the promoter is derived. Furthermore, the regulatory elements comprising a promoter are usually positioned within 2 kb of the start site of transcription of the gene. As is known in the art, some variation in this distance can be accommodated without loss of promoter function. Similarly, the preferred positioning of a regulatory sequence element with respect to a heterologous gene to be placed under its control is defined by the positioning of the element in its natural setting, i.e., the genes from which it is derived. Again, as is known in the art, some variation in this distance can also occur.

[0077] The prerequisite for producing intact polypeptides and peptides in bacteria such as E. coli is the use of a strong promoter with an effective ribosome binding site. Typical promoters suitable for expression in bacterial cells such as E. coli include, but are not limited to, the lacz promoter, temperature-sensitive λ_(L) or λ_(R) promoters, T7 promoter or the IPTG-inducible tac promoter. A number of other vector systems for expressing the nucleic acid molecule of the invention in E. coli are well-known in the art and are described, for example, in Ausubel et al (In: Current Protocols in Molecular Biology. Wiley Interscience, ISBN 047150338, 1987) or Sambrook et al (In: Molecular cloning. A laboratory manual, second edition, Cold Spring Harbor Laboratory, Cold Spring Harbor, N.Y., 1989). Numerous plasmids with suitable promoter sequences for expression in bacteria and efficient ribosome binding sites have been described, such as for example, pKC30 (λ_(L): Shimatake and Rosenberg, Nature 292, 128, 1981); pKK173-3 (tac: Amann and Brosius, Gene 40, 183, 1985), pET-3 (T7: Studier and Moffat, J. Mol. Biol. 189, 113, 1986); the pBAD/TOPO or pBAD/Thio-TOPO series of vectors containing an arabinose-inducible promoter (Invitrogen, Carlsbad, Calif.), the latter of which is designed to also produce fusion proteins with thioredoxin to enhance solubility of the expressed protein; the pFLEX series of expression vectors (Pfizer Inc., CT, USA); or the pQE series of expression vectors (Qiagen, CA), amongst others.

[0078] Typical promoters suitable for expression in viruses of eukaryotic cells and eukaryotic cells include the SV40 late promoter, SV40 early promoter and cytomegalovirus (CMV) promoter, CMV IE (cytomegalovirus immediate early) promoter amongst others. Preferred vectors for expression in mammalian cells (eg. 293, COS, CHO, 293T cells) include, but are not limited to, the pcDNA vector suite supplied by Invitrogen, in particular pcDNA 3.1 myc-His-tag comprising the CMV promoter and encoding a C-terminal 6× His and MYC tag; and the retrovirus vector pSRαtkneo (Muller et al., Mol. Cell. Biol., 11, 1785, 1991). The vector pcDNA 3.1 myc-His (Invitrogen) is particularly preferred for expressing a secreted form of GPR56 or a derivative thereof in 293T cells, wherein the expressed peptide or protein can be purified free of conspecific proteins, using standard affinity techniques that employ a Nickel column to bind the protein via the His tag.

[0079] A wide range of additional host/vector systems suitable for expressing GPR56 polypeptides or immunological derivatives thereof are available publicly, and described, for example, in Sambrook et al (In: Molecular cloning. A laboratory manual, second edition, Cold Spring Harbor Laboratory, Cold Spring Harbor, N.Y., 1989).

[0080] Means for introducing the isolated nucleic acid molecule or a gene construct comprising same into a cell for expression are well-known to those skilled in the art. The technique used for a given organism depends on the known successful techniques. Means for introducing recombinant DNA into animal cells include microinjection, transfection mediated by DEAE-dextran, transfection mediated by liposomes such as by using lipofectamine (Gibco, MD, USA) and/or cellfectin (Gibco, MD, USA), PEG-mediated DNA uptake, electroporation and microparticle bombardment such as by using DNA-coated tungsten or gold particles (Agracetus Inc., WI, USA) amongst others.

[0081] For producing mutants, nucleotide insertion derivatives of the protein-encoding region of SEQ ID NO: 1 or an equivalent thereof are produced by making 5′ and 3′ terminal fusions, or by making intra-sequence insertions of single or multiple nucleotides or nucleotide analogues. Insertion nucleotide sequence variants are produced by introducing one or more nucleotides or nucleotide analogues into a predetermined site in the nucleotide sequence of said sequence, although random insertion is also possible with suitable screening of the resulting product being performed. Deletion variants are produced by removing one or more nucleotides from the nucleotide sequence. Substitutional nucleotide variants are produced by substituting at least one nucleotide in the sequence with a different nucleotide or a nucleotide analogue in its place, with the immunologically active derivative encoded therefor having an identical amino acid sequence to a derivative of SEQ ID NO: 2, or only a limited number of amino acid modifications that do not alter its antigenicity compared to the base derivative of SEQ ID NO: 2 or its ability to bind antibodies prepared against the base to a derivative of SEQ ID NO: 2. Such mutant derivatives will preferably have at least 80% identity with the base amino acid sequence from which they are derived (ie. the base derivative of SEQ ID NO: 2).

[0082] Preferred immunologically active derivatives of the full-length GPR56 polypeptide will comprise at least about 5-10 contiguous amino acids of the full-length amino acid sequence, more preferably at least about 10-20 contiguous amino acids in length, and even more preferably 20-30 contiguous amino acids in length.

[0083] For the purposes of producing derivatives using standard peptide synthesis techniques, such as, for example, Fmoc chemistry, a length not exceeding about 30-50 amino acids in length is preferred, as longer peptides are difficult to produce at high efficiency. Longer peptide fragments are readily achieved using recombinant DNA techniques wherein the peptide is expressed in a cell-free or cellular expression system comprising nucleic acid encoding the desired peptide fragment.

[0084] In view of the very high percentage identity between the amino acid sequences of the human GPR56 isoforms exemplified herein, any sufficiently antigenic region of at least about 5-10 amino acid residues in length derived from SEQ ID NO: 1, with the exception of amino acid residues 430-435 which are specific for isoforms GPR56-1, GPR56-2 and GPR56-3, can be used to prepare antibodies that bind generally to human GPR56 polypeptides. In fact, any of the exemplified full-length human GPR56 polypeptides are contemplated to immunologically cross-react. Accordingly, immunologically active derivatives of any one of SEQ ID NOS: 4, 6, or 8 are functionally equivalent to immunologically active derivatives of SEQ ID NO: 2, and thus encompassed by the present invention.

[0085] Preferably, amino acid residues 430-435 of SEQ ID NO: 1 are used for preparing isoform-specific antibodies that bind to human GPR56-1, GPR56-2 and GPR56-3, but not to human GPR56-4 (or to murine GPR56).

[0086] Moreover, the high conservation between the amino acid sequences of the murine and human GPR56 polypeptides exemplified herein also indicates that it is possible to use specific regions of the murine GPR56 polypeptide to produce immunologically active derivatives of SEQ ID NO: 10 that are functionally equivalent to immunologically active derivatives of SEQ ID NO: 2. Such equivalents are clearly encompassed by the present invention.

[0087] Preferred derivatives of human GPR56 (SEQ ID NO: 2) that are absolutely conserved in the amino acid sequences of mammalian GPR56, as shown in FIG. 1, will comprise at least about 5 contiguous amino acid residues in length of a sequence selected from the group consisting of:

[0088] (i) amino acid residues 12-16 of SEQ ID NO: 2;

[0089] (ii) amino acid residues 19-24 of SEQ ID NO: 2;

[0090] (iii) amino acid residues 29-35 of SEQ ID NO: 2;

[0091] (iv) amino acid residues 37-41 of SEQ ID NO: 2;

[0092] (v) amino acid residues 84-94 of SEQ ID NO: 2;

[0093] (vi) amino acid residues 99-103 of SEQ ID NO: 2;

[0094] (vii) amino acid residues 105-109 of SEQ ID NO: 2;

[0095] (viii) amino acid residues 119-123 of SEQ ID NO: 2;

[0096] (ix) amino acid residues 170-177 of SEQ ID NO: 2;

[0097] (x) amino acid residues 192-196 of SEQ ID NO: 2;

[0098] (xi) amino acid residues 206-219 of SEQ ID NO: 2;

[0099] (xii) amino acid residues 227-232 of SEQ ID NO: 2;

[0100] (xiii) amino acid residues 234-240 of SEQ ID NO: 2;

[0101] (xiv) amino acid residues 242-253 of SEQ ID NO: 2;

[0102] (xv) amino acid residues 256-261 of SEQ ID NO: 2;

[0103] (xvi) amino acid residues 273-305 of SEQ ID NO: 2;

[0104] (xvii) amino acid residues 307-322 of SEQ ID NO: 2;

[0105] (xviii) amino acid residues 328-336 of SEQ ID NO: 2;

[0106] (xix) amino acid residues 338-353 of SEQ ID NO: 2;

[0107] (xx) amino acid residues 361-369 of SEQ ID NO: 2;

[0108] (xxi) amino acid residues 373-377 of SEQ ID NO: 2;

[0109] (xxii) amino acid residues 379-392 of SEQ ID NO: 2;

[0110] (xxiii) amino acid residues 398-403 of SEQ ID NO: 2;

[0111] (xxiv) amino acid residues 405-412 of SEQ ID NO: 2;

[0112] (xxv) amino acid residues 414-418 of SEQ ID NO: 2;

[0113] (xxvi) amino acid residues 421-429 of SEQ ID NO: 2;

[0114] (xxvii) amino acid residues 439-475 of SEQ ID NO: 2;

[0115] (xxviii) amino acid residues 4481-486 of SEQ ID NO: 2;

[0116] (xxix) amino acid residues 488-519 of SEQ ID NO: 2;

[0117] (xxx) amino acid residues 522-526 of SEQ ID NO: 2;

[0118] (xxxi) amino acid residues 528-548 of SEQ ID NO: 2;

[0119] (xxxii) amino acid residues 557-570 of SEQ ID NO: 2;

[0120] (xxxiii) amino acid residues 572-584 of SEQ ID NO: 2;

[0121] (xxxiv) amino acid residues 586-601 of SEQ ID NO: 2;

[0122] (xxxv) amino acid residues 607-624 of SEQ ID NO: 2;

[0123] (xxxvi) amino acid residues 626-637 of SEQ ID NO: 2;

[0124] (xxxvii) amino acid residues 639-647 of SEQ ID NO: 2;

[0125] (xxxviii) amino acid residues 649-654 of SEQ ID NO: 2;

[0126] (xxxix) amino acid residues 656-661 of SEQ ID NO: 2;

[0127] (xl) amino acid residues 666-672 of SEQ ID NO: 2;

[0128] (xli) amino acid residues 674-678 of SEQ ID NO: 2; and

[0129] (xlii) amino acid residues 680-693 of SEQ ID NO: 2.

[0130] The present invention clearly extends to any analogs of an isolated nucleic acid encoding GPR56 or an immunologically active derivative of GPR56. By “analog” is meant nucleic acid that encodes GPR56 or a derivative of GPR56 and includes one or more nucleotide or non-nucleotide substituents not normally present in said isolated nucleic acid, such as, for example a carbohydrate, radiochemical, fluorescent molecule, biotin, DIG, alkaline phosphatase, horseradish peroxidase, or other reporter molecule. Preferred reporter molecules include radioactively-labelled nucleotide triphosphates and biotinylated molecules. Analogs are generally produced to facilitate detection of the nucleic acid.

[0131] A second aspect of the present invention clearly extends to an isolated GPR polypeptide, and preferably a GPR56 polypeptide or an immunologically active derivative thereof.

[0132] In a particularly preferred embodiment, the isolated polypeptide of the invention is substantially free of conspecific proteins. Such purity can be assessed by standard procedures, such as, for example, SDS/polyacrylamide gel electrophoresis, 2-dimensional gene electrophoresis, chromatography, amino acid composition analysis, or amino acid sequence analysis.

[0133] To produce isolated GPR56 polypeptides or fragments, standard protein purification techniques may be employed. For example, gel filtration, ion exchange chromatography, reverse phase chromatography, or affinity chromatography, or a combination of any one or more said procedures, may be used. High pressure and low pressure procedures can also be employed, such as, for example, FPLC, or HPLC. To isolate the full-length GPR56 polypeptide, or a fragment thereof comprising more than about 50-100 amino acids in length, it is particularly preferred to express the polypeptide in a suitable cellular expression system in combination with a suitable affinity tag, such as a 6× His tag, and to purify the polypeptide using an affinity step that bonds it via the tag (supra). Optionally, the tag may then be cleaved from the expressed polypeptide.

[0134] Alternatively, for short immunologically active derivatives of the full-length polypeptide, preferably those peptide fragments comprising less than about 50 amino acids in length, chemical synthesis techniques are conveniently used. As will be known to those skilled in the art, such techniques may also produce contaminating peptides that are shorter than the desired peptide, in which case the desired peptide is conveniently purified using reverse phase and/or ion exchange chromatography procedures at high pressure (ie. HPLC or FPLC).

[0135] In a particularly preferred embodiment, the isolated polypeptide of the invention will comprise the amino acid sequence set forth in SEQ ID NO: 2 or an immunologically active derivative thereof.

[0136] A third aspect of the present invention provides a nucleic acid probe for detecting RNA encoding a GPR56 polypeptide in a sample.

[0137] A “nucleic acid probe” is any nucleic acid as hereinbefore defined that is useful for detecting RNA encoding a GPR56 polypeptide or a derivative or analog thereof in a sample. Nucleic acid probes can comprise inosine, adenine, guanine, thymidine, cytidine or uracil residues or functional analogues or derivatives thereof that are capable of being incorporated into a polynucleotide molecule, provided that the resulting probe or primer is capable of hybridizing under at least low stringency conditions to GPR56-encoding RNA or DNA.

[0138] Whilst the probes may comprise double-stranded or single-stranded nucleic acid, single-stranded probes are preferred because they do not require melting prior to use in hybridizations. On the other hand, longer probes are also preferred because they can be used at higher hybridization stringency than shorter probes and may produce lower background hybridization than shorter probes.

[0139] So far as shorter probes are concerned, single-stranded, chemically-synthesized oligonucleotide probes are particularly preferred by the present invention. To reduce the noise associated with the use of such probes during hybridization, the nucleotide sequence of the probe is carefully selected to maximize the Tm at which hybridizations can be performed, reduce non-specific hybridization, and to reduce self-hybridization. Such considerations may be particularly important for applications involving high throughput screening using microarray technology. In general, this means that the nucleotide sequence of an oligonucleotide probe is selected such that it is unique to GPR56 RNA or GPR56 protein-encoding sequence, has a low propensity to form secondary structure, low self-complementary, and is not highly A/T-rich.

[0140] The only requirement for the probes is that they cross-hybridize to nucleic acid encoding GPR56 or the complementary nucleotide sequence thereto and are sufficiently unique in sequence to generate high signal:noise ratios under specified hybridization conditions. As will be known to those skilled in the art, long nucleic acid probes are preferred because they tend to generate higher signal:noise ratios than shorter probes and/or the duplexes formed between longer molecules have higher melting temperatures (i.e. Tm values) than duplexes involving short probes. Accordingly, full-length DNA or RNA probes are contemplated by the present invention, as are specific probes comprising the sequence of the 3′-untranslated region or complementary thereto.

[0141] In a particularly preferred embodiment, the nucleotide sequence of an oligonucleotide probe has no detectable nucleotide sequence identity to a nucleotide sequence in a BLAST search (Altschul et al., J. Mol. Biol. 215, 403-410, 1990) or other database search, other than a sequence selected from the group consisting of: (a) a sequence encoding a human GPR56 polypeptide; (b) the 5′-untranslated region of a sequence encoding a human GPR56 polypeptide; (c) a 3′-untranslated region of a sequence encoding a human GPR56 polypeptide; and (d) an exon region of a sequence encoding a human GPR56 polypeptide.

[0142] Even more preferably, the nucleotide sequence of an oligonucleotide probe has the following properties:

[0143] (i) it comprises less than ten(10) A residues;

[0144] (ii) it comprises less than ten(10) T residues;

[0145] (iii) it comprises less than nine(9) C residues;

[0146] (iv) it comprises less than nine(9) G residues;

[0147] (v) it comprises less than seven(7) A residues in any window consisting of 8 nucleotides;

[0148] (vi) it comprises less than seven(7) T residues in any window consisting of 8 nucleotides;

[0149] (vii) it comprises less than eight(8) C residues in any window consisting of 8 nucleotides;

[0150] (viii) it comprises less than eight(8) G residues in any window consisting of 8 nucleotides;

[0151] (ix) it comprises less than six(6) consecutive A residues;

[0152] (x) it comprises less than six(6) consecutive T residues;

[0153] (xi) it comprises less than five(5) consecutive C residues; and

[0154] (xii) it comprises less than five(5) consecutive G residues.

[0155] Additionally, the self-complementarity of a nucleotide sequence can be determined by aligning the sequence with its reverse complement, wherein detectable regions of identity are indicative of potential self-complementarity. As will be known to those skilled in the art, such sequences may not necessarily form secondary structures during hybridization reaction, and, as a consequence, successfully identify a target nucleotide sequence. It is also known to those skilled in the art that, even where a sequence does form secondary structures during hybridization reactions, reaction conditions can be modified to reduce the adverse consequences of such structure formation. Accordingly, a potential for self-complementarity should not necessarily exclude a particular candidate oligonucleotide from selection. In cases where it is difficult to determine nucleotide sequences having no potential self-complementarity, the uniqueness of the sequence should outweigh a consideration of its potential for secondary structure formation.

[0156] Recommended pre-requisites for selecting oligonucleotide probes, particularly with respect to probes suitable for microarray technology, are described in detail by Lockhart et at., “Expression monitoring by hybridization to high-density oligonucleotide arrays”, Nature Biotech. 14, 1675-1680, 1996.

[0157] The nucleic acid probe may comprise a nucleotide sequence that is within the coding strand of the GPR56-encoding gene (ie. it is comprised within the nucleotide sequence of RNA encoding GPR56). Such “sense” probes are useful for detecting RNA encoding GPR56 by amplification procedures, such as, for example, polymerase chain reaction (PCR), and more preferably, quantitative PCR or reverse transcription polymerase chain reaction (RT-PCR). Alternatively, “sense” probes may be expressed to produce GPR56 polypeptides or immunologically active derivatives thereof that are useful for detecting the expressed GPR56 protein in samples.

[0158] Preferred sense probes for detecting RNA encoding GPR56 comprise a nucleotide sequence selected from the group consisting of:

[0159] (i) a nucleotide sequence having at least 80% identity to SEQ ID NO: 1;

[0160] (ii) a nucleotide sequence comprising nucleotide residues 131-1400 of SEQ ID NO: 1 or a sequence having 80% identity thereto;

[0161] (iii) a nucleotide sequence comprising nucleotide residues 1423-2239 of SEQ ID NO: 1 or a sequence having 80% identity thereto;

[0162] (iv) a nucleotide sequence comprising nucleotide residues 2264-2282 of SEQ ID NO: 1 or a sequence having 80% identity thereto;

[0163] (v) a nucleotide sequence comprising at least 20 contiguous nucleotides of any one of (i) through (iv); and

[0164] (vi) an analog of any one of (i) through (v) as herein before defined.

[0165] More particularly, a sense probe will comprise a nucleotide sequence selected from the group consisting of:

[0166] (i) the sequence set forth in SEQ ID NO: 11;

[0167] (ii) the sequence set forth in SEQ ID NO: 12; and

[0168] (iii) the sequence set forth in SEQ ID NO: 13,

[0169] Alternatively, within the antisense strand of said gene (i.e. it is complementary to RNA encoding GPR56). Such “antisense” probes are useful for directly hybridizing to RNA encoding GPR56, or alternatively, for detecting RNA encoding GPR56 by amplification, as described supra (eg. quantitative PCR or RT-PCR).

[0170] Particularly preferred antisense probes comprise a nucleotide sequence selected from the group consisting of:

[0171] (vii) a nucleotide sequence that is complementary to a sequence having at least 80% identity to SEQ ID NO: 1;

[0172] (viii) a nucleotide sequence that is complementary to nucleotide residues 131-1400 of SEQ ID NO: 1 or a sequence having 80% identity thereto;

[0173] (ix) a nucleotide sequence that is complementary to nucleotide residues 1423-2239 of SEQ ID NO: 1 or a sequence having 80% identity thereto;

[0174] (x) a nucleotide sequence that is complementary to nucleotide residues 2264-2282 of SEQ ID NO: 1 or a sequence having 80% identity thereto;

[0175] (xi) a nucleotide sequence comprising at least 20 contiguous nucleotides of any one of (i) through (iv); and

[0176] (xii) an analog of any one of (i) through (v) as herein before defined.

[0177] Particularly preferred antisense nucleic acid probes in accordance with this embodiment of the invention comprise a nucleotide sequence selected from SEQ ID NO: 14, SEQ ID NO: 15, SEQ ID NO: 16, SEQ ID NO: 17, SEQ ID NO: 18, and SEQ ID NO: 19.

[0178] In another embodiment of the invention, the nucleic acid is an antagonist of GPR56 expression, such as, for example, an antisense nucleic acid, peptide nucleic acid (PNA), ribozyme, or interfering RNA, which is complementary, in whole or in part, to a target molecule comprising a sense strand, and can hybridize with the target molecule, in particular, GPR56-encoding RNA. When introduced into a cell using suitable methods, such a nucleic acid inhibits the expression of the GPR56 gene encoded by the sense strand. Antisense nucleic acid, ribozymes (eg. Cech et al., U.S. Ser. No. 4,987,071; Cech et al., U.S. Ser. No. 5,116,742; Bartel and Szostak, Science 261, 1411-1418, 1993), nucleic acid capable of forming a triple helix (eg. Helene, Anticancer Drug Res. 6, 569-584, 1991), PNAs (Hyrup et al., Bioorganic & Med. Chem. 4, 5-23, 1996; O'Keefe et al., Proc. Natl Acad. Sci. USA 93, 14670-14675, 1996), or interfering RNAs may be produced by standard techniques known to the skilled artisan, based upon the sequences disclosed herein.

[0179] Preferably, the antisense nucleic acid, ribozyme, PNA, or interfering RNA, comprises a sequence that is complementary to at least about 20 contiguous nucleotides of a sequence having at least about 80% identity to SEQ ID NO: 1 (ie. It is complementary to GPR56 RNA) and can hybridize thereto. For example, such antagonistic nucleic acid can be complementary to a target nucleic acid having the sequence of SEQ ID NO: 1 or a portion thereof sufficient to allow hybridization. Longer molecules, comprising a sequence that is complementary to at least about 25, or 30, or 35, or 40, or 45, or 50 contiguous nucleotides of GPR56 RNA are also encompassed by the present invention.

[0180] Antisense nucleic acids, ribozymes, PNAs, or interfering RNAs, are useful for a variety of purposes, including research and therapeutic applications.

[0181] For example, a construct comprising an antisense nucleic acid, ribozyme, PNA, or interfering RNA, can be introduced into a suitable cell to inhibit GPR56 expression and/or activity therein. Such a cell provides a valuable control cell, for instance in assessing the specificity of the GPR56 receptor-ligand interaction with the parent cell or other related cell types. In another embodiment, such a construct can be introduced into some or all of the cells of a mammal. The antisense nucleic acid, ribozyme, PNA, or interfering RNA, inhibits receptor expression, and any cancer, hyperproliferative or inflammatory process mediated by GPR56 receptors in the cells containing the construct are inhibited. Thus, a cancer, hyperproliferative response, inflammatory process, or inflammatory disease or condition, can be treated using an antisense nucleic acid, ribozyme, PNA, or interfering RNA, of the present invention.

[0182] Antibodies that can inhibit one or more functions characteristic of a GPR56 protein, such as a binding activity, a signalling activity, and/or stimulation of a cellular response, are also encompassed by the present invention. In one embodiment, antibodies of the present invention can inhibit binding of a ligand (i.e., one or more ligands) to a mammalian GPR56 protein and/or can inhibit one or more functions mediated by a mammalian GPR56 protein in response to ligand binding. In a particularly preferred embodiment, the antibodies can inhibit (reduce or prevent) the interaction of receptor with a natural ligand.

[0183] Accordingly, a fourth aspect of the invention provides a probe comprising an antibody that binds to a GPR56 polypeptide of the invention.

[0184] Preferred antibodies will selectively bind to a GPR56 polypeptide or an immunological derivative thereof and will not bind, or will only bind weakly, to non-GPR56 polypeptides or peptides.

[0185] Anti-GPR56 antibodies that are particularly contemplated by the present invention include monoclonal and polyclonal antibodies as well as fragments thereof comprising the antigen-binding domain and/or one or more complementarity determining regions of the native antibody. As used herein, the term “antibody fragment” shall be taken to mean a portion of the variable region of the immunoglobulin molecule that binds to its target, i.e., the antigen-binding region.

[0186] For some applications, it may be desirable to generate antibodies that specifically react with a particular human GPR56 isoform, in which case an epitope comprising amino acid residues 430-435 may be used as the antigen of choice to elicit antibody production.

[0187] Preferred antibodies for use in diagnostic imaging are those which react with an epitope in an extracellular region of the GPR56 polypeptide as expressed in a cancer cell. Such antibodies may be generated by using the complete human GPR56 polypeptide (SEQ ID NO: 2) as an immunogen. Alternatively, a peptide fragment derived from a predicted extracellular domain thereof, can be used. In this regard, the region of the of the polypeptide that is N-terminal to the first transmembrane domain, or a peptide fragment thereof, may be selected and screened for its ability to elicit the production of extracellular-specific anti-GPR56 antibodies using standard immunoassays, such as, for example, ELISA.

[0188] The anti-GPR56 antibodies of the invention may be particularly useful in diagnostic and prognostic assays for cancer, particularly the early or later detection of ovarian cancer or a metastasis thereof (eg. metastases in the omentum), by standard immunoassay or imaging methodologies. Similarly, such antibodies may be useful diagnosis and/or prognosis of any cancer in which GPR56 is expressed at a level that differs from normal or healthy tissue, such as, for example, prostate cancer.

[0189] Conventional methods can be used to prepare the antibodies. For example, by using an isolated GPR56 polypeptide or immunologically active derivative thereof, polyclonal antisera or monoclonal antibodies can be made using standard methods. For example, a mammal, (e.g., a mouse, hamster, or rabbit) can be immunized with the polypeptide or peptide to elicit an antibody response in the mammal. Techniques for conferring immunogenicity on a polypeptide include conjugation to carriers, or other techniques well known in the art. For example, the polypeptide can be administered in the presence of adjuvant or can be coupled to a carrier molecule known in the art, that enhances the immunogenicity of the polypeptide. The progress of immunization can be monitored by detection of antibody titres in plasma or serum. Standard ELISA or other immunoassay can be used to assess the titer of antibodies produced. Following immunization, antisera are obtained and, for example, IgG molecules corresponding to the polyclonal antibodies can be isolated from the antisera.

[0190] To produce monoclonal antibodies, antibody producing cells (lymphocytes) can be harvested from an animal immunized with the polypeptide or peptide, and fused with myeloma cells by standard somatic cell fusion procedures, thus immortalizing those cells and yielding hybridoma cells. Such techniques are well known in the art, for example, the hybridoma technique originally developed by Kohler and Milstein Nature 256: 495-499, 1975, as well as other techniques such as the human B-cell hybridoma technique (Kozbor et al., Immunol. Today 4: 72, 1983), the EBV-hybridoma technique to produce human monoclonal antibodies (Cole et al., In: Monoclonal antibodies in cancer therapy, Alan R. Bliss Inc., pp 77-96, 1985), and screening of combinatorial antibody libraries (Huse et al., Science 246, 1275-1281, 1989). Hybridoma cells are isolated and screened immunochemically for production of antibodies that are specifically reactive with the polypeptide and monoclonal antibodies isolated therefrom.

[0191] As with all immunogenic compositions for eliciting antibodies, the immunogenically effective amounts of the peptides of the invention must be determined empirically. Factors to be considered include the immunogenicity of the native polypeptide, whether or not the polypeptide will be complexed with or covalently attached to an adjuvant or carrier protein or other carrier, the route of administration for the composition, i.e., intravenous, intramuscular, subcutaneous, etc., and the number of immunizing doses to be administered. Such factors are known in the vaccine art and it is well within the skill of immunologists to make such determinations without undue experimentation.

[0192] The term “antibody” as used herein, is intended to include fragments thereof which are also specifically reactive with a polypeptide that mimics or cross-reacts with a B-cell epitope of a GPR56 polypeptide. Antibodies can be fragmented using conventional techniques and the fragments screened for utility in the same manner as described above for whole antibodies. For example, F(ab′)₂ fragments can be generated by treating antibody with pepsin. The resulting F(ab′)₂ fragment can be treated to reduce disulfide bridges to produce Fab′ fragments.

[0193] It is within the scope of this invention to include any secondary antibodies (monoclonal, polyclonal or fragments of antibodies), including anti-idiotypic antibodies, directed to the first mentioned antibodies discussed above. Both the first and second antibodies can be used in detection assays or a first antibody can be used with a commercially available anti-immunoglobulin antibody.

[0194] A further aspect of the present invention provides methods for detecting a cancer cell in a subject, said method comprising determining the level of GPR56-encoding nucleic acid or a GPR56 polypeptide in a sample of said subject.

[0195] As exemplified herein, GPR56-encoding mRNA is abundant in several cancer cell types, such as, for example, selected from the group consisting of prostate, omentum, ovary, liver, placenta, and brain, as determined by the appearance of RNA encoding said polypeptide in those tissues. Additionally, a positive correlation has been found between the over-expression of GPR56-encoding RNA in ovaries or omentum of ovarian cancer patients, and the occurrence of ovarian cancer and metastases thereof. Accordingly, the diagnostic methods described herein for the detection of GPR56-encoding nucleic acid or GPR56 polypeptides or a derivative thereof in a sample are particularly useful for the diagnosis or prognosis of ovarian cancer or a metastasis thereof.

[0196] The present inventors have also found that GPR56 is expressed only in a subset of memory T cells having immediate effector function. Such T cells lack the CCR7 receptor and are characterized further by rapid production of IFN-γ, IL-4, IL-5, or, in the case of CD8⁺ memory T cells, perforin granules. Additionally, effector memory T cells are characterized by their expression of tissue-specific homing receptors and receptors for inflammatory cytokines. The combination of rapid effector function and receptors that promote migration to peripheral sites suggests that CCR7⁻ memory T cells play a role in immediate responses to re-infection (Tussey et al., Eur. J. Immunol. 30, 1823-1829, 2000). The determination of GPR56 as a marker for such effector memory T cells indicates that GPR56 probes can be used to assist in the isolation of effector memory T cells and/or to determine the strength of an immune response of an individual to a particular antigenic determinant. For example, enhanced T cell-specific GPR56 expression in the serum of an individual, or at a particular site of inflammation, is indicative of enhanced effector memory T cells in said serum or at said inflammation site.

[0197] It will be apparent from the preceding discussion that many of the diagnostic methods provided by the present invention involve a degree of quantification to determine, on the one hand, the over-expression of GPR56 in tissue that is suspected of comprising a cancer cell, or, on the other hand, an enhanced number of effector memory T cells. Such quantification can be readily provided by the inclusion of appropriate control samples in the assays described below, derived from healthy or normal individuals. Alternatively, if internal controls are not included in each assay conducted, the control may be derived from an established data set that has been generated from healthy or normal individuals.

[0198] In the present context, the term “healthy individual” shall be taken to mean an individual who is known not to suffer from cancer, such knowledge being derived from clinical data on the individual, including, but not limited to, a different cancer assay to that described herein. As the present invention is particularly useful for the early detection of cancer, it is preferred that the healthy individual is asymptomatic with respect to the early symptoms associated with a particular cancer. In the case of ovarian cancer, early detection using well-known procedures is difficult, however reduced urinary frequency, rectal pressure, and abdominal bloating and swelling, are associated with the disease in its early stages, and, as a consequence, healthy individuals should not have any of these symptoms. Clearly, subjects suffering from later symptoms associated with ovarian cancer, such as, for example, metastases in the omentum, abdominal fluid, lymph nodes, lung, liver, brain, or bone, and subjects suffering from spinal cord compression, elevated calcium level, chronic pain, or pleural effusion, should also be avoided from the “healthy individual” data set.

[0199] The term “normal individual” shall be taken to mean an individual having a normal level of GPR56 expression in a particular sample derived from said individual. As will be known to those skilled in the art, data obtained from a sufficiently large sample of the population will normalize, allowing the generation of a data set for determining the average level of a particular parameter. Accordingly, the level of expression of GPR56 can be determined for any population of individuals, and for any sample derived from said individual, for subsequent comparison to GPR56 levels determined for a sample being assayed. Where such normalized data sets are relied upon, internal controls are preferably included in each assay conducted to control for variation.

[0200] It will also be apparent the detection of an effector memory T cell per se requires no such internal or external control, because GPR56 expression is restricted to a T cell sub-population comprising effector memory T cells.

[0201] In one embodiment, the present invention provides a method for detecting a cancer cell in a subject, said method comprising:

[0202] (i) determining the level of GPR56 mRNA expressed in a test sample from said subject; and

[0203] (ii) comparing the level of GPR56 mRNA determined at (i) to the level of GPR56 mRNA expressed in a comparable sample from a healthy or normal individual,

[0204] wherein a level of GPR56 mRNA at (i) that is enhanced in the test sample relative to the comparable sample from the normal or healthy individual is indicative of the presence of a cancer cell in said subject.

[0205] By “GPR56 mRNA” is meant mRNA encoding a GPR56 polypeptide that has at least about 80% identity to SEQ ID NO: 2, and, more particularly, mRNA comprising a nucleotide sequence that has at least about 80% identity, more preferably at least about 95% identity, and still more preferably at least about 99% identity to the nucleotide sequence set forth in SEQ ID NO: 1.

[0206] As discussed in detail below, the status of GPR56 mRNA in patient samples may be analyzed by a variety protocols that are well known in the art including in situ hybridization, northern blotting techniques, RT-PCR analysis (such as, for example, performed on laser capture microdissected samples), and microarray technology, such as, for example, using tissue microarrays probed with nucleic acid probes, or nucleic acid microarrays (ie. RNA microarrays or amplified DNA microarrays) microarrays probed with nucleic acid probes. All such assay formats are encompassed by the present invention.

[0207] For high throughput screening of large numbers of samples, such as, for example, public health screening of subjects, particularly human subjects, having a higher risk of developing cancer, microarray technology is a preferred assay format.

[0208] In a preferred embodiment, the level of GPR56 mRNA in the test sample is determined by hybridizing a GPR56 probe to GPR56-encoding RNA in the test sample under at least low stringency hybridization conditions and detecting the hybridization using a detection means.

[0209] Similarly, the level of GPR56 mRNA in the comparable sample from the healthy or normal individual is preferably determined by hybridizing a GPR56 probe to GPR56-encoding RNA in said comparable sample under at least low stringency hybridization conditions and detecting the hybridization using a detection means.

[0210] Preferably, the sample comprises ovarian tissue, prostate tissue, kidney tissue, uterine tissue, placenta, a cervical specimen, omentum, rectal tissue, brain tissue, bone tissue, lung tissue, lymphatic tissue, urine, semen, blood, abdominal fluid, or serum, or a cell preparation or nucleic acid preparation derived therefrom. More preferably, the sample comprises serum or abdominal fluid, or a tissue selected from the group consisting of: ovary, lymph, lung, liver, brain, placenta, brain, omentum, and prostate. Even more preferably, the sample comprises serum or abdominal fluid, ovary (eg. OSE), or lymph node tissue. The sample can be prepared on a solid matrix for histological analyses, or alternatively, in a suitable solution such as, for example, an extraction buffer or suspension buffer, and the present invention clearly extends to the testing of biological solutions thus prepared.

[0211] The GPR56 probe may be any nucleic acid probe described herein above. As will be known to those skilled in the art, shorter probes are hybridized at lower stringency hybridization (ie. reduced temperature and/or higher salt concentration and/or higher detergent concentration) than longer nucleic acid probes. Generally, hybridization is carried out well below the calculated melting temperature (Tm) of a DNA duplex comprising the probe. Riboprobes are particularly preferred for applications utilizing oligonucleotides as RNA/RNA duplexes are more stable. For example, the oligonucleotide probes exemplified herein have calculated Tm values in the range of about 55° C. to about 60° C., suggesting that hybridization involving such probes should be carried out at a temperature in the range of ambient temperature to about 45° C., and more preferably between about 40° C. to about 45° C. (ie. low stringency to moderate stringency conditions). This contrasts with standard hybridization temperatures of about 65° C. for nucleic acid probes of about 100 nucleotides or longer (ie. moderate to high stringency hybridization conditions).

[0212] For the purposes of defining the level of stringency to be used in these diagnostic assays, a low stringency is defined herein as being a hybridization and/or a wash carried out in 6×SSC buffer, 0.1% (wlv) SDS at 28° C., or equivalent conditions. A moderate stringency is defined herein as being a hybridization and/or washing carried out in 2×SSC buffer, 0.1% (w/v) SDS at a temperature in the range 45° C. to 65° C., or equivalent conditions. A high stringency is defined herein as being a hybridization and/or wash carried out in 0.1×SSC buffer, 0.1% (w/v) SDS, or lower salt concentration, and at a temperature of at least 65° C., or equivalent conditions. Reference herein to a particular level of stringency encompasses equivalent conditions using wash/hybridization solutions other than SSC known to those skilled in the art.

[0213] Generally, the stringency is increased by reducing the concentration of SSC buffer, and/or increasing the concentration of SDS and/or increasing the temperature of the hybridization and/or wash. Those skilled in the art will be aware that the conditions for hybridization and/or wash may vary depending upon the nature of the hybridization matrix used to support the sample RNA, or the type of hybridization probe used.

[0214] In general, the sample or the probe is immobilized on a solid matrix or surface (e.g., nitrocellulose). For high throughput screening, the sample or probe will generally comprise an array of nucleic acids on glass or other solid matrix, such as, for example, as described in WO 96/17958. Techniques for producing high density arrays are described, for example, by Fodor et al., Science 767-773, 1991, and in U.S. Pat. No. 5,143,854. Typical protocols for other assay formats can be found, for example in Current Protocols In Molecular Biology, Unit 2 (Northern Blotting), Unit 4 (Southern Blotting), and Unit 18 (PCR Analysis), Frederick M. Ausubul et al. (ed)., 1995.

[0215] The detection means according to this aspect of the invention may be any nucleic acid-based detection means such as, for example, nucleic acid hybridization or amplification reaction (eg. PCR), a nucleic acid sequence-based amplification (NASBA) system, inverse polymerase chain reaction (iPCR), in situ polymerase chain reaction, or reverse transcription polymerase chain reaction (RT-PCR), amongst others.

[0216] The probe can be labelled with a reporter molecule capable of producing an identifiable signal (e.g., a radioisotope such as ³²P or ³⁵S, or a fluorescent or biotinylated molecule). According to this embodiment, those skilled in the art will be aware that the detection of said reporter molecule provides for identification of the probe and that, following the hybridization reaction, the detection of the corresponding nucleotide sequences in the sample is facilitated. Additional probes can be used to confirm the assay results obtained using a single probe.

[0217] Wherein the detection means is an amplification reaction such as, for example, a polymerase chain reaction or a nucleic acid sequence-based amplification (NASBA) system or a variant thereof, one or more nucleic acid probes molecules of at least about 20 contiguous nucleotides in length is hybridized to mRNA encoding GPR56, or alternatively, hybridized to cDNA or cRNA produced from said mRNA, and nucleic acid copies of the template are enzymically-amplified.

[0218] Those skilled in the art will be aware that there must be a sufficiently high percentage of nucleotide sequence identity between the probes and the RNA sequences in the sample template molecule for hybridization to occur. As stated previously, the stringency conditions can be selected to promote hybridization.

[0219] In one format, PCR provides for the hybridization of non-complementary probes to different strands of a double-stranded nucleic acid template molecule (ie. a DNA/RNA, RNA/RNA or DNA/DNA template), such that the hybridized probes are positioned to facilitate the 5′-to 3′ synthesis of nucleic acid in the intervening region, under the control of a thermostable DNA polymerase enzyme. In accordance with this embodiment, one sense probe and one antisense probe as described herein would be used to amplify DNA from the hybrid RNA/DNA template or cDNA.

[0220] In the present context, the cDNA would generally be produced by reverse transcription of mRNA present in the sample being tested (ie. RT-PCR). RT-PCR is particularly useful when it is desirable to determine expression of a GPR56-encoding gene. It is also known to those skilled in the art to use mRNA/DNA hybrid molecules as a template for such amplification reactions, and, as a consequence, first strand cDNA synthesis is all that is required to be performed prior to the amplification reaction.

[0221] Variations of the embodiments described herein are described in detail by McPherson et al., PCR: A Practical Approach. (series eds, D. Rickwood and B. D. Hames), IRL Press Limited, Oxford. pp 1-253, 1991.

[0222] The amplification reaction detection means described supra can be further coupled to a classical hybridization reaction detection means to further enhance sensitivity and specificity of the inventive method, such as by hybridizing the amplified DNA with a probe which is different from any of the probes used in the amplification reaction.

[0223] Similarly, the hybridization reaction detection means described supra can be further coupled to a second hybridization step employing a probe which is different from the probe used in the first hybridization reaction.

[0224] The comparison to be performed in accordance with the present invention may be a visual comparison of the signal generated by the probe, or alternatively, a comparison of data integrated from the signal, such as, for example, data that have been corrected or normalized to allow for variation between samples. Such comparisons can be readily performed by those skilled in the art.

[0225] In an alternative embodiment, the present invention provides a method for determining an effector memory T cell response in a subject, said method comprising:

[0226] (i) determining the level of GPR56 mRNA expressed in a test sample from said subject; and

[0227] (ii) comparing the level of GPR56 mRNA determined at (i) to the level of GPR56 mRNA expressed in a comparable sample from a healthy or normal individual,

[0228] wherein a level of GPR56 mRNA at (i) that is enhanced in the test sample relative to the comparable sample from the normal or healthy individual is indicative of an effector memory T cell response in the subject.

[0229] In an alternative embodiment, the present invention provides a method for determining whether or not a subject has been re-infected with an infectious agent, said method comprising:

[0230] (i) determining the level of GPR56 mRNA expressed in a test sample from said subject; and

[0231] (ii) comparing the level of GPR56 mRNA determined at (i) to the level of GPR56 mRNA expressed in a comparable sample from a healthy or normal individual,

[0232] wherein a level of GPR56 mRNA at (i) that is enhanced in the test sample relative to the comparable sample from the normal or healthy individual is indicative of re-infection in the subject.

[0233] This embodiment of the invention is readily performed using the assay formats described supra. Preferably, the test sample is blood or whole serum or a fraction thereof comprising T cells, such as, for example, buffy coat. Other tissues, such as those described supra are not excluded.

[0234] In an alternative embodiment, the present invention provides a method for determining the presence of effector memory T cells in a test sample, said method comprising:

[0235] (i) hybridizing a GPR56 probe to GPR56-encoding RNA in the test sample under at least low stringency hybridization conditions; and

[0236] (ii) detecting the hybridization using a detection means,

[0237] wherein said hybridization is indicative of the presence of an effector memory T cell in said test sample.

[0238] This embodiment of the invention is readily performed using the assay formats described supra, however no external or internal control, and no comparison is required, to perform this embodiment of the invention.

[0239] A further embodiment of the invention provides a process for counting effector memory T cells in a subject comprising for determining the presence of effector memory T cells in a test sample as described herein and normalizing the hybridization signal to determine T cell count.

[0240] The status of GPR56 gene expression in a subject may be also be determined at the protein level, using the peptides and antibodies described herein above, in combination with a variety protocols that are well known in the art, including immunohistochemical analysis, western blot analysis, ELISA or other immunoassay, and microarray technology, such as, for example, using tissue microarrays probed with antibodies. As with nucleic acid screens, high throughput screening is preferred for large numbers of samples.

[0241] Accordingly, a further embodiment of the invention provides a method for detecting a cancer cell in a subject, said method comprising:

[0242] (i) determining the level of a GPR56 polypeptide in a test sample from said subject; and

[0243] (ii) comparing the level of GPR56 polypeptide determined at (i) to the level of said GPR56 polypeptide in a comparable sample from a healthy or normal individual,

[0244] wherein a level of said GPR56 polypeptide at (i) that is enhanced in the test sample relative to the comparable sample from the normal or healthy individual is indicative of the presence of a cancer cell in said subject.

[0245] By “GPR56 polypeptide” is meant a polypeptide that comprises an amino acid sequence having at least about 80% identity to SEQ ID NO: 2, more preferably at least about 95% identity, and still more preferably at least about 99% identity to the sequence set forth in SEQ ID NO: 2.

[0246] Preferably, the subject is human. Samples from the subject will be those samples that are suitable for screening using nucleic acid probes, however histological specimens are particularly amenable to antibody-based detection.

[0247] In an alternative embodiment, the present invention provides a method for determining whether or not a subject has been re-infected with an infectious agent, said method comprising:

[0248] (iii) determining the level of a GPR56 polypeptide in a test sample from said subject; and

[0249] (iv) comparing the level of the GPR56 polypeptide determined at (i) to the level of said GPR56 polypeptide in a comparable sample from a healthy or normal individual,

[0250] wherein a level of said GPR56 polypeptide at (i) that is enhanced in the test sample relative to the comparable sample from the normal or healthy individual is indicative of re-infection in the subject.

[0251] Preferably, the test sample used in performing this embodiment of the invention is blood or whole serum or a fraction thereof comprising T cells, such as, for example, buffy coat. Other tissues, such as those described supra are not excluded.

[0252] Preferably, the level of GPR56 polypeptide in the test sample is determined by a process comprising:

[0253] (i) contacting said sample with an antibody that binds to a GPR56 polypeptide under conditions sufficient for binding to occur; and

[0254] (ii) determining the binding.

[0255] Similarly, the level of GPR56 mRNA in the comparable sample from the healthy or normal individual is preferably determined by a process comprising:

[0256] (i) contacting said sample with an antibody that binds to a GPR56 polypeptide under conditions sufficient for binding to occur; and

[0257] (ii) determining the binding.

[0258] Standard assays are used to determine binding of the antibody to the GPR56 polypeptide in the samples, such as, for example, ELISA, radioimmunoassay, western blot immunoassay, amongst others. Protocols are provided, for example, by Ausubel et al (supra).

[0259] In an alternative embodiment, the present invention provides a method for determining the presence of effector memory T cells in a test sample, said method comprising:

[0260] (i) contacting said sample with an antibody that binds to a GPR56 polypeptide under conditions sufficient for binding to occur; and

[0261] (ii) determining the binding.

[0262] wherein binding of the antibody to the test sample is indicative of the presence of an effector memory T cell in said test sample.

[0263] A further embodiment of the invention provides a process for counting effector memory T cells in a subject comprising for determining the presence of effector memory T cells in a test sample as described herein and normalizing the antibody binding signal, such as, for example, a signal in an ELISA assay or radio immunoassay that is provided by the reporter (ie. second antibody conjugated to horseradish peroxidase, alkaline phosphatase, or I¹²⁵-label, amongst others) to determine T cell count.

[0264] Modulation of GPR56 function according to the present invention, through the inhibition or promotion of at least one function characteristic of a mammalian GPR56 protein, provides an effective and selective way of inhibiting or promoting receptor-mediated functions. As GPR56 is selectively expressed on effector memory T cells, mammalian GPR56 proteins provide a target for selectively interfering with or promoting effector memory T cell function in a mammal, such as a human. Once lymphocytes are recruited to a site, other leukocyte types, such as monocytes, may be recruited by secondary signals. Thus, agents which inhibit or promote GPR56 function, including ligands, inhibitors and/or promoters, such as those identified as described herein, can be used to modulate leukocyte function (e.g., leukocyte infiltration including recruitment and/or accumulation), particularly of lymphocytes, for therapeutic purposes.

[0265] In one aspect, the present invention provides a method of inhibiting or promoting an inflammatory response in an individual in need of such therapy, comprising administering an agent which inhibits or promotes mammalian GPR56 function to an individual in need of such therapy. In one embodiment, a compound which inhibits one or more functions of a mammalian GPR56 protein (e.g., a human GPR56) is administered to inhibit (i.e., reduce or prevent) inflammation. For example, anti-GPR56 antibodies of the present invention, or antagonistic nucleic acid (antisense nucleic acid, PNA, interfering RNA, ribozyme, etc) can be used in the method. As a result, one or more hyperproliferative disorders, inflammatory processes, such as leukocyte emigration, chemotaxis, exocytosis (e.g., of enzymes) or inflammatory mediator release, is inhibited. For example, leukocytic infiltration of inflammatory sites (e.g., in a delayed-type hypersensitivity response) can be inhibited according to the present method.

[0266] In a further embodiment, a compound that inhibits one or more functions of a mammalian GPR56 protein (e.g., a human GPR56) is administered to prevent, inhibit, or delay tumor growth, particularly in the treatment of carcinoma, such as, for example, an epitehlial carcinoma, and more particularly, in the case of ovarian cancer or a metastasis thereof. For example, anti-GPR56 antibodies of the present invention, or antagonistic nucleic acid (antisense nucleic acid, PNA, interfering RNA, ribozyme, etc) can be used in the method.

[0267] In another embodiment, an agent (e.g., receptor agonist) which promotes one or more functions of a mammalian GPR56 protein (e.g., a human GPR56) is administered to induce (trigger or enhance) an inflammatory response, such as leukocyte emigration, chemotaxis, exocytosis (e.g., of enzymes) or inflammatory mediator release, resulting in the beneficial stimulation of inflammatory processes. For example, natural killer cells can be recruited to combat viral infections or neoplastic disease.

[0268] The term “individual” is defined herein to include animals such as mammals, including, but not limited to, primates (e.g., humans), cows, sheep, goats, horses, dogs, cats, rabbits, guinea pigs, rats, mice or other bovine, ovine, equine, canine, feline, rodent or murine species. Diseases and conditions associated with inflammation, infection, and cancer can be treated using the method. In a preferred embodiment, the disease or condition is one in which the actions of lymphocytes, particularly effector memory T cells, are to be inhibited or promoted for therapeutic (including prophylactic) purposes. In a particularly preferred embodiment, the inflammatory disease or condition is a T cell-mediated disease or condition.

[0269] Diseases or conditions, including chronic diseases, of humans or other species which can be treated with inhibitors of GPR56 function, include, but are not limited to: inflammatory or allergic diseases and conditions, including systemic anaphylaxis or hypersensitivity responses, drug allergies (e.g., to penicillin, cephalosporins), insect sting allergies; inflammatory bowel diseases, such as Crohn's disease, ulcerative colitis, ileitis and enteritis; vaginitis; psoriasis and inflammatory dermatoses such as dermatitis, eczema, atopic dermatitis, allergic contact dermatitis, urticaria; vasculitis (e.g., necrotizing, cutaneous, and hypersensitivity vasculitis); spondyloarthropathies; scleroderma; respiratory allergic diseases such as asthma, allergic rhinitis, hypersensitivity lung diseases, hypersensitivity pneumonitis, interstitial lung diseases (ILD) (e.g., idiopathic pulmonary fibrosis, or ILD associated with rheumatoid arthritis, or other autoimmune conditions); autoimmune diseases, such as arthritis (e.g., rheumatoid arthritis, psoriatic arthritis), multiple sclerosis, systemic lupus erythematosus, myasthenia gravis, diabetes, including diabetes mellitus and juvenile onset diabetes, glomerulonephritis and other nephritides, autoimmune thyroiditis, Behcet's disease; graft rejection (e.g., in transplantation), including allograft rejection or graft-versus-host disease; other diseases or conditions in which undesirable inflammatory responses are to be inhibited can be treated, including, but not limited to, atherosclerosis, cytokine-induced toxicity, myositis (including polymyositis, dermatomyositis).

[0270] Diseases or conditions of humans or other species which can be treated with agonists of GPR56 function, include, but are not limited to: diseases in which angiogenesis or neovascularization plays a role, including neoplastic disease, retinopathy (e.g., diabetic retinopathy), and macular degeneration; infectious diseases, such as bacterial infections and tuberculoid leprosy, and especially viral infections; immunosuppression, such as that in individuals with immunodeficiency syndromes such as AIDS, individuals undergoing radiation therapy, chemotherapy, or other therapy which causes immunosuppression; immunosuppression due congenital deficiency in receptor function or other causes; and re-infection. Agonists of GPR56 function can also have protective effects useful to combat stem cell depletion during cancer chemotherapy (Sarris, A. H. et al., J. Exp. Med., 178, 1127-1132, 1993).

[0271] According to the method, one or more agents can be administered to the host by an appropriate route, either alone or in combination with another drug. An effective amount of a nucleic acid or antibody agent having antagonist or agonist activity is administered. An effective amount is an amount sufficient to achieve the desired therapeutic or prophylactic effect, under the conditions of administration, such as an amount sufficient for inhibition or promotion of GPR56 receptor function, and thereby, inhibition or promotion, respectively, of a receptor-mediated process (e.g., an inflammatory response).

[0272] A variety of routes of administration are possible including, but not necessarily limited to oral, dietary, topical, parenteral (e.g., intravenous, intraarterial, intramuscular, subcutaneous injection), and inhalation (e.g., intrabronchial, intranasal or oral inhalation, intranasal drops) routes of administration, depending on the agent and disease or condition to be treated. For respiratory allergic diseases such as asthma, inhalation is a preferred mode of administration.

[0273] Formulation of an agent to be administered will vary according to the route of administration selected (e.g., solution, emulsion, capsule). An appropriate composition comprising the agent to be administered can be prepared in a physiologically acceptable vehicle or carrier. For solutions or emulsions, suitable carriers include, for example, aqueous or alcoholic/aqueous solutions, emulsions or suspensions, including saline and buffered media. Parenteral vehicles can include sodium chloride solution, Ringer's dextrose, dextrose and sodium chloride, lactated Ringer's or fixed oils, for instance. Intravenous vehicles can include various additives, preservatives, or fluid, nutrient or electrolyte replenishers and the like (See, generally, Remington's Pharmaceutical Sciences, 17th Edition, Mack Publishing Co., Pa., 1985). For inhalation, the agent can be solubilized and loaded into a suitable dispenser for administration (e.g., an atomizer, nebulizer or pressurized aerosol dispenser).

[0274] Furthermore, where the agent is a protein or peptide, the agent can be administered via in vivo expression of the recombinant protein. In vivo expression can be accomplished via somatic cell expression according to suitable methods (see, e.g. U.S. Pat. No. 5,399,346). In this embodiment, nucleic acid encoding the protein can be incorporated into a retroviral, adenoviral or other suitable vector (preferably, a replication deficient infectious vector) for delivery, or can be introduced into a transfected or transformed host cell capable of expressing the protein for delivery. In the latter embodiment, the cells can be implanted (alone or in a barrier device), injected or otherwise introduced in an amount effective to express the protein in a therapeutically effective amount.

[0275] The present invention is further described by the following non-limiting Examples.

EXAMPLE 1

[0276] Isolation of a cDNA Encoding GPR56 and Characterization of Homologous GPR56-Encoding Sequences in Mammals

[0277] Degenerate oligonucleotides corresponding to conserved regions within the human Glucagon-like peptide receptor (GLP1) family were used to amplify specific DNA sequences from a variety of cDNA libraries. DNA from human hypothalamus and heart yielded fragments of the expected size for generating libraries. These fragments were subcloned and sequenced. One fragment, 456 bp long, revealed a novel 7 TM receptor sequence distantly related to the secretin receptor family.

[0278] A human heart cDNA library (Stratagene) was screened by standard hybridization using the fragment supra, under high stringency conditions. Two positive hybridizing clones were identified, of 1 and 2.9 kb in size, respectively. Nucleotide sequence analysis revealed that the longer clone contains an open reading frame of 2079 nucleotides encoding a 693 amino acid long protein (designated GPR56 or TSR32). The nucleotide and putative amino acid sequence of this clone is provided in SEQ ID NOS: 1 and 2, respectively.

[0279] A search of the EMBL/GenBank database revealed low but significant sequence similarities between SEQ ID NO: 2 and polypeptides of the secretin receptor family of 7 TM receptors. In particular, the percentage identity between SEQ ID NO: 2 and other 7 TM polypeptides was only about 25% to 35%, and homology was limited to the transmembrane region. The highest overall sequence similarity was found to four other G-protein coupled receptor subtypes, the human epididymis-specific HE6 (31% identity), the human lymphocyte antigen CD97 (33% identity), the orphan human receptor EMR1 (27% identity), the insect DHR (26% identity) and the rat latrophilin-related protein 1 precursor (35% identity) all of which share a large extracellular domain with numerous putative O- and N-glycosylation sites. Except for DHR, in all of the receptors there is a cysteine motif preceding the first transmembrane domain. Further, in contrast to the CD97 and EMR1 receptors, TSR32 does not contain any EGF-domains or calcium binding sites in the extracellular domain.

[0280] Interestingly, at the gene level the exon/intron organization of the TSR32-encoding cDNA, at least within the region encoding the transmembrane domain, is most similar to the gene structure of the PACAP receptor family, with fewer but identical exon/intron borders.

[0281] Subsequent BLAST searching revealed homologs of the originally-isolated GPR56-encoding cDNA clone (ie. homologs of SEQ ID NOS: 1 and 2). In particular, using the default parameters of the BLAST program at the NCBI database, three additional GPR56-encoding nucleotide sequences from humans or human cell lines were identified, having about 99% identity to SEQ ID NO: 1. The different human GPR56 alleles have been designated as GPR56-1, GPR56-2, GPR56-3, and GPR56-4, with GPR56-1 being the originally-isolated sequence. The nucleotide sequences of GPR56-2, GPR56-3, and GPR56-4 are set forth in SEQ ID NOS: 3, 5, and 7, respectively.

[0282] The GPR56 polypeptides encoded by these homologs, which are set forth in SEQ ID NOS: 4, 6, and 8, are also highly conserved with the amino acid sequence set forth in SEQ ID NO: 2, as evidenced by the alignment shown in FIG. 1. In particular, the amino acid sequences of GPR56-1 (SEQ ID NO: 2) and GPR56-3 (SEQ ID NO: 6) are 100% identical, and GPR56-2 (SEQ ID NO: 4) differs from this isoform only by the conservative substitution of Gln306 for His306. In contrast, the amino acid sequence of GPR56-4 (SEQ ID NO: 8) comprises a six amino acid deletion at positions 430-435 relative to the other two isoforms. These data indicate the existence of a small multigene family encoding GPR56 in humans.

[0283] Additionally, BLAST searching using the default parameters of the BLAST program at the NCBI database has revealed a murine homolog of human GPR56-1 that is about 83% identical thereto over its entire length. The nucleotide sequence of the murine GPR56-encoding gene is set forth in SEQ ID NO: 9 and the derived amino acid sequence is set forth in SEQ ID NO: 10. Alignment of the amino acid sequence of the murine and human genes (FIG. 1) reveals that the murine sequence also comprises the same amino acid deletion present in human GPR56-4, and is most highly identical to that isoform.

EXAMPLE 2

[0284] Expression Analysis of the GPR56 Gene

[0285] Northern and expression microarray analyses indicates a low level of expression of human GPR56 mRNA in a large variety of tissues including thyroid, prostate, ovary, omentum, kidney, lung, cerebellum, and heart. The highest level of GPR56 mRNA was found in the thyroid gland. This expression pattern of the receptor mRNA indicates that GPR56 has important functions in metabolic regulations throughout the body, possibly mediated via the thyroid gland.

[0286] Additionally, the human GPR56 homologs, GPR56-2, and GPR56-4, were isolated as cDNAs from placental choriocarcinoma cells and brain anaplastic oligodendroglioma, indicating that GPR56 is also expressed in the placenta and brain.

[0287] Similarly, the murine GPR56 was isolated from hemopoietic cells of mice.

[0288] The gene encoding GPR56 has been mapped to human chromosome 16q31 using in situ hybridization. This localization has been confirmed by radiation hybrid analysis. An autosomal recessive disorder (Bardet Biedi Syndrome; Kwitek-Black, A. E. et al., Nature Genetics 5:392-396, 1993) has also been linked to this region. Features of this syndrome include obesity, retinal degeneration, hypogonadism and mental retardation. The expression of GPR56 examined by in situ hybridization and Northern analysis overlaps strongly with the tissues affected in the Bardet Biedl Syndrome making GPR56 a good candidate for this locus.

EXAMPLE 3

[0289] Identification of Unique Nucleic Acid Probes for Detecting GPR56 mRNA

[0290] The nucleotide sequence set forth in SEQ ID NO: 1 was analyzed by the criteria described herein above to identify suitable probes for use in diagnostic applications relating to the expression or over-expression of GPR56 mRNA. In particular, analysis was limited to sequences comprising about 20-30 contiguous nucleotides of SEQ ID NO: 1.

[0291] In particular, SEQ ID NO: 1 was subjected to a BLAST search (Altschul et al., J. Mol. Biol. 215, 403-410, 1990), and the alignments that were generated were analyzed to identify regions within the entire sequence that were not present in genes other than human GPR56-encoding genes.

[0292] The nucleotide sequences of unique regions within SEQ ID NO: 1 were also analyzed for such 20-mer to 30-mer regions that satisfied the following criteria:

[0293] (i) it comprises less than ten(10) A residues;

[0294] (ii) it comprises less than ten(10) T residues;

[0295] (iii) it comprises less than nine(9) C residues;

[0296] (iv) it comprises less than nine(9) G residues;

[0297] (v) it comprises less than seven(7) A residues in any window consisting of 8 nucleotides;

[0298] (vi) it comprises less than seven(7) T residues in any window consisting of 8 nucleotides;

[0299] (vii) it comprises less than eight(8) C residues in any window consisting of 8 nucleotides;

[0300] (viii) it comprises less than eight(8) G residues in any window consisting of 8 nucleotides;

[0301] (ix) it comprises less than six(6) consecutive A residues;

[0302] (x) it comprises less than six(6) consecutive T residues;

[0303] (xi) it comprises less than five(5) consecutive C residues; and

[0304] (xii) it comprises less than five(5) consecutive G residues.

[0305] Furthermore, the self-complementarity of those unique sequences satisfying the above criteria was assessed, by aligning each sequence with its reverse complement.

[0306] Suitable nucleotide sequences were identified as being potentially useful probes, and these are set forth in Table 1 (SEQ ID NOS: 11-19).

EXAMPLE 4

[0307] Restriction of GPR56 Gene Expression in T Cells to Effector Memory (ie. CCR7⁻) T Cells

[0308] Introduction

[0309] T cells are at the heart of the adaptive immune response. Our ability to combat pathogenic infections depends to a large extent on the ability of our immune system to remember past infections. This phenomenon is known as immunological memory. Although well recognized and the principal behind vaccinations we still understand the process of immunological memory very poorly. A typical primary immune response would involve activation and clonal expansion of antigen-specific T cells and differentiation into effector T cells. While most of these effector cells are short-lived and will die shortly after the antigen is cleared, a few antigen-experienced cells persist for a longer-time and are known as memory cells which confer long term protection. It is still unclear whether memory cells arise from fully differentiated effector cells or through a separate pathway.

[0310] Memory T cells can be divided into two broad categories on the basis of their is activation status and expression of chemokine receptor CCR7. CCR7 controls homing to secondary lymphoid organs. CCR7⁻ memory T cells (effector memory) which express receptors for migration to sites of inflammation and possess immediate effector functions. On the other hand, CCR7⁺ memory T cells (central memory) express receptors for homing to lymph nodes and are in a quiescent state lacking immediate effector functions. GPR56 gene expression was compared in the two memory subsets using Affymetrix microarray technology.

[0311] Experimental Methods

[0312] 3. Cell Isolation

[0313] Peripheral blood was collected from a volunteer and peripheral blood mononuclear cells (PBMC) were isolated using Ficoll density centrigugation. These cells were then enriched using RosetteSep kit as per manufacturer's instructions. Enriched cells were labeled with fluorescent antibodies CD4 FITC (marker for T helper subset of T cells), CCR7 PE (lymphoid tissue homing receptor) and CD45RO APC (marker for memory T cells). Labeled cells were then sorted into two distinct populations using FACS Star cell sorter. Total RNA was isolated from cells using the Rneasy Total RNA Isolation kit (Qiagen) as per manufacturer's instructions.

[0314] 4. Preparation of cRNA and GeneChip Hybridization

[0315] cDNA was specifically transcribed from the poly-A mRNA using a poly-T nucleotide primer, containing a T7 RNA polymerase promoter (GeneWorks, Australia). Biotinylated, antisense target cRNA was subsequently synthesized by in vitro transcription, using the Enzo BioArray High Yield RNA Transcript Labeling kit. The biotin-labeled target cRNA was then fragmented, and used to prepare a hybridization cocktail, which included probe array controls and blocking agents. This cocktail was initially hybridized to test arrays to evaluate the quality of the cRNA, and then to U95A arrays containing approximately 12,000 human genes for expression analysis. Washing and staining of the hybridized probe array were performed by an automated fluidics station, according to the manufacturer's protocols. The stained array was then scanned and the resultant image captured as a data image file.

[0316] 5. Data Analysis

[0317] From data image files, gene transcript levels were determined using algorithms in the GeneChip Analysis Suit software (Affymetrix). The expression levels of all genes on the array set were compared between type 1 and type 2 cells, with differences of 2-fold or larger likely to reflect significant changes in gene expression. Genes that showed a change of 2-fold or greater in at least two separate experiments were considered as differentially expressed. Each probe was assigned a call of present (expressed) or absent (not expressed) using Affymetrix decision matrix.

[0318] 6. Results

[0319] Results were analyzed using Affymetrix software. We identified a large number of genes differentially expressed between central and effector memory subsets of T cells. GPR56 was specifically expressed by effector memory cells whereas CCR7 was expressed on central memory T cells (data not provided).

EXAMPLE 5

[0320] Association between GPR56 Expression and Ovarian Cancer or Metastases Thereof

[0321] GeneChips were prepared and hybridized to labeled single-strand probes prepared from ovary or omentum RNA, using standard procedures. The RNA samples were either from a number of healthy subjects, or from a number of subjects having ovarian cancer at various stages of the disease, including those subjects having early symptoms of ovarian cancer, or alternatively, metastases in the omentum. Samples from subjects having cancer of the prostate cancer were also analyzed (data not shown).

[0322] Data shown in FIG. 2 indicate that there is a significant enhancement of GPR56 expression detected in subjects having early stage or advanced ovarian cancer, relative to healthy subjects. The level of enhancement of GPR56 expression in subjects having cancer is at least about 6-fold.

[0323] High levels of expression are also seen in the omentum of ovarian cancer patients having secondary tumors of the omentum, relative to the level present in normal omentum tissue subjects (FIG. 2).

[0324] Similarly, high levels of expression were observed in subjects having prostate cancer (not shown).

1 20 1 2822 DNA Human GPR56-1(TSR32) CDS (163)..(2241) 1 cggcagcagg gtctcgctct gtcacacagg ctggagtgca gtggtgtgat cttggctcat 60 cgtaacctcc acctcccggg ttcaagtgat tctcatgcct cagcctcccg agtagctggg 120 attacaggtg gtgacttcca agagtgactc cgtcggagga aa atg act ccc cag 174 Met Thr Pro Gln 1 tcg ctg ctg cag acg aca ctg ttc ctg ctg agt ctg ctc ttc ctg gtc 222 Ser Leu Leu Gln Thr Thr Leu Phe Leu Leu Ser Leu Leu Phe Leu Val 5 10 15 20 caa ggt gcc cac ggc agg ggc cac agg gaa gac ttt cgc ttc tgc agc 270 Gln Gly Ala His Gly Arg Gly His Arg Glu Asp Phe Arg Phe Cys Ser 25 30 35 cag cgg aac cag aca cac agg agc agc ctc cac tac aaa ccc aca cca 318 Gln Arg Asn Gln Thr His Arg Ser Ser Leu His Tyr Lys Pro Thr Pro 40 45 50 gac ctg cgc atc tcc atc gag aac tcc gaa gag gcc ctc aca gtc cat 366 Asp Leu Arg Ile Ser Ile Glu Asn Ser Glu Glu Ala Leu Thr Val His 55 60 65 gcc cct ttc cct gca gcc cac cct gct tcc cga tcc ttc cct gac ccc 414 Ala Pro Phe Pro Ala Ala His Pro Ala Ser Arg Ser Phe Pro Asp Pro 70 75 80 agg ggc ctc tac cac ttc tgc ctc tac tgg aac cga cat gct ggg aga 462 Arg Gly Leu Tyr His Phe Cys Leu Tyr Trp Asn Arg His Ala Gly Arg 85 90 95 100 tta cat ctt ctc tat ggc aag cgt gac ttc ttg ctg agt gac aaa gcc 510 Leu His Leu Leu Tyr Gly Lys Arg Asp Phe Leu Leu Ser Asp Lys Ala 105 110 115 tct agc ctc ctc tgc ttc cag cac cag gag gag agc ctg gct cag ggc 558 Ser Ser Leu Leu Cys Phe Gln His Gln Glu Glu Ser Leu Ala Gln Gly 120 125 130 ccc ccg ctg tta gcc act tct gtc acc tcc tgg tgg agc cct cag aac 606 Pro Pro Leu Leu Ala Thr Ser Val Thr Ser Trp Trp Ser Pro Gln Asn 135 140 145 atc agc ctg ccc agt gcc gcc agc ttc acc ttc tcc ttc cac agt cct 654 Ile Ser Leu Pro Ser Ala Ala Ser Phe Thr Phe Ser Phe His Ser Pro 150 155 160 ccc cac acg gcc gct cac aat gcc tcg gtg gac atg tgc gag ctc aaa 702 Pro His Thr Ala Ala His Asn Ala Ser Val Asp Met Cys Glu Leu Lys 165 170 175 180 agg gac ctc cag ctg ctc agc cag ttc ctg aag cat ccc cag aag gcc 750 Arg Asp Leu Gln Leu Leu Ser Gln Phe Leu Lys His Pro Gln Lys Ala 185 190 195 tca agg agg ccc tcg gct gcc ccc gcc agc cag cag ttg cag agc ctg 798 Ser Arg Arg Pro Ser Ala Ala Pro Ala Ser Gln Gln Leu Gln Ser Leu 200 205 210 gag tcg aaa ctg acc tct gtg aga ttc atg ggg gac atg gtg tcc ttc 846 Glu Ser Lys Leu Thr Ser Val Arg Phe Met Gly Asp Met Val Ser Phe 215 220 225 gag gag gac cgg atc aac gcc acg gta tgg aag ctc cag ccc aca gcc 894 Glu Glu Asp Arg Ile Asn Ala Thr Val Trp Lys Leu Gln Pro Thr Ala 230 235 240 ggc ctc cag gac ctg cac atc cac tcc cgg cag gag gag gag cag agc 942 Gly Leu Gln Asp Leu His Ile His Ser Arg Gln Glu Glu Glu Gln Ser 245 250 255 260 gag atc atg gag tac tcg gtg ctg ctg cct cga aca ctc ttc cag agg 990 Glu Ile Met Glu Tyr Ser Val Leu Leu Pro Arg Thr Leu Phe Gln Arg 265 270 275 acg aaa ggc cgg agc ggg gag gct gag aag aga ctc ctc ctg gtg gac 1038 Thr Lys Gly Arg Ser Gly Glu Ala Glu Lys Arg Leu Leu Leu Val Asp 280 285 290 ttc agc agc caa gcc ctg ttc cag gac aag aat tcc agc caa gtc ctg 1086 Phe Ser Ser Gln Ala Leu Phe Gln Asp Lys Asn Ser Ser Gln Val Leu 295 300 305 ggt gag aag gtc ttg ggg att gtg gta cag aac acc aaa gta gcc aac 1134 Gly Glu Lys Val Leu Gly Ile Val Val Gln Asn Thr Lys Val Ala Asn 310 315 320 ctc acg gag ccc gtg gtg ctc act ttc cag cac cag cta cag ccg aag 1182 Leu Thr Glu Pro Val Val Leu Thr Phe Gln His Gln Leu Gln Pro Lys 325 330 335 340 aat gtg act ctg caa tgt gtg ttc tgg gtt gaa gac ccc aca ttg agc 1230 Asn Val Thr Leu Gln Cys Val Phe Trp Val Glu Asp Pro Thr Leu Ser 345 350 355 agc ccg ggg cat tgg agc agt gct ggg tgt gag acc gtc agg aga gaa 1278 Ser Pro Gly His Trp Ser Ser Ala Gly Cys Glu Thr Val Arg Arg Glu 360 365 370 acc caa aca tcc tgc ttc tgc aac cac ttg acc tac ttt gca gtg ctg 1326 Thr Gln Thr Ser Cys Phe Cys Asn His Leu Thr Tyr Phe Ala Val Leu 375 380 385 atg gtc tcc tcg gtg gag gtg gac gcc gtg cac aag cac tac ctg agc 1374 Met Val Ser Ser Val Glu Val Asp Ala Val His Lys His Tyr Leu Ser 390 395 400 ctc ctc tcc tac gtg ggc tgt gtc gtc tct gcc ctg gcc tgc ctt gtc 1422 Leu Leu Ser Tyr Val Gly Cys Val Val Ser Ala Leu Ala Cys Leu Val 405 410 415 420 acc att gcc gcc tac ctc tgc tcc agg gtg ccc ctg ccg tgc agg agg 1470 Thr Ile Ala Ala Tyr Leu Cys Ser Arg Val Pro Leu Pro Cys Arg Arg 425 430 435 aaa cct cgg gac tac acc atc aag gtg cac atg aac ctg ctg ctg gcc 1518 Lys Pro Arg Asp Tyr Thr Ile Lys Val His Met Asn Leu Leu Leu Ala 440 445 450 gtc ttc ctg ctg gac acg agc ttc ctg ctc agc gag ccg gtg gcc ctg 1566 Val Phe Leu Leu Asp Thr Ser Phe Leu Leu Ser Glu Pro Val Ala Leu 455 460 465 aca ggc tct gag gct ggc tgc cga gcc agt gcc atc ttc ctg cac ttc 1614 Thr Gly Ser Glu Ala Gly Cys Arg Ala Ser Ala Ile Phe Leu His Phe 470 475 480 tcc ctg ctc acc tgc ctt tcc tgg atg ggc ctc gag ggg tac aac ctc 1662 Ser Leu Leu Thr Cys Leu Ser Trp Met Gly Leu Glu Gly Tyr Asn Leu 485 490 495 500 tac cga ctc gtg gtg gag gtc ttt ggc acc tat gtc cct ggc tac cta 1710 Tyr Arg Leu Val Val Glu Val Phe Gly Thr Tyr Val Pro Gly Tyr Leu 505 510 515 ctc aag ctg agc gcc atg ggc tgg ggc ttc ccc atc ttt ctg gtg acg 1758 Leu Lys Leu Ser Ala Met Gly Trp Gly Phe Pro Ile Phe Leu Val Thr 520 525 530 ctg gtg gcc ctg gtg gat gtg gac aac tat ggc ccc atc atc ttg gct 1806 Leu Val Ala Leu Val Asp Val Asp Asn Tyr Gly Pro Ile Ile Leu Ala 535 540 545 gtg cat agg act cca gag ggc gtc atc tac cct tcc atg tgc tgg atc 1854 Val His Arg Thr Pro Glu Gly Val Ile Tyr Pro Ser Met Cys Trp Ile 550 555 560 cgg gac tcc ctg gtc agc tac atc acc aac ctg ggc ctc ttc agc ctg 1902 Arg Asp Ser Leu Val Ser Tyr Ile Thr Asn Leu Gly Leu Phe Ser Leu 565 570 575 580 gtg ttt ctg ttc aac atg gcc atg cta gcc acc atg gtg gtg cag atc 1950 Val Phe Leu Phe Asn Met Ala Met Leu Ala Thr Met Val Val Gln Ile 585 590 595 ctg cgg ctg cgc ccc cac acc caa aag tgg tca cat gtg ctg aca ctg 1998 Leu Arg Leu Arg Pro His Thr Gln Lys Trp Ser His Val Leu Thr Leu 600 605 610 ctg ggc ctc agc ctg gtc ctt ggc ctg ccc tgg gcc ttg atc ttc ttc 2046 Leu Gly Leu Ser Leu Val Leu Gly Leu Pro Trp Ala Leu Ile Phe Phe 615 620 625 tcc ttt gct tct ggc acc ttc cag ctt gtc gtc ctc tac ctt ttc agc 2094 Ser Phe Ala Ser Gly Thr Phe Gln Leu Val Val Leu Tyr Leu Phe Ser 630 635 640 atc atc acc tcc ttc caa ggc ttc ctc atc ttc atc tgg tac tgg tcc 2142 Ile Ile Thr Ser Phe Gln Gly Phe Leu Ile Phe Ile Trp Tyr Trp Ser 645 650 655 660 atg cgg ctg cag gcc cgg ggt ggc ccc tcc cct ctg aag agc aac tca 2190 Met Arg Leu Gln Ala Arg Gly Gly Pro Ser Pro Leu Lys Ser Asn Ser 665 670 675 gac tgc gcc agg ctc ccc atc agc tcg ggc agc acc tcg tcc agc cgc 2238 Asp Cys Ala Arg Leu Pro Ile Ser Ser Gly Ser Thr Ser Ser Ser Arg 680 685 690 atc taggcctcca gcccacctgc ccatgtgatg aagcagagat gcggcctcgt 2291 Ile cgcacactgc ctgtggcccc cgagccaggc ccagccccag gccagtcagc cgcagacttt 2351 ggaaagccca acgaccatgg agagatgggc cgttgccatg gtggacggac tcccggggct 2411 ggggcttttg aattggcctt ggggactact cggctctcac tcagctccca cgggactcag 2471 aagtgcgccg ccatgctgcc tagggtactg tccccacatc tgtcccaacc cagctggagg 2531 cctggtctct ccttacaacc cctgggccca gcctcattgc tgggggccag gccttggatc 2591 ttgagggtct ggcacatcct taatcctgtg cccctgcctg ggacagaaat gtggctccag 2651 ttgctctgtc tctcgtggtc accctgaggg cactctgcat cctctgtcat tttaacctca 2711 ggtggcaccc agggcgaatg gggcccaggg cagaccttca gggccagagc cctggcggag 2771 gagaggccct ttgccaggag cacagcagca gctcgcctac ctctgagccc g 2822 2 693 PRT Human GPR56-1(TSR32) 2 Met Thr Pro Gln Ser Leu Leu Gln Thr Thr Leu Phe Leu Leu Ser Leu 1 5 10 15 Leu Phe Leu Val Gln Gly Ala His Gly Arg Gly His Arg Glu Asp Phe 20 25 30 Arg Phe Cys Ser Gln Arg Asn Gln Thr His Arg Ser Ser Leu His Tyr 35 40 45 Lys Pro Thr Pro Asp Leu Arg Ile Ser Ile Glu Asn Ser Glu Glu Ala 50 55 60 Leu Thr Val His Ala Pro Phe Pro Ala Ala His Pro Ala Ser Arg Ser 65 70 75 80 Phe Pro Asp Pro Arg Gly Leu Tyr His Phe Cys Leu Tyr Trp Asn Arg 85 90 95 His Ala Gly Arg Leu His Leu Leu Tyr Gly Lys Arg Asp Phe Leu Leu 100 105 110 Ser Asp Lys Ala Ser Ser Leu Leu Cys Phe Gln His Gln Glu Glu Ser 115 120 125 Leu Ala Gln Gly Pro Pro Leu Leu Ala Thr Ser Val Thr Ser Trp Trp 130 135 140 Ser Pro Gln Asn Ile Ser Leu Pro Ser Ala Ala Ser Phe Thr Phe Ser 145 150 155 160 Phe His Ser Pro Pro His Thr Ala Ala His Asn Ala Ser Val Asp Met 165 170 175 Cys Glu Leu Lys Arg Asp Leu Gln Leu Leu Ser Gln Phe Leu Lys His 180 185 190 Pro Gln Lys Ala Ser Arg Arg Pro Ser Ala Ala Pro Ala Ser Gln Gln 195 200 205 Leu Gln Ser Leu Glu Ser Lys Leu Thr Ser Val Arg Phe Met Gly Asp 210 215 220 Met Val Ser Phe Glu Glu Asp Arg Ile Asn Ala Thr Val Trp Lys Leu 225 230 235 240 Gln Pro Thr Ala Gly Leu Gln Asp Leu His Ile His Ser Arg Gln Glu 245 250 255 Glu Glu Gln Ser Glu Ile Met Glu Tyr Ser Val Leu Leu Pro Arg Thr 260 265 270 Leu Phe Gln Arg Thr Lys Gly Arg Ser Gly Glu Ala Glu Lys Arg Leu 275 280 285 Leu Leu Val Asp Phe Ser Ser Gln Ala Leu Phe Gln Asp Lys Asn Ser 290 295 300 Ser Gln Val Leu Gly Glu Lys Val Leu Gly Ile Val Val Gln Asn Thr 305 310 315 320 Lys Val Ala Asn Leu Thr Glu Pro Val Val Leu Thr Phe Gln His Gln 325 330 335 Leu Gln Pro Lys Asn Val Thr Leu Gln Cys Val Phe Trp Val Glu Asp 340 345 350 Pro Thr Leu Ser Ser Pro Gly His Trp Ser Ser Ala Gly Cys Glu Thr 355 360 365 Val Arg Arg Glu Thr Gln Thr Ser Cys Phe Cys Asn His Leu Thr Tyr 370 375 380 Phe Ala Val Leu Met Val Ser Ser Val Glu Val Asp Ala Val His Lys 385 390 395 400 His Tyr Leu Ser Leu Leu Ser Tyr Val Gly Cys Val Val Ser Ala Leu 405 410 415 Ala Cys Leu Val Thr Ile Ala Ala Tyr Leu Cys Ser Arg Val Pro Leu 420 425 430 Pro Cys Arg Arg Lys Pro Arg Asp Tyr Thr Ile Lys Val His Met Asn 435 440 445 Leu Leu Leu Ala Val Phe Leu Leu Asp Thr Ser Phe Leu Leu Ser Glu 450 455 460 Pro Val Ala Leu Thr Gly Ser Glu Ala Gly Cys Arg Ala Ser Ala Ile 465 470 475 480 Phe Leu His Phe Ser Leu Leu Thr Cys Leu Ser Trp Met Gly Leu Glu 485 490 495 Gly Tyr Asn Leu Tyr Arg Leu Val Val Glu Val Phe Gly Thr Tyr Val 500 505 510 Pro Gly Tyr Leu Leu Lys Leu Ser Ala Met Gly Trp Gly Phe Pro Ile 515 520 525 Phe Leu Val Thr Leu Val Ala Leu Val Asp Val Asp Asn Tyr Gly Pro 530 535 540 Ile Ile Leu Ala Val His Arg Thr Pro Glu Gly Val Ile Tyr Pro Ser 545 550 555 560 Met Cys Trp Ile Arg Asp Ser Leu Val Ser Tyr Ile Thr Asn Leu Gly 565 570 575 Leu Phe Ser Leu Val Phe Leu Phe Asn Met Ala Met Leu Ala Thr Met 580 585 590 Val Val Gln Ile Leu Arg Leu Arg Pro His Thr Gln Lys Trp Ser His 595 600 605 Val Leu Thr Leu Leu Gly Leu Ser Leu Val Leu Gly Leu Pro Trp Ala 610 615 620 Leu Ile Phe Phe Ser Phe Ala Ser Gly Thr Phe Gln Leu Val Val Leu 625 630 635 640 Tyr Leu Phe Ser Ile Ile Thr Ser Phe Gln Gly Phe Leu Ile Phe Ile 645 650 655 Trp Tyr Trp Ser Met Arg Leu Gln Ala Arg Gly Gly Pro Ser Pro Leu 660 665 670 Lys Ser Asn Ser Asp Cys Ala Arg Leu Pro Ile Ser Ser Gly Ser Thr 675 680 685 Ser Ser Ser Arg Ile 690 3 3711 DNA human GPR56-2 CDS (168)..(2246) 3 ggcacgaggt ggagggtctc gctctgtcac acaggctgga gtgcagtggt gtgatcttgg 60 ctcatcgtaa cctccacctc ccgggttcaa gtgattctca tgcctcagcc tcccgagtag 120 ctgggattac aggtggtgac ttccaagagt gactccgtcg gaggaaa atg act ccc 176 Met Thr Pro 1 cag tcg ctg ctg cag acg aca ctg ttc ctg ctg agt ctg ctc ttc ctg 224 Gln Ser Leu Leu Gln Thr Thr Leu Phe Leu Leu Ser Leu Leu Phe Leu 5 10 15 gtc caa ggt gcc cac ggc agg ggc cac agg gaa gac ttt cgc ttc tgc 272 Val Gln Gly Ala His Gly Arg Gly His Arg Glu Asp Phe Arg Phe Cys 20 25 30 35 agc cag cgg aac cag aca cac agg agc agc ctc cac tac aaa ccc aca 320 Ser Gln Arg Asn Gln Thr His Arg Ser Ser Leu His Tyr Lys Pro Thr 40 45 50 cca gac ctg cgc atc tcc atc gag aac tcc gaa gag gcc ctc aca gtc 368 Pro Asp Leu Arg Ile Ser Ile Glu Asn Ser Glu Glu Ala Leu Thr Val 55 60 65 cat gcc cct ttc cct gca gcc cac cct gct tcc cga tcc ttc cct gac 416 His Ala Pro Phe Pro Ala Ala His Pro Ala Ser Arg Ser Phe Pro Asp 70 75 80 ccc agg ggc ctc tac cac ttc tgc ctc tac tgg aac cga cat gct ggg 464 Pro Arg Gly Leu Tyr His Phe Cys Leu Tyr Trp Asn Arg His Ala Gly 85 90 95 aga tta cat ctt ctc tat ggc aag cgt gac ttc ttg ctg agt gac aaa 512 Arg Leu His Leu Leu Tyr Gly Lys Arg Asp Phe Leu Leu Ser Asp Lys 100 105 110 115 gcc tct agc ctc ctc tgc ttc cag cac cag gag gag agc ctg gct cag 560 Ala Ser Ser Leu Leu Cys Phe Gln His Gln Glu Glu Ser Leu Ala Gln 120 125 130 ggc ccc ccg ctg tta gcc act tct gtc acc tcc tgg tgg agc cct cag 608 Gly Pro Pro Leu Leu Ala Thr Ser Val Thr Ser Trp Trp Ser Pro Gln 135 140 145 aac atc agc ctg ccc agt gcc gcc agc ttc acc ttc tcc ttc cac agt 656 Asn Ile Ser Leu Pro Ser Ala Ala Ser Phe Thr Phe Ser Phe His Ser 150 155 160 cct ccc cac acg gcc gct cac aat gcc tcg gtg gac atg tgc gag ctc 704 Pro Pro His Thr Ala Ala His Asn Ala Ser Val Asp Met Cys Glu Leu 165 170 175 aaa agg gac ctc cag ctg ctc agc cag ttc ctg aag cat ccc cag aag 752 Lys Arg Asp Leu Gln Leu Leu Ser Gln Phe Leu Lys His Pro Gln Lys 180 185 190 195 gcc tca agg agg ccc tcg gct gcc ccc gcc agc cag cag ttg cag agc 800 Ala Ser Arg Arg Pro Ser Ala Ala Pro Ala Ser Gln Gln Leu Gln Ser 200 205 210 ctg gag tcg aaa ctg acc tct gtg aga ttc atg ggg gac atg gtg tcc 848 Leu Glu Ser Lys Leu Thr Ser Val Arg Phe Met Gly Asp Met Val Ser 215 220 225 ttc gag gag gac cgg atc aac gcc acg gtg tgg aag ctc cag ccc aca 896 Phe Glu Glu Asp Arg Ile Asn Ala Thr Val Trp Lys Leu Gln Pro Thr 230 235 240 gcc ggc ctc cag gac ctg cac atc cac tcc cgg cag gag gag gag cag 944 Ala Gly Leu Gln Asp Leu His Ile His Ser Arg Gln Glu Glu Glu Gln 245 250 255 agc gag atc atg gag tac tcg gtg ctg ctg cct cga aca ctc ttc cag 992 Ser Glu Ile Met Glu Tyr Ser Val Leu Leu Pro Arg Thr Leu Phe Gln 260 265 270 275 agg acg aaa ggc cgg agc ggg gag gct gag aag aga ctc ctc ctg gtg 1040 Arg Thr Lys Gly Arg Ser Gly Glu Ala Glu Lys Arg Leu Leu Leu Val 280 285 290 gac ttc agc agc caa gcc ctg ttc cag gac aag aat tcc agc cac gtc 1088 Asp Phe Ser Ser Gln Ala Leu Phe Gln Asp Lys Asn Ser Ser His Val 295 300 305 ctg ggt gag aag gtc ttg ggg att gtg gta cag aac acc aaa gta gcc 1136 Leu Gly Glu Lys Val Leu Gly Ile Val Val Gln Asn Thr Lys Val Ala 310 315 320 aac ctc acg gag ccc gtg gtg ctc acc ttc cag cac cag cta cag ccg 1184 Asn Leu Thr Glu Pro Val Val Leu Thr Phe Gln His Gln Leu Gln Pro 325 330 335 aag aat gtg act ctg caa tgt gtg ttc tgg gtt gaa gac ccc aca ttg 1232 Lys Asn Val Thr Leu Gln Cys Val Phe Trp Val Glu Asp Pro Thr Leu 340 345 350 355 agc agc ccg ggg cat tgg agc agt gct ggg tgt gag acc gtc agg aga 1280 Ser Ser Pro Gly His Trp Ser Ser Ala Gly Cys Glu Thr Val Arg Arg 360 365 370 gaa acc caa aca tcc tgc ttc tgc aac cac ttg acc tac ttt gca gtg 1328 Glu Thr Gln Thr Ser Cys Phe Cys Asn His Leu Thr Tyr Phe Ala Val 375 380 385 ctg atg gtc tcc tcg gtg gag gtg gac gcc gtg cac aag cac tac ctg 1376 Leu Met Val Ser Ser Val Glu Val Asp Ala Val His Lys His Tyr Leu 390 395 400 agc ctc ctc tcc tac gtg ggc tgt gtc gtc tct gcc ctg gcc tgc ctt 1424 Ser Leu Leu Ser Tyr Val Gly Cys Val Val Ser Ala Leu Ala Cys Leu 405 410 415 gtc acc att gcc gcc tac ctc tgc tcc agg gtg ccc ctg ccg tgc agg 1472 Val Thr Ile Ala Ala Tyr Leu Cys Ser Arg Val Pro Leu Pro Cys Arg 420 425 430 435 agg aaa cct cgg gac tac acc atc aag gtg cac atg aac ctg ctg ctg 1520 Arg Lys Pro Arg Asp Tyr Thr Ile Lys Val His Met Asn Leu Leu Leu 440 445 450 gcc gtc ttc ctg ctg gac acg agc ttc ctg ctc agc gag ccg gtg gcc 1568 Ala Val Phe Leu Leu Asp Thr Ser Phe Leu Leu Ser Glu Pro Val Ala 455 460 465 ctg aca ggc tct gag gct ggc tgc cga gcc agt gcc atc ttc ctg cac 1616 Leu Thr Gly Ser Glu Ala Gly Cys Arg Ala Ser Ala Ile Phe Leu His 470 475 480 ttc tcc ctg ctc acc tgc ctt tcc tgg atg ggc ctc gag ggg tac aac 1664 Phe Ser Leu Leu Thr Cys Leu Ser Trp Met Gly Leu Glu Gly Tyr Asn 485 490 495 ctc tac cga ctc gtg gtg gag gtc ttt ggc acc tat gtc cct ggc tac 1712 Leu Tyr Arg Leu Val Val Glu Val Phe Gly Thr Tyr Val Pro Gly Tyr 500 505 510 515 cta ctc aag ctg agc gcc atg ggc tgg ggc ttc ccc atc ttt ctg gtg 1760 Leu Leu Lys Leu Ser Ala Met Gly Trp Gly Phe Pro Ile Phe Leu Val 520 525 530 acg ctg gtg gcc ctg gtg gat gtg gac aac tat ggc ccc atc atc ttg 1808 Thr Leu Val Ala Leu Val Asp Val Asp Asn Tyr Gly Pro Ile Ile Leu 535 540 545 gct gtg cat agg act cca gag ggc gtc atc tac cct tcc atg tgc tgg 1856 Ala Val His Arg Thr Pro Glu Gly Val Ile Tyr Pro Ser Met Cys Trp 550 555 560 atc cgg gac tcc ctg gtc agc tac atc acc aac ctg ggc ctc ttc agc 1904 Ile Arg Asp Ser Leu Val Ser Tyr Ile Thr Asn Leu Gly Leu Phe Ser 565 570 575 ctg gtg ttt ctg ttc aac atg gcc atg cta gcc acc atg gtg gtg cag 1952 Leu Val Phe Leu Phe Asn Met Ala Met Leu Ala Thr Met Val Val Gln 580 585 590 595 atc ctg cgg ctg cgc ccc cac acc caa aag tgg tca cat gtg ctg aca 2000 Ile Leu Arg Leu Arg Pro His Thr Gln Lys Trp Ser His Val Leu Thr 600 605 610 ctg ctg ggc ctc agc ctg gtc ctt ggc ctg ccc tgg gcc ttg atc ttc 2048 Leu Leu Gly Leu Ser Leu Val Leu Gly Leu Pro Trp Ala Leu Ile Phe 615 620 625 ttc tcc ttt gct tct ggc acc ttc cag ctt gtc gtc ctc tac ctt ttc 2096 Phe Ser Phe Ala Ser Gly Thr Phe Gln Leu Val Val Leu Tyr Leu Phe 630 635 640 agc atc atc acc tcc ttc caa ggc ttc ctc atc ttc atc tgg tac tgg 2144 Ser Ile Ile Thr Ser Phe Gln Gly Phe Leu Ile Phe Ile Trp Tyr Trp 645 650 655 tcc atg cgg ctg cag gcc cgg ggt ggc ccc tcc cct ctg aag agc aac 2192 Ser Met Arg Leu Gln Ala Arg Gly Gly Pro Ser Pro Leu Lys Ser Asn 660 665 670 675 tca gac agc gcc agg ctc ccc atc agc tcg ggc agc acc tcg tcc agc 2240 Ser Asp Ser Ala Arg Leu Pro Ile Ser Ser Gly Ser Thr Ser Ser Ser 680 685 690 cgc atc taggcctcca gcccacctgc ccatgtgatg aagcagagat gcggcctcgt 2296 Arg Ile cgcacactgc ctgtggcccc cgagccaggc ccagccccag gccagtcagc cgcagacttt 2356 ggaaagccca acgaccatgg agagatgggc cgttgccatg gtggacggac tcccgggctg 2416 ggcttttgaa ttggccttgg ggactactcg gctctcactc agctcccacg ggactcagaa 2476 gtgcgccgcc atgctgccta gggtactgtc cccacatctg tcccaaccca gctggaggcc 2536 tggtctctcc ttacaaaccc tgggcccagc cctcattgct gggggccagg ccttggatct 2596 tgagggtctg gcacatcctt aatcctgtgc ccctgcctgg gacagaaatg tggctccagt 2656 tgctctgtct ctcgtggtca ccctgagggc actctgcatc ctctgtcatt ttaacctcag 2716 gtggcaccca gggcgaatgg ggcccagggc agaccttcag ggccagagcc ctggcggagg 2776 agaggccctt tgccaggagc acagcagcag ctcgcctacc tctgagccca ggccccctcc 2836 ctccctcagc cccccagtcc tccctccatc ttccctgggg ttctcctcct ctcccagggc 2896 ctccttgctc cttcgttcac agctgggggt ccccgattcc aatgctgttt tttggggagt 2956 ggtttccagg agctgcctgg tgtctgctgt aaatgtttgt ctactgcaca agcctcggcc 3016 tgcccctgag ccaggctcgg taccgatgcg tgggctgggc taggtccctc tgtccatctg 3076 ggcctttgta tgagctgcat tgcccttgct caccctgacc aagcacacgc ctcagagggg 3136 ccctcagcct ctcctgaagc cctcttgtgg caagaactgt ggaccatgcc agtcccgtct 3196 ggtttccatc ccaccactcc aaggactgag actgacctcc tctggtgaca ctggcctaga 3256 gcctgacact ctcctaagag gttctctcca agcccccaaa tagctccagg cgccctcggc 3316 cgcccatcat ggttaattct gtccaacaaa cacacacggg tagattgctg gcctgttgta 3376 ggtggtaggg acacagatga ccgacctggt cactcctcct gccaacattc agtctggtat 3436 gtgaggcgtg cgtgaagcaa gaactcctgg agctacaggg acagggagcc atcattcctg 3496 cctgggaatc ctggaagact tcctgcagga gtcagcgttc aatcttgacc ttgaagatgg 3556 gaaggatgtt ctttttacgt accaattctt ttgtcttttg atattaaaaa gaagtacatg 3616 ttcattgtag agaatttgga aactgtagaa gagaatcaag aagaaaaata aaaatcagct 3676 gttgtaatcg cctagcaaaa aaaaaaaaaa aaaaa 3711 4 693 PRT human GPR56-2 4 Met Thr Pro Gln Ser Leu Leu Gln Thr Thr Leu Phe Leu Leu Ser Leu 1 5 10 15 Leu Phe Leu Val Gln Gly Ala His Gly Arg Gly His Arg Glu Asp Phe 20 25 30 Arg Phe Cys Ser Gln Arg Asn Gln Thr His Arg Ser Ser Leu His Tyr 35 40 45 Lys Pro Thr Pro Asp Leu Arg Ile Ser Ile Glu Asn Ser Glu Glu Ala 50 55 60 Leu Thr Val His Ala Pro Phe Pro Ala Ala His Pro Ala Ser Arg Ser 65 70 75 80 Phe Pro Asp Pro Arg Gly Leu Tyr His Phe Cys Leu Tyr Trp Asn Arg 85 90 95 His Ala Gly Arg Leu His Leu Leu Tyr Gly Lys Arg Asp Phe Leu Leu 100 105 110 Ser Asp Lys Ala Ser Ser Leu Leu Cys Phe Gln His Gln Glu Glu Ser 115 120 125 Leu Ala Gln Gly Pro Pro Leu Leu Ala Thr Ser Val Thr Ser Trp Trp 130 135 140 Ser Pro Gln Asn Ile Ser Leu Pro Ser Ala Ala Ser Phe Thr Phe Ser 145 150 155 160 Phe His Ser Pro Pro His Thr Ala Ala His Asn Ala Ser Val Asp Met 165 170 175 Cys Glu Leu Lys Arg Asp Leu Gln Leu Leu Ser Gln Phe Leu Lys His 180 185 190 Pro Gln Lys Ala Ser Arg Arg Pro Ser Ala Ala Pro Ala Ser Gln Gln 195 200 205 Leu Gln Ser Leu Glu Ser Lys Leu Thr Ser Val Arg Phe Met Gly Asp 210 215 220 Met Val Ser Phe Glu Glu Asp Arg Ile Asn Ala Thr Val Trp Lys Leu 225 230 235 240 Gln Pro Thr Ala Gly Leu Gln Asp Leu His Ile His Ser Arg Gln Glu 245 250 255 Glu Glu Gln Ser Glu Ile Met Glu Tyr Ser Val Leu Leu Pro Arg Thr 260 265 270 Leu Phe Gln Arg Thr Lys Gly Arg Ser Gly Glu Ala Glu Lys Arg Leu 275 280 285 Leu Leu Val Asp Phe Ser Ser Gln Ala Leu Phe Gln Asp Lys Asn Ser 290 295 300 Ser His Val Leu Gly Glu Lys Val Leu Gly Ile Val Val Gln Asn Thr 305 310 315 320 Lys Val Ala Asn Leu Thr Glu Pro Val Val Leu Thr Phe Gln His Gln 325 330 335 Leu Gln Pro Lys Asn Val Thr Leu Gln Cys Val Phe Trp Val Glu Asp 340 345 350 Pro Thr Leu Ser Ser Pro Gly His Trp Ser Ser Ala Gly Cys Glu Thr 355 360 365 Val Arg Arg Glu Thr Gln Thr Ser Cys Phe Cys Asn His Leu Thr Tyr 370 375 380 Phe Ala Val Leu Met Val Ser Ser Val Glu Val Asp Ala Val His Lys 385 390 395 400 His Tyr Leu Ser Leu Leu Ser Tyr Val Gly Cys Val Val Ser Ala Leu 405 410 415 Ala Cys Leu Val Thr Ile Ala Ala Tyr Leu Cys Ser Arg Val Pro Leu 420 425 430 Pro Cys Arg Arg Lys Pro Arg Asp Tyr Thr Ile Lys Val His Met Asn 435 440 445 Leu Leu Leu Ala Val Phe Leu Leu Asp Thr Ser Phe Leu Leu Ser Glu 450 455 460 Pro Val Ala Leu Thr Gly Ser Glu Ala Gly Cys Arg Ala Ser Ala Ile 465 470 475 480 Phe Leu His Phe Ser Leu Leu Thr Cys Leu Ser Trp Met Gly Leu Glu 485 490 495 Gly Tyr Asn Leu Tyr Arg Leu Val Val Glu Val Phe Gly Thr Tyr Val 500 505 510 Pro Gly Tyr Leu Leu Lys Leu Ser Ala Met Gly Trp Gly Phe Pro Ile 515 520 525 Phe Leu Val Thr Leu Val Ala Leu Val Asp Val Asp Asn Tyr Gly Pro 530 535 540 Ile Ile Leu Ala Val His Arg Thr Pro Glu Gly Val Ile Tyr Pro Ser 545 550 555 560 Met Cys Trp Ile Arg Asp Ser Leu Val Ser Tyr Ile Thr Asn Leu Gly 565 570 575 Leu Phe Ser Leu Val Phe Leu Phe Asn Met Ala Met Leu Ala Thr Met 580 585 590 Val Val Gln Ile Leu Arg Leu Arg Pro His Thr Gln Lys Trp Ser His 595 600 605 Val Leu Thr Leu Leu Gly Leu Ser Leu Val Leu Gly Leu Pro Trp Ala 610 615 620 Leu Ile Phe Phe Ser Phe Ala Ser Gly Thr Phe Gln Leu Val Val Leu 625 630 635 640 Tyr Leu Phe Ser Ile Ile Thr Ser Phe Gln Gly Phe Leu Ile Phe Ile 645 650 655 Trp Tyr Trp Ser Met Arg Leu Gln Ala Arg Gly Gly Pro Ser Pro Leu 660 665 670 Lys Ser Asn Ser Asp Ser Ala Arg Leu Pro Ile Ser Ser Gly Ser Thr 675 680 685 Ser Ser Ser Arg Ile 690 5 2816 DNA human GPR56-3 CDS (159)..(2237) 5 agcagggtct cactctgtca cccaggctgg agtgcagtgg cgcagttata gctcactgca 60 gccttgaact cctgggctca agtgatcctt ccacctcagc ctccctagta gctgggacca 120 caggtggtga cttccaagag tgactccgtc ggaggaaa atg act ccc cag tcg ctg 176 Met Thr Pro Gln Ser Leu 1 5 ctg cag acg aca ctg ttc ctg ctg agt ctg ctc ttc ctg gtc caa ggt 224 Leu Gln Thr Thr Leu Phe Leu Leu Ser Leu Leu Phe Leu Val Gln Gly 10 15 20 gcc cac ggc agg ggc cac agg gaa gac ttt cgc ttc tgc agc cag cgg 272 Ala His Gly Arg Gly His Arg Glu Asp Phe Arg Phe Cys Ser Gln Arg 25 30 35 aac cag aca cac agg agc agc ctc cac tac aaa ccc aca cca gac ctg 320 Asn Gln Thr His Arg Ser Ser Leu His Tyr Lys Pro Thr Pro Asp Leu 40 45 50 cgc atc tcc atc gag aac tcc gaa gag gcc ctc aca gtc cat gcc cct 368 Arg Ile Ser Ile Glu Asn Ser Glu Glu Ala Leu Thr Val His Ala Pro 55 60 65 70 ttc cct gca gcc cac cct gct tcc cga tcc ttc cct gac ccc agg ggc 416 Phe Pro Ala Ala His Pro Ala Ser Arg Ser Phe Pro Asp Pro Arg Gly 75 80 85 ctc tac cac ttc tgc ctc tac tgg aac cga cat gct ggg aga tta cat 464 Leu Tyr His Phe Cys Leu Tyr Trp Asn Arg His Ala Gly Arg Leu His 90 95 100 ctt ctc tat ggc aag cgt gac ttc ttg ctg agt gac aaa gcc tct agc 512 Leu Leu Tyr Gly Lys Arg Asp Phe Leu Leu Ser Asp Lys Ala Ser Ser 105 110 115 ctc ctc tgc ttc cag cac cag gag gag agc ctg gct cag ggc ccc ccg 560 Leu Leu Cys Phe Gln His Gln Glu Glu Ser Leu Ala Gln Gly Pro Pro 120 125 130 ctg tta gcc act tct gtc acc tcc tgg tgg agc cct cag aac atc agc 608 Leu Leu Ala Thr Ser Val Thr Ser Trp Trp Ser Pro Gln Asn Ile Ser 135 140 145 150 ctg ccc agt gcc gcc agc ttc acc ttc tcc ttc cac agt cct ccc cac 656 Leu Pro Ser Ala Ala Ser Phe Thr Phe Ser Phe His Ser Pro Pro His 155 160 165 acg gcc gct cac aat gcc tcg gtg gac atg tgc gag ctc aaa agg gac 704 Thr Ala Ala His Asn Ala Ser Val Asp Met Cys Glu Leu Lys Arg Asp 170 175 180 ctc cag ctg ctc agc cag ttc ctg aag cat ccc cag aag gcc tca agg 752 Leu Gln Leu Leu Ser Gln Phe Leu Lys His Pro Gln Lys Ala Ser Arg 185 190 195 agg ccc tcg gct gcc ccc gcc agc cag cag ttg cag agc ctg gag tcg 800 Arg Pro Ser Ala Ala Pro Ala Ser Gln Gln Leu Gln Ser Leu Glu Ser 200 205 210 aaa ctg acc tct gtg aga ttc atg ggg gac atg gtg tcc ttc gag gag 848 Lys Leu Thr Ser Val Arg Phe Met Gly Asp Met Val Ser Phe Glu Glu 215 220 225 230 gac cgg atc aac gcc acg gtg tgg aag ctc cag ccc aca gcc ggc ctc 896 Asp Arg Ile Asn Ala Thr Val Trp Lys Leu Gln Pro Thr Ala Gly Leu 235 240 245 cag gac ctg cac atc cac tcc cgg cag gag gag gag cag agc gag atc 944 Gln Asp Leu His Ile His Ser Arg Gln Glu Glu Glu Gln Ser Glu Ile 250 255 260 atg gag tac tcg gtg ctg ctg cct cga aca ctc ttc cag agg acg aaa 992 Met Glu Tyr Ser Val Leu Leu Pro Arg Thr Leu Phe Gln Arg Thr Lys 265 270 275 ggc cgg agc ggg gag gct gag aag aga ctc ctc ctg gtg gac ttc agc 1040 Gly Arg Ser Gly Glu Ala Glu Lys Arg Leu Leu Leu Val Asp Phe Ser 280 285 290 agc caa gcc ctg ttc cag gac aag aat tcc agc caa gtc ctg ggt gag 1088 Ser Gln Ala Leu Phe Gln Asp Lys Asn Ser Ser Gln Val Leu Gly Glu 295 300 305 310 aag gtc ttg ggg att gtg gta cag aac acc aaa gta gcc aac ctc acg 1136 Lys Val Leu Gly Ile Val Val Gln Asn Thr Lys Val Ala Asn Leu Thr 315 320 325 gag ccc gtg gtg ctc act ttc cag cac cag cta cag ccg aag aat gtg 1184 Glu Pro Val Val Leu Thr Phe Gln His Gln Leu Gln Pro Lys Asn Val 330 335 340 act ctg caa tgt gtg ttc tgg gtt gaa gac ccc aca ttg agc agc ccg 1232 Thr Leu Gln Cys Val Phe Trp Val Glu Asp Pro Thr Leu Ser Ser Pro 345 350 355 ggg cat tgg agc agt gct ggg tgt gag acc gtc agg aga gaa acc caa 1280 Gly His Trp Ser Ser Ala Gly Cys Glu Thr Val Arg Arg Glu Thr Gln 360 365 370 aca tcc tgc ttc tgc aac cac ttg acc tac ttt gca gtg ctg atg gtc 1328 Thr Ser Cys Phe Cys Asn His Leu Thr Tyr Phe Ala Val Leu Met Val 375 380 385 390 tcc tcg gtg gag gtg gac gcc gtg cac aag cac tac ctg agc ctc ctc 1376 Ser Ser Val Glu Val Asp Ala Val His Lys His Tyr Leu Ser Leu Leu 395 400 405 tcc tac gtg ggc tgt gtc gtc tct gcc ctg gcc tgc ctt gtc acc att 1424 Ser Tyr Val Gly Cys Val Val Ser Ala Leu Ala Cys Leu Val Thr Ile 410 415 420 gcc gcc tac ctc tgc tcc agg gtg ccc ctg ccg tgc agg agg aaa cct 1472 Ala Ala Tyr Leu Cys Ser Arg Val Pro Leu Pro Cys Arg Arg Lys Pro 425 430 435 cgg gac tac acc atc aag gtg cac atg aac ctg ctg ctg gcc gtc ttc 1520 Arg Asp Tyr Thr Ile Lys Val His Met Asn Leu Leu Leu Ala Val Phe 440 445 450 ctg ctg gac acg agc ttc ctg ctc agc gag ccg gtg gcc ctg aca ggc 1568 Leu Leu Asp Thr Ser Phe Leu Leu Ser Glu Pro Val Ala Leu Thr Gly 455 460 465 470 tct gag gct ggc tgc cga gcc agt gcc atc ttc ctg cac ttc tcc ctg 1616 Ser Glu Ala Gly Cys Arg Ala Ser Ala Ile Phe Leu His Phe Ser Leu 475 480 485 ctc acc tgc ctt tcc tgg atg ggc ctc gag ggg tac aac ctc tac cga 1664 Leu Thr Cys Leu Ser Trp Met Gly Leu Glu Gly Tyr Asn Leu Tyr Arg 490 495 500 ctc gtg gtg gag gtc ttt ggc acc tat gtc cct ggc tac cta ctc aag 1712 Leu Val Val Glu Val Phe Gly Thr Tyr Val Pro Gly Tyr Leu Leu Lys 505 510 515 ctg agc gcc atg ggc tgg ggc ttc ccc atc ttt ctg gtg acg ctg gtg 1760 Leu Ser Ala Met Gly Trp Gly Phe Pro Ile Phe Leu Val Thr Leu Val 520 525 530 gcc ctg gtg gat gtg gac aac tat ggc ccc atc atc ttg gct gtg cat 1808 Ala Leu Val Asp Val Asp Asn Tyr Gly Pro Ile Ile Leu Ala Val His 535 540 545 550 agg act cca gag ggc gtc atc tac cct tcc atg tgc tgg atc cgg gac 1856 Arg Thr Pro Glu Gly Val Ile Tyr Pro Ser Met Cys Trp Ile Arg Asp 555 560 565 tcc ctg gtc agc tac atc acc aac ctg ggc ctc ttc agc ctg gtg ttt 1904 Ser Leu Val Ser Tyr Ile Thr Asn Leu Gly Leu Phe Ser Leu Val Phe 570 575 580 ctg ttc aac atg gcc atg cta gcc acc atg gtg gtg cag atc ctg cgg 1952 Leu Phe Asn Met Ala Met Leu Ala Thr Met Val Val Gln Ile Leu Arg 585 590 595 ctg cgc ccc cac acc caa aag tgg tca cat gtg ctg aca ctg ctg ggc 2000 Leu Arg Pro His Thr Gln Lys Trp Ser His Val Leu Thr Leu Leu Gly 600 605 610 ctc agc ctg gtc ctt ggc ctg ccc tgg gcc ttg atc ttc ttc tcc ttt 2048 Leu Ser Leu Val Leu Gly Leu Pro Trp Ala Leu Ile Phe Phe Ser Phe 615 620 625 630 gct tct ggc acc ttc cag ctt gtc gtc ctc tac ctt ttc agc atc atc 2096 Ala Ser Gly Thr Phe Gln Leu Val Val Leu Tyr Leu Phe Ser Ile Ile 635 640 645 acc tcc ttc caa ggc ttc ctc atc ttc atc tgg tac tgg tcc atg cgg 2144 Thr Ser Phe Gln Gly Phe Leu Ile Phe Ile Trp Tyr Trp Ser Met Arg 650 655 660 ctg cag gcc cgg ggt ggc ccc tcc cct ctg aag agc aac tca gac agc 2192 Leu Gln Ala Arg Gly Gly Pro Ser Pro Leu Lys Ser Asn Ser Asp Ser 665 670 675 gcc agg ctc ccc atc agc tcg ggc agc acc tcg tcc agc cgc atc 2237 Ala Arg Leu Pro Ile Ser Ser Gly Ser Thr Ser Ser Ser Arg Ile 680 685 690 taggcctcca gcccacctgc ccatgtgatg aagcagagat tcggcctcgt cgcacactgc 2297 ctgtggcccc cgagcccggc ccagccccag gccagtcagc cgcagacttt ggaaagccca 2357 acgaccatgg agagatgggc cgttgccatg gtggacggac tcccgggctg ggcttttgaa 2417 ttggccttgg ggactactcg gctctcactc agctcccacg ggactcagaa gtgcgccgcc 2477 atgctgccta gggtactgtc cccacatctg tcccaaccca gctggaggcc tggtctctcc 2537 ttacaacccc tgggcccagc cctcattgct gggggccagg ccttggatct tgagggtctg 2597 gcacatcctt aatcctgtgc ccctgcctgg gacagaaatg tggctccagt tgctctgtct 2657 ctcgtggtca ccctgagggc actctgcatc ctctgtcatt ttaacctcag gtggcaccca 2717 gggcgaatgg ggcccagggc agaccttcag ggccagagcc ctggcggagg agaggccctt 2777 tgccaggagc acagcagcag ctcgcctacc tctgagccc 2816 6 693 PRT human GPR56-3 6 Met Thr Pro Gln Ser Leu Leu Gln Thr Thr Leu Phe Leu Leu Ser Leu 1 5 10 15 Leu Phe Leu Val Gln Gly Ala His Gly Arg Gly His Arg Glu Asp Phe 20 25 30 Arg Phe Cys Ser Gln Arg Asn Gln Thr His Arg Ser Ser Leu His Tyr 35 40 45 Lys Pro Thr Pro Asp Leu Arg Ile Ser Ile Glu Asn Ser Glu Glu Ala 50 55 60 Leu Thr Val His Ala Pro Phe Pro Ala Ala His Pro Ala Ser Arg Ser 65 70 75 80 Phe Pro Asp Pro Arg Gly Leu Tyr His Phe Cys Leu Tyr Trp Asn Arg 85 90 95 His Ala Gly Arg Leu His Leu Leu Tyr Gly Lys Arg Asp Phe Leu Leu 100 105 110 Ser Asp Lys Ala Ser Ser Leu Leu Cys Phe Gln His Gln Glu Glu Ser 115 120 125 Leu Ala Gln Gly Pro Pro Leu Leu Ala Thr Ser Val Thr Ser Trp Trp 130 135 140 Ser Pro Gln Asn Ile Ser Leu Pro Ser Ala Ala Ser Phe Thr Phe Ser 145 150 155 160 Phe His Ser Pro Pro His Thr Ala Ala His Asn Ala Ser Val Asp Met 165 170 175 Cys Glu Leu Lys Arg Asp Leu Gln Leu Leu Ser Gln Phe Leu Lys His 180 185 190 Pro Gln Lys Ala Ser Arg Arg Pro Ser Ala Ala Pro Ala Ser Gln Gln 195 200 205 Leu Gln Ser Leu Glu Ser Lys Leu Thr Ser Val Arg Phe Met Gly Asp 210 215 220 Met Val Ser Phe Glu Glu Asp Arg Ile Asn Ala Thr Val Trp Lys Leu 225 230 235 240 Gln Pro Thr Ala Gly Leu Gln Asp Leu His Ile His Ser Arg Gln Glu 245 250 255 Glu Glu Gln Ser Glu Ile Met Glu Tyr Ser Val Leu Leu Pro Arg Thr 260 265 270 Leu Phe Gln Arg Thr Lys Gly Arg Ser Gly Glu Ala Glu Lys Arg Leu 275 280 285 Leu Leu Val Asp Phe Ser Ser Gln Ala Leu Phe Gln Asp Lys Asn Ser 290 295 300 Ser Gln Val Leu Gly Glu Lys Val Leu Gly Ile Val Val Gln Asn Thr 305 310 315 320 Lys Val Ala Asn Leu Thr Glu Pro Val Val Leu Thr Phe Gln His Gln 325 330 335 Leu Gln Pro Lys Asn Val Thr Leu Gln Cys Val Phe Trp Val Glu Asp 340 345 350 Pro Thr Leu Ser Ser Pro Gly His Trp Ser Ser Ala Gly Cys Glu Thr 355 360 365 Val Arg Arg Glu Thr Gln Thr Ser Cys Phe Cys Asn His Leu Thr Tyr 370 375 380 Phe Ala Val Leu Met Val Ser Ser Val Glu Val Asp Ala Val His Lys 385 390 395 400 His Tyr Leu Ser Leu Leu Ser Tyr Val Gly Cys Val Val Ser Ala Leu 405 410 415 Ala Cys Leu Val Thr Ile Ala Ala Tyr Leu Cys Ser Arg Val Pro Leu 420 425 430 Pro Cys Arg Arg Lys Pro Arg Asp Tyr Thr Ile Lys Val His Met Asn 435 440 445 Leu Leu Leu Ala Val Phe Leu Leu Asp Thr Ser Phe Leu Leu Ser Glu 450 455 460 Pro Val Ala Leu Thr Gly Ser Glu Ala Gly Cys Arg Ala Ser Ala Ile 465 470 475 480 Phe Leu His Phe Ser Leu Leu Thr Cys Leu Ser Trp Met Gly Leu Glu 485 490 495 Gly Tyr Asn Leu Tyr Arg Leu Val Val Glu Val Phe Gly Thr Tyr Val 500 505 510 Pro Gly Tyr Leu Leu Lys Leu Ser Ala Met Gly Trp Gly Phe Pro Ile 515 520 525 Phe Leu Val Thr Leu Val Ala Leu Val Asp Val Asp Asn Tyr Gly Pro 530 535 540 Ile Ile Leu Ala Val His Arg Thr Pro Glu Gly Val Ile Tyr Pro Ser 545 550 555 560 Met Cys Trp Ile Arg Asp Ser Leu Val Ser Tyr Ile Thr Asn Leu Gly 565 570 575 Leu Phe Ser Leu Val Phe Leu Phe Asn Met Ala Met Leu Ala Thr Met 580 585 590 Val Val Gln Ile Leu Arg Leu Arg Pro His Thr Gln Lys Trp Ser His 595 600 605 Val Leu Thr Leu Leu Gly Leu Ser Leu Val Leu Gly Leu Pro Trp Ala 610 615 620 Leu Ile Phe Phe Ser Phe Ala Ser Gly Thr Phe Gln Leu Val Val Leu 625 630 635 640 Tyr Leu Phe Ser Ile Ile Thr Ser Phe Gln Gly Phe Leu Ile Phe Ile 645 650 655 Trp Tyr Trp Ser Met Arg Leu Gln Ala Arg Gly Gly Pro Ser Pro Leu 660 665 670 Lys Ser Asn Ser Asp Ser Ala Arg Leu Pro Ile Ser Ser Gly Ser Thr 675 680 685 Ser Ser Ser Arg Ile 690 7 3835 DNA human GPR56-4 CDS (307)..(2367) 7 ccagcttcaa agtctctgtc ctcttgaaaa aaggtggtcg ggggacattg acccaccagc 60 cccgcaggct actgcctgca aacaagaacc cctcatctgc cacgcacgtt cttaatgtat 120 ctatagtctg cctgatgcca caaaggagtc cagggtctcg ctctgtcaca caggctggag 180 tgcagtggtg tgatcttggc tcatcgtaac ctccacctcc cgggttcaag tgattctcat 240 gcctcagcct cccgagtagc tgggattaca ggtggtgact tccaagagtg actccgtcgg 300 aggaaa atg act ccc cag tcg ctg ctg cag acg aca ctg ttc ctg ctg 348 Met Thr Pro Gln Ser Leu Leu Gln Thr Thr Leu Phe Leu Leu 1 5 10 agt ctg ctc ttc ctg gtc caa ggt gcc cac ggc agg ggc cac agg gaa 396 Ser Leu Leu Phe Leu Val Gln Gly Ala His Gly Arg Gly His Arg Glu 15 20 25 30 gac ttt cgc ttc tgc agc cag cgg aac cag aca cac agg agc agc ctc 444 Asp Phe Arg Phe Cys Ser Gln Arg Asn Gln Thr His Arg Ser Ser Leu 35 40 45 cac tac aaa ccc aca cca gac ctg cgc atc tcc atc gag aac tcc gaa 492 His Tyr Lys Pro Thr Pro Asp Leu Arg Ile Ser Ile Glu Asn Ser Glu 50 55 60 gag gcc ctc aca gtc cat gcc cct ttc cct gca gcc cac cct gct tcc 540 Glu Ala Leu Thr Val His Ala Pro Phe Pro Ala Ala His Pro Ala Ser 65 70 75 cga tcc ttc cct gac ccc agg ggc ctc tac cac ttc tgc ctc tac tgg 588 Arg Ser Phe Pro Asp Pro Arg Gly Leu Tyr His Phe Cys Leu Tyr Trp 80 85 90 aac cga cat gct ggg aga tta cat ctt ctc tat ggc aag cgt gac ttc 636 Asn Arg His Ala Gly Arg Leu His Leu Leu Tyr Gly Lys Arg Asp Phe 95 100 105 110 ttg ctg agt gac aaa gcc tct agc ctc ctc tgc ttc cag cac cag gag 684 Leu Leu Ser Asp Lys Ala Ser Ser Leu Leu Cys Phe Gln His Gln Glu 115 120 125 gag agc ctg gct cag ggc ccc ccg ctg tta gcc act tct gtc acc tcc 732 Glu Ser Leu Ala Gln Gly Pro Pro Leu Leu Ala Thr Ser Val Thr Ser 130 135 140 tgg tgg agc cct cag aac atc agc ctg ccc agt gcc gcc agc ttc acc 780 Trp Trp Ser Pro Gln Asn Ile Ser Leu Pro Ser Ala Ala Ser Phe Thr 145 150 155 ttc tcc ttc cac agt cct ccc cac acg gcc gct cac aat gcc tcg gtg 828 Phe Ser Phe His Ser Pro Pro His Thr Ala Ala His Asn Ala Ser Val 160 165 170 gac atg tgc gag ctc aaa agg gac ctc cag ctg ctc agc cag ttc ctg 876 Asp Met Cys Glu Leu Lys Arg Asp Leu Gln Leu Leu Ser Gln Phe Leu 175 180 185 190 aag cat ccc cag aag gcc tca agg agg ccc tcg gct gcc ccc gcc agc 924 Lys His Pro Gln Lys Ala Ser Arg Arg Pro Ser Ala Ala Pro Ala Ser 195 200 205 cag cag ttg cag agc ctg gag tcg aaa ctg acc tct gtg aga ttc atg 972 Gln Gln Leu Gln Ser Leu Glu Ser Lys Leu Thr Ser Val Arg Phe Met 210 215 220 ggg gac atg gtg tcc ttc gag gag gac cgg atc aac gcc acg gtg tgg 1020 Gly Asp Met Val Ser Phe Glu Glu Asp Arg Ile Asn Ala Thr Val Trp 225 230 235 aag ctc cag ccc aca gcc ggc ctc cag gac ctg cac atc cac tcc cgg 1068 Lys Leu Gln Pro Thr Ala Gly Leu Gln Asp Leu His Ile His Ser Arg 240 245 250 cag gag gag gag cag agc gag atc atg gag tac tcg gtg ctg ctg cct 1116 Gln Glu Glu Glu Gln Ser Glu Ile Met Glu Tyr Ser Val Leu Leu Pro 255 260 265 270 cga aca ctc ttc cag agg acg aaa ggc cgg agc ggg gag gct gag aag 1164 Arg Thr Leu Phe Gln Arg Thr Lys Gly Arg Ser Gly Glu Ala Glu Lys 275 280 285 aga ctc ctc ctg gtg gac ttc agc agc caa gcc ctg ttc cag gac aag 1212 Arg Leu Leu Leu Val Asp Phe Ser Ser Gln Ala Leu Phe Gln Asp Lys 290 295 300 aat tcc agc caa gtc ctg ggt gag aag gtc ttg ggg att gtg gta cag 1260 Asn Ser Ser Gln Val Leu Gly Glu Lys Val Leu Gly Ile Val Val Gln 305 310 315 aac acc aaa gta gcc aac ctc acg gag ccc gtg gtg ctc act ttc cag 1308 Asn Thr Lys Val Ala Asn Leu Thr Glu Pro Val Val Leu Thr Phe Gln 320 325 330 cac cag cta cag ccg aag aat gtg act ctg caa tgt gtg ttc tgg gtt 1356 His Gln Leu Gln Pro Lys Asn Val Thr Leu Gln Cys Val Phe Trp Val 335 340 345 350 gaa gac ccc aca ttg agc agc ccg ggg cat tgg agc agt gct ggg tgt 1404 Glu Asp Pro Thr Leu Ser Ser Pro Gly His Trp Ser Ser Ala Gly Cys 355 360 365 gag acc gtc agg aga gaa acc caa aca tcc tgc ttc tgc aac cac ttg 1452 Glu Thr Val Arg Arg Glu Thr Gln Thr Ser Cys Phe Cys Asn His Leu 370 375 380 acc tac ttt gca gtg ctg atg gtc tcc tcg gtg gag gtg gac gcc gtg 1500 Thr Tyr Phe Ala Val Leu Met Val Ser Ser Val Glu Val Asp Ala Val 385 390 395 cac aag cac tac ctg agc ctc ctc tcc tac gtg ggc tgt gtc gtc tct 1548 His Lys His Tyr Leu Ser Leu Leu Ser Tyr Val Gly Cys Val Val Ser 400 405 410 gcc ctg gcc tgc ctt gtc acc att gcc gcc tac ctc tgc tcc agg agg 1596 Ala Leu Ala Cys Leu Val Thr Ile Ala Ala Tyr Leu Cys Ser Arg Arg 415 420 425 430 aaa cct cgg gac tac acc atc aag gtg cac atg aac ctg ctg ctg gcc 1644 Lys Pro Arg Asp Tyr Thr Ile Lys Val His Met Asn Leu Leu Leu Ala 435 440 445 gtc ttc ctg ctg gac acg agc ttc ctg ctc agc gag ccg gtg gcc ctg 1692 Val Phe Leu Leu Asp Thr Ser Phe Leu Leu Ser Glu Pro Val Ala Leu 450 455 460 aca ggc tct gag gct ggc tgc cga gcc agt gcc atc ttc ctg cac ttc 1740 Thr Gly Ser Glu Ala Gly Cys Arg Ala Ser Ala Ile Phe Leu His Phe 465 470 475 tcc ctg ctc acc tgc ctt tcc tgg atg ggc ctc gag ggg tac aac ctc 1788 Ser Leu Leu Thr Cys Leu Ser Trp Met Gly Leu Glu Gly Tyr Asn Leu 480 485 490 tac cga ctc gtg gtg gag gtc ttt ggc acc tat gtc cct ggc tac cta 1836 Tyr Arg Leu Val Val Glu Val Phe Gly Thr Tyr Val Pro Gly Tyr Leu 495 500 505 510 ctc aag ctg agc gcc atg ggc tgg ggc ttc ccc atc ttt ctg gtg acg 1884 Leu Lys Leu Ser Ala Met Gly Trp Gly Phe Pro Ile Phe Leu Val Thr 515 520 525 ctg gtg gcc ctg gtg gat gtg gac aac tat ggc ccc atc atc ttg gct 1932 Leu Val Ala Leu Val Asp Val Asp Asn Tyr Gly Pro Ile Ile Leu Ala 530 535 540 gtg cat agg act cca gag ggc gtc atc tac cct tcc atg tgc tgg atc 1980 Val His Arg Thr Pro Glu Gly Val Ile Tyr Pro Ser Met Cys Trp Ile 545 550 555 cgg gac tcc ctg gtc agc tac atc acc aac ctg ggc ctc ttc agc ctg 2028 Arg Asp Ser Leu Val Ser Tyr Ile Thr Asn Leu Gly Leu Phe Ser Leu 560 565 570 gtg ttt ctg ttc aac atg gcc atg cta gcc acc atg gtg gtg cag atc 2076 Val Phe Leu Phe Asn Met Ala Met Leu Ala Thr Met Val Val Gln Ile 575 580 585 590 ctg cgg ctg cgc ccc cac acc caa aag tgg tca cat gtg ctg aca ctg 2124 Leu Arg Leu Arg Pro His Thr Gln Lys Trp Ser His Val Leu Thr Leu 595 600 605 ctg ggc ctc agc ctg gtc ctt ggc ctg ccc tgg gcc ttg atc ttc ttc 2172 Leu Gly Leu Ser Leu Val Leu Gly Leu Pro Trp Ala Leu Ile Phe Phe 610 615 620 tcc ttt gct tct ggc acc ttc cag ctt gtc gtc ctc tac ctt ttc agc 2220 Ser Phe Ala Ser Gly Thr Phe Gln Leu Val Val Leu Tyr Leu Phe Ser 625 630 635 atc atc acc tcc ttc caa ggc ttc ctc atc ttc atc tgg tac tgg tcc 2268 Ile Ile Thr Ser Phe Gln Gly Phe Leu Ile Phe Ile Trp Tyr Trp Ser 640 645 650 atg cgg ctg cag gcc cgg ggt ggc ccc tcc cct ctg aag agc aac tca 2316 Met Arg Leu Gln Ala Arg Gly Gly Pro Ser Pro Leu Lys Ser Asn Ser 655 660 665 670 gac agc gcc agg ctc ccc atc agc tcg ggc agc acc tcg tcc agc cgc 2364 Asp Ser Ala Arg Leu Pro Ile Ser Ser Gly Ser Thr Ser Ser Ser Arg 675 680 685 atc taggcctcca gcccacctgc ccatgtgatg aagcagagat gcggcctcgt 2417 Ile cgcacactgc ctgtggcccc cgagccaggc ccagccccag gccagtcagc cgcagacttt 2477 ggaaagccca acgaccatgg agagatgggc cgttgccatg gtggacggac tcccgggctg 2537 ggcttttgaa ttggccttgg ggactactcg gctctcactc agctcccacg ggactcagaa 2597 gtgcgccgcc atgctgccta gggtactgtc cccacatctg tcccaaccca gctggaggcc 2657 tggtctctcc ttacaacccc tgggcccagc cctcattgct gggggccagg ccttggatct 2717 tgagggtctg gcacatcctt aatcctgtgc ccctgcctgg gacagaaatg tggctccagt 2777 tgctctgtct ctcgtggtca ccctgagggc actctgcatc ctctgtcatt ttaacctcag 2837 gtggcaccca gggcgaatgg ggcccagggc agaccttcag ggccagagcc ctggcggagg 2897 agaggccctt tgccaggagc acagcagcag ctcgcctacc tctgagccca ggccccctcc 2957 ctccctcagc cccccagtcc tccctccatc ttccctgggg ttctcctcct ctcccagggc 3017 ctccttgctc cttcgttcac agctgggggt ccccgattcc aatgctgttt tttggggagt 3077 ggtttccagg agctgcctgg tgtctgctgt aaatgtttgt ctactgcaca agcctcggcc 3137 tgcccctgag ccaggctcgg taccgatgcg tgggctgggc taggtccctc tgtccatctg 3197 ggcctttgta tgagctgcat tgcccttgct caccctgacc aagcacacgc ctcagagggg 3257 ccctcagcct ctcctgaagc cctcttgtgg caagaactgt ggaccatgcc agtcccgtct 3317 ggtttccatc ccaccactcc aaggactgag actgacctcc tctggtgaca ctggcctaga 3377 gcctgacact ctcctaagag gttctctcca agcccccaaa tagctccagg cgccctcggc 3437 cgcccatcat ggttaattct gtccaacaaa cacacacggg tagattgctg gcctgttgta 3497 ggtggtaggg acacagatga ccgacctggt cactcctcct gccaacattc agtctggtat 3557 gtgaggcgtg cgtgaagcaa gaactcctgg agctacaggg acagggagcc atcattcctg 3617 cctgggaatc ctggaagact tcctgcagga gtcagcgttc aatcttgacc ttgaagatgg 3677 gaaggatgtt ctttttacgt accaattctt ttgtcttttg atattaaaaa gaagtacatg 3737 ttcattgtag agaatttgga aactgtagaa gagaatcaag aagaaaaata aaaatcagct 3797 gttgtaatcg cctagcaaac tggaaaaaaa aaaaaaaa 3835 8 687 PRT human GPR56-4 8 Met Thr Pro Gln Ser Leu Leu Gln Thr Thr Leu Phe Leu Leu Ser Leu 1 5 10 15 Leu Phe Leu Val Gln Gly Ala His Gly Arg Gly His Arg Glu Asp Phe 20 25 30 Arg Phe Cys Ser Gln Arg Asn Gln Thr His Arg Ser Ser Leu His Tyr 35 40 45 Lys Pro Thr Pro Asp Leu Arg Ile Ser Ile Glu Asn Ser Glu Glu Ala 50 55 60 Leu Thr Val His Ala Pro Phe Pro Ala Ala His Pro Ala Ser Arg Ser 65 70 75 80 Phe Pro Asp Pro Arg Gly Leu Tyr His Phe Cys Leu Tyr Trp Asn Arg 85 90 95 His Ala Gly Arg Leu His Leu Leu Tyr Gly Lys Arg Asp Phe Leu Leu 100 105 110 Ser Asp Lys Ala Ser Ser Leu Leu Cys Phe Gln His Gln Glu Glu Ser 115 120 125 Leu Ala Gln Gly Pro Pro Leu Leu Ala Thr Ser Val Thr Ser Trp Trp 130 135 140 Ser Pro Gln Asn Ile Ser Leu Pro Ser Ala Ala Ser Phe Thr Phe Ser 145 150 155 160 Phe His Ser Pro Pro His Thr Ala Ala His Asn Ala Ser Val Asp Met 165 170 175 Cys Glu Leu Lys Arg Asp Leu Gln Leu Leu Ser Gln Phe Leu Lys His 180 185 190 Pro Gln Lys Ala Ser Arg Arg Pro Ser Ala Ala Pro Ala Ser Gln Gln 195 200 205 Leu Gln Ser Leu Glu Ser Lys Leu Thr Ser Val Arg Phe Met Gly Asp 210 215 220 Met Val Ser Phe Glu Glu Asp Arg Ile Asn Ala Thr Val Trp Lys Leu 225 230 235 240 Gln Pro Thr Ala Gly Leu Gln Asp Leu His Ile His Ser Arg Gln Glu 245 250 255 Glu Glu Gln Ser Glu Ile Met Glu Tyr Ser Val Leu Leu Pro Arg Thr 260 265 270 Leu Phe Gln Arg Thr Lys Gly Arg Ser Gly Glu Ala Glu Lys Arg Leu 275 280 285 Leu Leu Val Asp Phe Ser Ser Gln Ala Leu Phe Gln Asp Lys Asn Ser 290 295 300 Ser Gln Val Leu Gly Glu Lys Val Leu Gly Ile Val Val Gln Asn Thr 305 310 315 320 Lys Val Ala Asn Leu Thr Glu Pro Val Val Leu Thr Phe Gln His Gln 325 330 335 Leu Gln Pro Lys Asn Val Thr Leu Gln Cys Val Phe Trp Val Glu Asp 340 345 350 Pro Thr Leu Ser Ser Pro Gly His Trp Ser Ser Ala Gly Cys Glu Thr 355 360 365 Val Arg Arg Glu Thr Gln Thr Ser Cys Phe Cys Asn His Leu Thr Tyr 370 375 380 Phe Ala Val Leu Met Val Ser Ser Val Glu Val Asp Ala Val His Lys 385 390 395 400 His Tyr Leu Ser Leu Leu Ser Tyr Val Gly Cys Val Val Ser Ala Leu 405 410 415 Ala Cys Leu Val Thr Ile Ala Ala Tyr Leu Cys Ser Arg Arg Lys Pro 420 425 430 Arg Asp Tyr Thr Ile Lys Val His Met Asn Leu Leu Leu Ala Val Phe 435 440 445 Leu Leu Asp Thr Ser Phe Leu Leu Ser Glu Pro Val Ala Leu Thr Gly 450 455 460 Ser Glu Ala Gly Cys Arg Ala Ser Ala Ile Phe Leu His Phe Ser Leu 465 470 475 480 Leu Thr Cys Leu Ser Trp Met Gly Leu Glu Gly Tyr Asn Leu Tyr Arg 485 490 495 Leu Val Val Glu Val Phe Gly Thr Tyr Val Pro Gly Tyr Leu Leu Lys 500 505 510 Leu Ser Ala Met Gly Trp Gly Phe Pro Ile Phe Leu Val Thr Leu Val 515 520 525 Ala Leu Val Asp Val Asp Asn Tyr Gly Pro Ile Ile Leu Ala Val His 530 535 540 Arg Thr Pro Glu Gly Val Ile Tyr Pro Ser Met Cys Trp Ile Arg Asp 545 550 555 560 Ser Leu Val Ser Tyr Ile Thr Asn Leu Gly Leu Phe Ser Leu Val Phe 565 570 575 Leu Phe Asn Met Ala Met Leu Ala Thr Met Val Val Gln Ile Leu Arg 580 585 590 Leu Arg Pro His Thr Gln Lys Trp Ser His Val Leu Thr Leu Leu Gly 595 600 605 Leu Ser Leu Val Leu Gly Leu Pro Trp Ala Leu Ile Phe Phe Ser Phe 610 615 620 Ala Ser Gly Thr Phe Gln Leu Val Val Leu Tyr Leu Phe Ser Ile Ile 625 630 635 640 Thr Ser Phe Gln Gly Phe Leu Ile Phe Ile Trp Tyr Trp Ser Met Arg 645 650 655 Leu Gln Ala Arg Gly Gly Pro Ser Pro Leu Lys Ser Asn Ser Asp Ser 660 665 670 Ala Arg Leu Pro Ile Ser Ser Gly Ser Thr Ser Ser Ser Arg Ile 675 680 685 9 3021 DNA murine GPR56 CDS (321)..(2384) 9 agacagcgtg atcccggcct cccacggggc agcttttact gtctagggaa gaaatcccca 60 aagtccatgg agtctgaaga ctctgtcaag cctcgctagg aaacctagga gttttagagg 120 gcacttggca ccggaagcta gccgggtagg cggagcctca cctggattga gttcacagct 180 gcctagacag gctcagacta ggtgctgggc acctgggagg aggaggagac attagcagca 240 aaggctgtta acagaagtgc ctgcctaggc ttggaggcaa gacgctgctg ttcacagtgc 300 gagacggagg taggagtata atg gct gtc cag gtg ctg cgg cag atg gtc tac 353 Met Ala Val Gln Val Leu Arg Gln Met Val Tyr 1 5 10 ttc cta ctg agt ctg ttt tct ctg gtg caa ggt gca cac agt ggc agc 401 Phe Leu Leu Ser Leu Phe Ser Leu Val Gln Gly Ala His Ser Gly Ser 15 20 25 ccc cga gaa gac ttc cgc ttc tgt ggc cag cgg aac cag acc caa cag 449 Pro Arg Glu Asp Phe Arg Phe Cys Gly Gln Arg Asn Gln Thr Gln Gln 30 35 40 agc acc ctc cac tat gat caa tct tca gag cct cac atc ttt gtg tgg 497 Ser Thr Leu His Tyr Asp Gln Ser Ser Glu Pro His Ile Phe Val Trp 45 50 55 aac aca gag gag acc ctc aca att cgt gcc ccc ttc ctg gca gcc cca 545 Asn Thr Glu Glu Thr Leu Thr Ile Arg Ala Pro Phe Leu Ala Ala Pro 60 65 70 75 gat att ccc cgc ttc ttc cca gag cct aga ggg ctc tat cac ttc tgc 593 Asp Ile Pro Arg Phe Phe Pro Glu Pro Arg Gly Leu Tyr His Phe Cys 80 85 90 ctc tac tgg agt cgc cac act ggg aga ctc cac ttg cgc tat ggc aag 641 Leu Tyr Trp Ser Arg His Thr Gly Arg Leu His Leu Arg Tyr Gly Lys 95 100 105 cat gac tac ctg ctt agt agc caa gcc tcc aga ctc ctc tgc ttc cag 689 His Asp Tyr Leu Leu Ser Ser Gln Ala Ser Arg Leu Leu Cys Phe Gln 110 115 120 aaa cag gag cag agc ctg aag cag gga gcc ccg ctg atc gcc acc tct 737 Lys Gln Glu Gln Ser Leu Lys Gln Gly Ala Pro Leu Ile Ala Thr Ser 125 130 135 gtc agc tcc tgg cag att ccc cag aac acc agc ctg cct ggg gct ccg 785 Val Ser Ser Trp Gln Ile Pro Gln Asn Thr Ser Leu Pro Gly Ala Pro 140 145 150 155 agc ttc atc ttc tcc ttc cac aat gcc cca cac aag gtc tcc cac aat 833 Ser Phe Ile Phe Ser Phe His Asn Ala Pro His Lys Val Ser His Asn 160 165 170 gca tct gtg gac atg tgt gat ctc aag aag gaa ttg cag cag ctt agc 881 Ala Ser Val Asp Met Cys Asp Leu Lys Lys Glu Leu Gln Gln Leu Ser 175 180 185 agg tac ctg cag cac cct caa aag gct gcc aag cgg ccc acc gca gcg 929 Arg Tyr Leu Gln His Pro Gln Lys Ala Ala Lys Arg Pro Thr Ala Ala 190 195 200 ttc atc agc cag cag tta cag agc ctg gag tca aag ctg acc tct gtg 977 Phe Ile Ser Gln Gln Leu Gln Ser Leu Glu Ser Lys Leu Thr Ser Val 205 210 215 agc ttc ctg gga gac aca tta tcc ttt gag gag gac cgg gtc aat gct 1025 Ser Phe Leu Gly Asp Thr Leu Ser Phe Glu Glu Asp Arg Val Asn Ala 220 225 230 235 aca gtg tgg aag ctg cca ccc aca gcc ggt cta gag gat ctg cat atc 1073 Thr Val Trp Lys Leu Pro Pro Thr Ala Gly Leu Glu Asp Leu His Ile 240 245 250 cac tcc cag aag gag gag gag cag agt gag gtc cag gca tac tcg ctg 1121 His Ser Gln Lys Glu Glu Glu Gln Ser Glu Val Gln Ala Tyr Ser Leu 255 260 265 ttg ctt ccc cgg gcc gta ttc cag cag acc aga ggc cgt cgc cgg gat 1169 Leu Leu Pro Arg Ala Val Phe Gln Gln Thr Arg Gly Arg Arg Arg Asp 270 275 280 gac gcc aag agg ctc ctg gta gta gac ttc agc agc caa gct ttg ttc 1217 Asp Ala Lys Arg Leu Leu Val Val Asp Phe Ser Ser Gln Ala Leu Phe 285 290 295 cag gac aag aat tct agc caa gtc ctg ggt gag aag gtc ttg ggt att 1265 Gln Asp Lys Asn Ser Ser Gln Val Leu Gly Glu Lys Val Leu Gly Ile 300 305 310 315 gtc gtg cag aac acc aaa gtc acc aac ctc tca gat ccg gtg gta ctc 1313 Val Val Gln Asn Thr Lys Val Thr Asn Leu Ser Asp Pro Val Val Leu 320 325 330 acc ttc cag cac cag cct cag cca aaa aat gtg act ctg cag tgc gtg 1361 Thr Phe Gln His Gln Pro Gln Pro Lys Asn Val Thr Leu Gln Cys Val 335 340 345 ttc tgg gtt gaa gac ccg gca tca agc agc aca ggg agc tgg agc agt 1409 Phe Trp Val Glu Asp Pro Ala Ser Ser Ser Thr Gly Ser Trp Ser Ser 350 355 360 gca ggc tgc gag aca gtg agc aga gac aca cag aca tcc tgc ctg tgc 1457 Ala Gly Cys Glu Thr Val Ser Arg Asp Thr Gln Thr Ser Cys Leu Cys 365 370 375 aac cac ctg acc tac ttt gca gtg ctg atg gtg tca tcc aca gag gta 1505 Asn His Leu Thr Tyr Phe Ala Val Leu Met Val Ser Ser Thr Glu Val 380 385 390 395 gaa gcc act cac aaa cac tac ctc acg ctc ctg tcc tac gtg ggc tgt 1553 Glu Ala Thr His Lys His Tyr Leu Thr Leu Leu Ser Tyr Val Gly Cys 400 405 410 gtc atc tct gct ctg gct tgt gtc ttc act atc gct gcc tac ctc tgc 1601 Val Ile Ser Ala Leu Ala Cys Val Phe Thr Ile Ala Ala Tyr Leu Cys 415 420 425 tcc agg agg aag tca cgt gac tac acc atc aaa gtc cac atg aac ctg 1649 Ser Arg Arg Lys Ser Arg Asp Tyr Thr Ile Lys Val His Met Asn Leu 430 435 440 ctg tcc gct gtc ttc ctg ctg gac gtg agc ttc ctg ctc agc gag cct 1697 Leu Ser Ala Val Phe Leu Leu Asp Val Ser Phe Leu Leu Ser Glu Pro 445 450 455 gtg gca ctg acg ggc tcc gaa gca gcc tgt cgc acc agt gcc atg ttc 1745 Val Ala Leu Thr Gly Ser Glu Ala Ala Cys Arg Thr Ser Ala Met Phe 460 465 470 475 ctg cac ttc tcc ctg ctt gcc tgc ctc tcc tgg atg ggc ctc gag ggc 1793 Leu His Phe Ser Leu Leu Ala Cys Leu Ser Trp Met Gly Leu Glu Gly 480 485 490 tac aat ctc tac cga ctg gtg gtg gag gtc ttc ggt acc tat gtg ccc 1841 Tyr Asn Leu Tyr Arg Leu Val Val Glu Val Phe Gly Thr Tyr Val Pro 495 500 505 ggc tat ctg ctc aag ctg agc atc gtg ggc tgg ggt ttt cct gtc ttc 1889 Gly Tyr Leu Leu Lys Leu Ser Ile Val Gly Trp Gly Phe Pro Val Phe 510 515 520 ctg gtc act ctg gtg gcg ttg gtg gat gtg aat aac tac ggc ccc att 1937 Leu Val Thr Leu Val Ala Leu Val Asp Val Asn Asn Tyr Gly Pro Ile 525 530 535 atc cta gct gtg cgc cgg act ccg gaa cgt gtc acc tac ccc tct atg 1985 Ile Leu Ala Val Arg Arg Thr Pro Glu Arg Val Thr Tyr Pro Ser Met 540 545 550 555 tgc tgg atc cgg gac tcc ctg gtg agc tat gtc acc aac ctg ggc ctc 2033 Cys Trp Ile Arg Asp Ser Leu Val Ser Tyr Val Thr Asn Leu Gly Leu 560 565 570 ttc agt ctg gtg ttc ctg ttc aac ctg gct atg ctg gcc acc atg gtg 2081 Phe Ser Leu Val Phe Leu Phe Asn Leu Ala Met Leu Ala Thr Met Val 575 580 585 gtg cag atc ctg cgg ctt cgc ccg cac agc cag aac tgg ccc cac gtg 2129 Val Gln Ile Leu Arg Leu Arg Pro His Ser Gln Asn Trp Pro His Val 590 595 600 ctg acc ctg ctg ggc ctc agc ctg gtc ctt ggc ctc ccc tgg gcc ttg 2177 Leu Thr Leu Leu Gly Leu Ser Leu Val Leu Gly Leu Pro Trp Ala Leu 605 610 615 gtc ttc ttt tcc ttt gct tcc ggc acc ttc cag ctt gtc atc ctc tac 2225 Val Phe Phe Ser Phe Ala Ser Gly Thr Phe Gln Leu Val Ile Leu Tyr 620 625 630 635 ctc ttc agc atc ata act tcc tac caa ggc ttc ctc atc ttc ctg tgg 2273 Leu Phe Ser Ile Ile Thr Ser Tyr Gln Gly Phe Leu Ile Phe Leu Trp 640 645 650 tac tgg tcc atg cgg ttc cag gcc caa ggc ggc ccc tcc cct ctg aag 2321 Tyr Trp Ser Met Arg Phe Gln Ala Gln Gly Gly Pro Ser Pro Leu Lys 655 660 665 aac aac tca gac agc gcc aaa ctc ccc atc agc tcc ggc agc acc tcc 2369 Asn Asn Ser Asp Ser Ala Lys Leu Pro Ile Ser Ser Gly Ser Thr Ser 670 675 680 tcc agc cgc atc taa gccaccgcca cacctcccct ccgggaggac acatgcatgg 2424 Ser Ser Arg Ile 685 cgtccgctca cgatgtctgt ggcccagtgc tgtgcccacc cagcctttgt tggttagtgg 2484 catactagag aaggccctgg tccttgaagg cgtagggctg ttgctctgag ggacctccat 2544 ctctcctgaa gcctcctccc tctggcaagt actgggatac agccaccctt tcaacccagc 2604 actctgaaga ccaagacagc cccctctggt gacactggcc aagcttgatc tttttcctaa 2664 gaagtggtct tcagatcccc gcaggtcgct cagaagacac tgggctgcct agtgtgaatt 2724 ctgtcctact aacgtacagt gagcagctcc tcacccccac ccccgcaaaa gctctcacca 2784 agtcctggag tgtcaggcag ggggctggaa atccaggagg acttcctgca aaaggcagca 2844 tttcatcttg acctcagcct tcaggttggg gagaatgttc tttttaaata ccagttcatt 2904 tgtcttttga tattaaagct ctttatagag agtctggaaa ctgtaggcga ttgtcgagaa 2964 gagaaataaa aatgagctgt tatctaatgc catggcaaag cagcacaaaa aaaaaaa 3021 10 687 PRT murine GPR56 10 Met Ala Val Gln Val Leu Arg Gln Met Val Tyr Phe Leu Leu Ser Leu 1 5 10 15 Phe Ser Leu Val Gln Gly Ala His Ser Gly Ser Pro Arg Glu Asp Phe 20 25 30 Arg Phe Cys Gly Gln Arg Asn Gln Thr Gln Gln Ser Thr Leu His Tyr 35 40 45 Asp Gln Ser Ser Glu Pro His Ile Phe Val Trp Asn Thr Glu Glu Thr 50 55 60 Leu Thr Ile Arg Ala Pro Phe Leu Ala Ala Pro Asp Ile Pro Arg Phe 65 70 75 80 Phe Pro Glu Pro Arg Gly Leu Tyr His Phe Cys Leu Tyr Trp Ser Arg 85 90 95 His Thr Gly Arg Leu His Leu Arg Tyr Gly Lys His Asp Tyr Leu Leu 100 105 110 Ser Ser Gln Ala Ser Arg Leu Leu Cys Phe Gln Lys Gln Glu Gln Ser 115 120 125 Leu Lys Gln Gly Ala Pro Leu Ile Ala Thr Ser Val Ser Ser Trp Gln 130 135 140 Ile Pro Gln Asn Thr Ser Leu Pro Gly Ala Pro Ser Phe Ile Phe Ser 145 150 155 160 Phe His Asn Ala Pro His Lys Val Ser His Asn Ala Ser Val Asp Met 165 170 175 Cys Asp Leu Lys Lys Glu Leu Gln Gln Leu Ser Arg Tyr Leu Gln His 180 185 190 Pro Gln Lys Ala Ala Lys Arg Pro Thr Ala Ala Phe Ile Ser Gln Gln 195 200 205 Leu Gln Ser Leu Glu Ser Lys Leu Thr Ser Val Ser Phe Leu Gly Asp 210 215 220 Thr Leu Ser Phe Glu Glu Asp Arg Val Asn Ala Thr Val Trp Lys Leu 225 230 235 240 Pro Pro Thr Ala Gly Leu Glu Asp Leu His Ile His Ser Gln Lys Glu 245 250 255 Glu Glu Gln Ser Glu Val Gln Ala Tyr Ser Leu Leu Leu Pro Arg Ala 260 265 270 Val Phe Gln Gln Thr Arg Gly Arg Arg Arg Asp Asp Ala Lys Arg Leu 275 280 285 Leu Val Val Asp Phe Ser Ser Gln Ala Leu Phe Gln Asp Lys Asn Ser 290 295 300 Ser Gln Val Leu Gly Glu Lys Val Leu Gly Ile Val Val Gln Asn Thr 305 310 315 320 Lys Val Thr Asn Leu Ser Asp Pro Val Val Leu Thr Phe Gln His Gln 325 330 335 Pro Gln Pro Lys Asn Val Thr Leu Gln Cys Val Phe Trp Val Glu Asp 340 345 350 Pro Ala Ser Ser Ser Thr Gly Ser Trp Ser Ser Ala Gly Cys Glu Thr 355 360 365 Val Ser Arg Asp Thr Gln Thr Ser Cys Leu Cys Asn His Leu Thr Tyr 370 375 380 Phe Ala Val Leu Met Val Ser Ser Thr Glu Val Glu Ala Thr His Lys 385 390 395 400 His Tyr Leu Thr Leu Leu Ser Tyr Val Gly Cys Val Ile Ser Ala Leu 405 410 415 Ala Cys Val Phe Thr Ile Ala Ala Tyr Leu Cys Ser Arg Arg Lys Ser 420 425 430 Arg Asp Tyr Thr Ile Lys Val His Met Asn Leu Leu Ser Ala Val Phe 435 440 445 Leu Leu Asp Val Ser Phe Leu Leu Ser Glu Pro Val Ala Leu Thr Gly 450 455 460 Ser Glu Ala Ala Cys Arg Thr Ser Ala Met Phe Leu His Phe Ser Leu 465 470 475 480 Leu Ala Cys Leu Ser Trp Met Gly Leu Glu Gly Tyr Asn Leu Tyr Arg 485 490 495 Leu Val Val Glu Val Phe Gly Thr Tyr Val Pro Gly Tyr Leu Leu Lys 500 505 510 Leu Ser Ile Val Gly Trp Gly Phe Pro Val Phe Leu Val Thr Leu Val 515 520 525 Ala Leu Val Asp Val Asn Asn Tyr Gly Pro Ile Ile Leu Ala Val Arg 530 535 540 Arg Thr Pro Glu Arg Val Thr Tyr Pro Ser Met Cys Trp Ile Arg Asp 545 550 555 560 Ser Leu Val Ser Tyr Val Thr Asn Leu Gly Leu Phe Ser Leu Val Phe 565 570 575 Leu Phe Asn Leu Ala Met Leu Ala Thr Met Val Val Gln Ile Leu Arg 580 585 590 Leu Arg Pro His Ser Gln Asn Trp Pro His Val Leu Thr Leu Leu Gly 595 600 605 Leu Ser Leu Val Leu Gly Leu Pro Trp Ala Leu Val Phe Phe Ser Phe 610 615 620 Ala Ser Gly Thr Phe Gln Leu Val Ile Leu Tyr Leu Phe Ser Ile Ile 625 630 635 640 Thr Ser Tyr Gln Gly Phe Leu Ile Phe Leu Trp Tyr Trp Ser Met Arg 645 650 655 Phe Gln Ala Gln Gly Gly Pro Ser Pro Leu Lys Asn Asn Ser Asp Ser 660 665 670 Ala Lys Leu Pro Ile Ser Ser Gly Ser Thr Ser Ser Ser Arg Ile 675 680 685 11 22 DNA probe 11 catctccatc gagaactccg aa 22 12 21 DNA probe 12 ctacgtgggc tgtgtcgtct c 21 13 23 DNA probe 13 agcgagatca tggagtactc ggt 23 14 22 DNA probe 14 ttcggagttc tcgatggaga tc 22 15 21 DNA probe 15 gagacgacac agcccacgta g 21 16 23 DNA probe 16 accgagtact ccatgatctc gct 23 17 21 DNA probe 17 acctccacca cgagtcggta g 21 18 21 DNA probe 18 aaagacctcc accacgagtc g 21 19 25 DNA probe 19 aaagacctcc accacgagtc ggtag 25 20 10 PRT N-terminal peptide 20 Met Thr Pro Gln Ser Leu Leu Gln Thr Thr 1 5 10 

We claim:
 1. An isolated nucleic acid comprising a nucleotide sequence that encodes a GPR56 polypeptide or an immunologically active derivative thereof.
 2. The isolated nucleic acid of claim 1, wherein said nucleic acid encodes a human GPR56 polypeptide.
 3. The isolated nucleic acid of claim 1 comprising a nucleotide sequence that is at least 80% identical to SEQ ID NO:
 1. 4. The isolated nucleic acid of claim 1 wherein said nucleic acid hybridizes under moderate or high stringency conditions to a sequence that is complementary to SEQ ID NO:
 1. 5. The isolated nucleic acid of claim 3 wherein the percentage identity to SEQ ID NO: 1 is at least about 95%.
 6. The isolated nucleic acid of claim 3 wherein the percentage identity to SEQ ID NO: 1 is about 99%.
 7. The isolated nucleic acid of claim 4 wherein the hybridization comprises a hybridization or wash buffer comprising a parameter selected from the group consisting of: (i) a salt concentration that is equivalent to 0.1×SSC-0.2×SSC buffer or lower salt concentration; (ii) a detergent concentration equivalent to 0.1% (w/v) SDS or higher; and (iii) an incubation temperature of about 45° C. to 65° C. or higher.
 8. A gene construct comprising the isolated nucleic acid of claim 1 in operable connection with a promoter sequence.
 9. An isolated nucleic acid comprising a nucleotide sequence selected from the group consisting of: (i) the nucleotide sequence set forth in SEQ ID NO: 1; (ii) nucleotide residues 163 to 2241 of SEQ ID NO: 1; (iii) a nucleotide sequence that encodes the amino acid sequence set forth in SEQ ID NO: 2; and (iv) a nucleotide sequence that is complementary to any one of (i) to (iii).
 10. A gene construct comprising the isolated nucleic acid of claim 9 in operable connection with a promoter sequence.
 11. An isolated GPR56 polypeptide or an immunologically active derivative thereof, substantially free of conspecific proteins.
 12. The isolated GPR56 polypeptide of claim 11 comprising an amino acid sequence that is at least 80% identical to SEQ ID NO:
 2. 13. The isolated GPR56 polypeptide of claim 12 wherein the percentage identity to SEQ ID NO: 2 is at least about 99%.
 14. An isolated GPR56 polypeptide comprising the amino acid sequence set forth in SEQ ID NO:
 2. 15. An antibody that binds to the isolated polypeptide of claim
 11. 16. A nucleic acid probe for detecting RNA encoding a GPR56 polypeptide in a sample, said probe comprising at least about 20 contiguous nucleotides of the nucleotide sequence set forth in SEQ ID NO: 1 or a complementary nucleotide sequence thereto.
 17. The nucleic acid probe of claim 16 comprising a nucleotide sequence selected from the group consisting of: (i) a nucleotide sequence comprising nucleotide residues 131-1400 of SEQ ID NO: 1; (ii) a nucleotide sequence comprising nucleotide residues 1423-2239 of SEQ ID NO: 1; (iii) a nucleotide sequence comprising nucleotide residues 2264-2282 of SEQ ID NO: 1; and (iv) a nucleotide sequence comprising about 20-30 contiguous nucleotides of any one of (i) through (iv).
 18. A nucleic acid probe comprising a nucleotide sequence selected from the group consisting of: (i) the sequence set forth in SEQ ID NO: 11; (ii) the sequence set forth in SEQ ID NO: 12; and (iii) the sequence set forth in SEQ ID NO:
 13. 19. The nucleic acid probe of claim 16 comprising a nucleotide sequence selected from the group consisting of: (i) a nucleotide sequence that is complementary to nucleotide residues 131-1400 of SEQ ID NO: 1; (ii) a nucleotide sequence that is complementary to nucleotide residues 1423-2239 of SEQ ID NO: 1; (iii) a nucleotide sequence that is complementary to nucleotide residues 2264-2282 of SEQ ID NO: 1; and (iv) a nucleotide sequence comprising at least 20 contiguous nucleotides of any one of (i) through (iv).
 20. A nucleic acid probe comprising a nucleotide sequence selected from the group consisting of SEQ ID NO: 14, SEQ ID NO: 15, SEQ ID NO: 16, SEQ ID NO: 17, SEQ ID NO: 18, and SEQ ID NO:
 19. 21. A method for detecting a cancer cell in a subject, said method comprising: (i) determining the level of GPR56 mRNA expressed in a test sample from said subject; and (ii) comparing the level of GPR56 mRNA determined at (i) to the level of GPR56 mRNA expressed in a comparable sample from a healthy or normal individual, wherein a level of GPR56 mRNA at (i) that is enhanced in the test sample relative to the comparable sample from the normal or healthy individual is indicative of the presence of a cancer cell in said subject.
 22. The method of claim 21 wherein the cancer is a carcinoma.
 23. The method of claim 22 wherein the carcinoma is a carcinoma of a tissue selected from the group consisting of: prostate, omentum, ovary, liver, placenta, and brain.
 24. The method of claim 21 wherein the samples comprise cells derived from a tissue or selected from the group consisting of: ovary, prostate, kidney, uterus, placenta, cervix, omentum, rectum, brain, bone, lung, lymph, and blood, or urine, semen, abdominal fluid, or serum, or a cell preparation or nucleic acid preparation derived therefrom.
 25. A method for detecting ovarian cancer or a metastases thereof in a subject, said method comprising: (i) determining the level of GPR56 mRNA expressed in a test sample from said subject; and (ii) comparing the level of GPR56 mRNA determined at (i) to the level of GPR56 mRNA expressed in a comparable sample from a healthy or normal individual, wherein a level of GPR56 mRNA at (i) that is enhanced in the test sample relative to the comparable sample from the normal or healthy individual is indicative of the presence of ovarian cancer or a metastases thereof in said subject.
 26. The method of claim 25 comprising: (i) hybridizing a GPR56 probe to GPR56-encoding RNA in both the test sample and the comparable sample from the normal or healthy individual under at least low stringency hybridization conditions; (ii) detecting the hybridization using a detection means; and (iii) comparing the hybridization signals produced for each sample.
 27. The method of claim 25 wherein the sample comprises serum or abdominal fluid, or a tissue selected from the group consisting of: ovary, lymph, lung, liver, brain, placenta, brain, and omentum.
 28. The method of claim 25 wherein the sample comprises cells from the ovary or ovarian surface epithelium or cells from the omentum.
 29. The method of claim 26 wherein the probe is labeled and the detection means comprises detecting said label following hybridization.
 30. The method of claim 29 wherein the GPR56 probe comprises a nucleotide sequence complementary to SEQ ID NO:
 1. 31. The method of claim 29 wherein the GPR56 probe comprises a nucleotide sequence selected from the group consisting of: SEQ ID NO: 14, SEQ ID NO: 15, SEQ ID NO: 16, SEQ ID NO: 17, SEQ ID NO: 18, and SEQ ID NO:
 19. 32. The method of claim 26 wherein the detection means comprises reverse transcription polymerase chain reaction (RT-PCR).
 33. The method of claim 32 wherein one or more sense GPR56 probes comprises a nucleotide sequence selected from the group consisting of SEQ ID NO: 11, SEQ ID NO: 12, and SEQ ID NO:
 13. 34. The method of claim 32 wherein one or more antisense GPR56 probes comprises a nucleotide sequence selected from the group consisting of SEQ ID NO: 14, SEQ ID NO: 15, SEQ ID NO: 16, SEQ ID NO: 17, SEQ ID NO: 18, and SEQ ID NO:
 19. 35. A method for determining an effector memory T cell response in a subject, said method comprising: (i) determining the level of GPR56 mRNA expressed in a test sample from said subject; and (ii) comparing the level of GPR56 mRNA determined at (i) to the level of GPR56 mRNA expressed in a comparable sample from a healthy or normal individual, wherein a level of GPR56 mRNA at (i) that is enhanced in the test sample relative to the comparable sample from the normal or healthy individual is indicative of an effector memory T cell response in the subject.
 36. The method of claim 35 wherein the effector memory T cell response is indicative of inflammatory disease or inflammation in the subject.
 37. A method for determining whether or not a subject has been re-infected with an infectious agent, said method comprising: (i) determining the level of GPR56 mRNA expressed in a test sample from said subject; and (ii) comparing the level of GPR56 mRNA determined at (i) to the level of GPR56 mRNA expressed in a comparable sample from a healthy or normal individual, wherein a level of GPR56 mRNA at (i) that is enhanced in the test sample relative to the comparable sample from the normal or healthy individual is indicative of re-infection in the subject.
 38. A method for determining the presence of effector memory T cells in a test sample, said method comprising: (i) hybridizing a GPR56 probe to GPR56-encoding RNA in the test sample under at least low stringency hybridization conditions; and (ii) detecting the hybridization using a detection means, wherein said hybridization is indicative of the presence of an effector memory T cell in said test sample.
 39. The method of claim 38 wherein the test sample comprises blood or whole serum or a fraction thereof comprising T cells.
 40. The method of claim 38 wherein the test sample comprises peripheral blood mononuclear cells (PBMC).
 41. A process for counting effector memory T cells in a subject comprising performing the method of claim 38 on a sample from said subject and normalizing the hybridization signal to determine T cell count.
 42. A method for detecting a cancer cell in a subject, said method comprising: (i) determining the level of a GPR56 polypeptide in a test sample from said subject; and (ii) comparing the level of GPR56 polypeptide determined at (i) to the level of said GPR56 polypeptide in a comparable sample from a healthy or normal individual, wherein a level of said GPR56 polypeptide at (i) that is enhanced in the test sample relative to the comparable sample from the normal or healthy individual is indicative of the presence of a cancer cell in said subject.
 43. The method of claim 42 wherein the level of GPR56 polypeptide is determined by a process comprising: (i) contacting a sample with an antibody that binds to a GPR56 polypeptide under conditions sufficient for binding to occur; and (ii) determining the binding.
 44. A method for determining whether or not a subject has been re-infected with an infectious agent, said method comprising: (i) determining the level of a GPR56 polypeptide in a test sample from said subject; and (ii) comparing the level of the GPR56 polypeptide determined at (i) to the level of said GPR56 polypeptide in a comparable sample from a healthy or normal individual, wherein a level of said GPR56 polypeptide at (i) that is enhanced in the test sample relative to the comparable sample from the normal or healthy individual is indicative of re-infection in the subject.
 45. The method of claim 44 wherein the level of GPR56 polypeptide is determined by a process comprising: (i) contacting a sample with an antibody that binds to a GPR56 polypeptide under conditions sufficient for binding to occur; and (ii) determining the binding.
 46. A method for determining the presence of effector memory T cells in a test sample, said method comprising: (i) contacting said sample with an antibody that binds to a GPR56 polypeptide under conditions sufficient for binding to occur; and (ii) determining the binding. wherein binding of the antibody to the test sample is indicative of the presence of an effector memory T cell in said test sample. 